

# **LSR RECEPTOR, ITS ACTIVITY, ITS CLONING AND ITS APPLICATIONS TO THE DIAGNOSIS, PREVENTION AND/OR TREATMENT OF OBESITY AND RELATED RISKS OR COMPLICATIONS.**

## **5 INTRODUCTION**

The present invention relates to a new complex receptor polypeptide LSR (Lipolysis Stimulated Receptor), characterized by its functional activities, the cloning of the cDNAs complementary to the messenger RNAs encoding each of the subunits of the multimeric complex, vectors and transformed cells, methods of diagnosis and of selection of  
10 compounds which can be used as medicament for the prevention and/or treatment of pathologies and/or of pathogeneses such as obesity and anorexia, hyperlipidemias, atherosclerosis, diabetes, hypertension, and more generally the various pathologies associated with abnormalities in the metabolism of cytokines.

Obesity is a public health problem which is both serious and widespread: in  
15 industrialized countries, a third of the population has an excess weight of at least 20% relative to the ideal weight. The phenomenon continues to worsen, in regions of the globe whose economies are being modernized, such as the Pacific islands, and in general. In the United States, the number of obese people has passed from 25% at the end of the 70s to 33% at the beginning of the 90s.

Obesity considerably increases the risk of developing cardiovascular or metabolic  
20 diseases. It is estimated that if the entire population had an ideal weight, the risk of coronary insufficiency would decrease by 25% and that of cardiac insufficiency and of cerebral vascular accidents by 35%. Coronary insufficiency, atheromatous disease and cardiac insufficiency are at the forefront of the cardiovascular complications induced by obesity. For  
25 an excess weight greater than 30%, the incidence of coronary diseases is doubled in subjects under 50 years. Studies carried out for other diseases are equally eloquent. For an excess weight of 20%, the risk of high blood pressure is doubled. For an excess weight of 30%, the risk of developing a non-insulin-dependent diabetes is tripled. That of hyperlipidemias is multiplied by 6.

The list of diseases whose onset is promoted by obesity is long: hyperuricemia  
30 (11.4% in obese subjects, against 3.4% in the general population), digestive pathologies, abnormalities in hepatic functions, and even certain cancers.

Whether the physiological changes in obesity are characterized by an increase in the number of adipose cells, or by an increase in the quantity of triglycerides stored in each  
35 adipose cell, or by both, this excess weight results mainly from an imbalance between the quantities of calories consumed and those of the calories used by the body. Studies on the

causes of this imbalance have been in several directions. Some have focused on studying the mechanism of absorption of foods, and therefore the molecules which control food intake and the feeling of satiety. Other studies have been related to the basal metabolism, that is to say the manner in which the body uses the calories consumed.

5           The treatments for obesity which have been proposed are of four types. Food restriction is the most frequently used. The obese individuals are advised to change their dietary habits so as to consume fewer calories. This type of treatment is effective in the short-term. However, the recidivation rate is very high. The increase in calorie use through physical exercise is also proposed. This treatment is ineffective when applied alone, but it  
10 improves, however, weight loss in subjects on a low-calorie diet. Gastrointestinal surgery, which reduces the absorption of the calories ingested, is effective but has been virtually abandoned because of the side effects which it causes. The medicinal approach uses either the anorexigenic action of molecules involved at the level of the central nervous system, or the effect of molecules which increase energy use by increasing the production of heat. The  
15 prototypes of this type of molecule are the thyroid hormones which uncouple oxidative phosphorylations of the mitochondrial respiratory chain. The side effects and the toxicity of this type of treatment make their use dangerous. An approach which aims to reduce the absorption of dietary lipids by sequestering them in the lumen of the digestive tube is also in place. However, it induces physiological imbalances which are difficult to tolerate: deficiency  
20 in the absorption of fat-soluble vitamins, flatulence and steatorrhoea. Whatever the envisaged therapeutic approach, the treatments of obesity are all characterized by an extremely high recidivation rate.

          The molecular mechanisms responsible for obesity in humans are complex and involve genetic and environmental factors. Because of the low efficiency of the treatments  
25 known up until now, it is urgent to define the genetic mechanisms which determine obesity, so as to be able to develop better targeted medicaments.

          More than 20 genes have been studied as possible candidates, either because they have been implicated in diseases of which obesity is one of the clinical manifestations, or because they are homologues of genes involved in obesity in animal models. Situated in the  
30 7q31 chromosomal region, the OB gene is one of the most widely studied. Its product, leptin, is involved in the mechanisms of satiety. Leptin is a plasma protein of 16 kDa produced by the adipocytes under the action of various stimuli. Obese mice of the ob/ob type exhibit a deficiency in the leptin gene; this protein is undetectable in the plasma of these animals. The administration of leptin obtained by genetic engineering to ob/ob mice  
35 corrects their relative hyperphagia and allows normalization of their weight. This anorexigenic effect of leptin calls into play a receptor of the central nervous system: the ob receptor which belongs to the family of class 1 cytokine receptors. The ob receptor is

deficient in obese mice of the db/db strain. The administration of leptin to these mice has no effect on their food intake and does not allow substantial reduction in their weight. The mechanisms by which the ob receptors transmit the signal for satiety are not precisely known. It is possible that neuropeptide Y is involved in this signalling pathway. It is important  
 5 to specify at this stage that the ob receptors are not the only regulators of appetite. The Melanocortin 4 receptor is also involved since mice made deficient in this receptor are obese (Gura, 1997).

The discovery of leptin and the characterization of the leptin receptor at the level of the central nervous system have opened a new route for the search for medicaments  
 10 against obesity. This model, however, rapidly proved disappointing. Indeed, with only one exception (Montague et al., 1997), the genes encoding leptin or its ob receptor have proved to be normal in obese human subjects. Furthermore and paradoxically, the plasma concentrations of leptin, the satiety hormone, are abnormally high in most obese human subjects. Most of the therapeutic research efforts in this direction have centred on the  
 15 characterization of the effect of leptin at the level of the central nervous system.

## **SUMMARY OF THE INVENTION**

The present invention results from a focusing of the research effort on the discovery of the mechanisms of leptin elimination. The most widely accepted working hypothesis is  
 20 that the plasma levels of leptin are high in obese subjects because this hormone is produced by the adipose tissue and that the fatty mass is increased in obese subjects. The inventors have formulated a different hypothesis and have postulated that the concentrations of leptin are increased in obese individuals because the clearance of this hormone is reduced. This deficiency causes a leptin resistance syndrome and the obese  
 25 individual develops a suitable response to the high concentrations of leptin. In this perspective, the treatment of obese subjects ought to consist not in an increase in the leptin levels but in a normalization thereof. At this stage, it is essential to recall that the ob type receptors are signalling type receptors. These receptors can bind leptin at the level of the plasma membrane but cannot cause the protein to enter inside the cell for it to be degraded  
 30 therein. The ob receptors are not endocytosis receptors.

### ***LSR receptor***

The inventors have characterized a receptor, in particular hepatic, called LSR receptor, whose activity is dual. The LSR receptor allows, on the one hand, endocytosis of  
 35 lipoproteins, when it is activated by the free fatty acids, thus serving as a pathway for the clearance of lipoproteins. This pathway serves mainly, but not exclusively, for the clearance

of particles high in triglycerides of intestinal origin (Mann et al., 1995). This activity, expressed most particularly at the hepatic level, is dependent on the presence of free fatty acids which, by binding to the receptor, induce a reversible change in the conformation of this complex and allow it to bind, with a high affinity, various classes of lipoproteins such as those containing apoprotein B or apoprotein E.

On the other hand, under normal conditions, in the absence of free fatty acids, the complex receptor LSR does not bind lipoproteins, but is capable of binding a cytokine, in particular leptin, and then of internalizing it and of degrading it.

The present invention therefore relates to a purified LSR receptor, in particular of hepatic cells, characterized in that it is capable, in the presence of free fatty acids, of binding lipoproteins, and in the absence of free fatty acids, of binding a cytokine, preferably leptin.

According to the invention, this LSR receptor is, in addition, characterized in that the bound lipoproteins or the bound cytokine are incorporated into the cell and then degraded, the bound lipoproteins containing in particular apoprotein B or E.

It should be understood that the invention does not relate to the LSR receptors in a natural form, that is to say that they are not taken in their natural environment but obtained by purification from natural sources, or alternatively obtained by genetic recombination, or alternatively by chemical synthesis and capable, in this case, of containing non-natural amino acids, as will be described below. The production of a recombinant LSR receptor, which may be carried out using one of the nucleotide sequences according to the invention, is particularly advantageous because it makes it possible to obtain an increased level of purity of the receptor.

More particularly, the invention relates to a purified rat LSR receptor, characterized in that it comprises at least one subunit having a molecular weight of about 66 kDa and a subunit having a molecular weight of about 58 kDa.

Preferably, the purified rat LSR receptor of the present invention is characterized in that it contains an  $\alpha$  subunit comprising the amino acid sequence of SEQ ID 2 or a sequence homologous thereto, or an  $\alpha'$  subunit comprising the amino acid sequence of SEQ ID 4 or a sequence homologous thereto, and one, preferably three,  $\beta$  subunits comprising the amino acid sequence of SEQ ID 6 or a sequence homologous thereto.

The invention also relates to a purified mouse LSR receptor, characterized in that it comprises at least one subunit having a molecular weight of about 66 kDa and a subunit having a molecular weight of about 58 kDa.

Preferably, the purified mouse LSR receptor of the present invention is characterized in that it contains an  $\alpha$  subunit comprising the amino acid sequence of SEQ



ID 16 or a sequence homologous thereto, or an  $\alpha'$  subunit comprising the amino acid sequence of SEQ ID 17 or a sequence homologous thereto, and one, preferably three,  $\beta$  subunits comprising the amino acid sequence of SEQ ID 18 or a sequence homologous thereto.

5           The invention also relates to a purified human LSR receptor, characterized in that it comprises at least one subunit having a molecular weight of about 72 kDa and a subunit having a molecular weight of about 64 kDa.

          Preferably, the purified human LSR receptor of the present invention is characterized in that it contains an  $\alpha$  subunit comprising the amino acid sequence of SEQ  
10 ID 8 or a sequence homologous thereto, or an  $\alpha'$  subunit comprising the amino acid sequence of SEQ ID 10 or a sequence homologous thereto, and one, preferably three,  $\beta$  subunits comprising the amino acid sequence of SEQ ID 12 or a sequence homologous thereto.

          A particularly preferred embodiment of the LSR receptors of the present invention  
15 is a recombinant LSR receptor obtained by expressing, in a recombinant host, one or more nucleotide sequences according to the invention. This preferred recombinant receptor consists of an  $\alpha$  or  $\alpha'$  subunit and one, preferably three,  $\beta$  subunits, in particular an  $\alpha$  or  $\alpha'$  subunit and three  $\beta$  subunits of a human LSR receptor.

## 20   ***Polypeptide sequences of LSR***

          The invention relates to polypeptides, characterized in that they are a constituent of an LSR receptor according to the invention.

          It should be understood that the invention does not relate to the polypeptides in a natural form, that is to say that they are not taken in their natural environment. Indeed, the  
25 invention relates to the peptides obtained by purification from natural sources, or alternatively obtained by genetic recombination, or alternatively by chemical synthesis, and capable, in this case, of containing non-natural amino acids, as will be described below. The production of a recombinant polypeptide, which may be carried out using one of the nucleotide sequences according to the invention or a fragment of one of these  
30 sequences, is particularly advantageous because it makes it possible to obtain an increased level of purity of the desired polypeptide.

          The invention therefore relates to a purified, isolated or recombinant polypeptide comprising a sequence of at least 5, preferably at least 10 to 15, consecutive amino acids of an LSR receptor, as well as the homologues, equivalents or variants of the said  
35 polypeptide, or one of their fragments. Preferably, the sequence of at least 10 to 15 amino acids of the LSR receptor is a biologically active fragment of an LSR receptor.

More particularly, the invention relates to purified, isolated or recombinant polypeptides comprising a sequence of at least 10 to 15 amino acids of a rat LSR receptor, of a mouse LSR receptor or of a human LSR receptor.

In the present description, the term polypeptide will be used to also designate a  
5 protein or a peptide.

### ***Nucleotide sequences of LSR***

The subject of the present invention is also purified nucleic acid sequences, characterized in that they encode an LSR receptor or a polypeptide according to the  
10 invention.

The invention relates to a purified nucleic acid, characterized in that it comprises at least 8, preferably at least 10 and more particularly at least 15 consecutive nucleotides of the polynucleotide of a genomic, cDNA or RNA sequence of the LSR receptor, as well as the nucleic acid sequences complementary to this nucleic acid.

15 More particularly, the invention relates to the purified, isolated or recombinant nucleic acids comprising a sequence of at least 8, preferably at least 10 and more particularly at least 15 consecutive nucleotides of the polynucleotide of a nucleic sequence of a mouse LSR receptor or of a human LSR receptor.

The invention also relates to the variant, mutated, equivalent or homologous  
20 nucleic sequences of the nucleic sequences according to the invention, or one of their fragments. It finally relates to the sequences capable of hybridizing specifically with the nucleic sequences according to the invention.

The invention therefore also relates to the nucleic acid sequences contained in the gene encoding the LSR receptor, in particular each of the exons of the said gene or a  
25 combination of exons of the said gene, or alternatively a polynucleotide extending over a portion of one or more exons. Preferably, these nucleic acids encode one or more biologically active fragments of the human LSR receptor.

The present invention also relates to the purified nucleic acid sequences encoding one or more elements for regulating the expression of the LSR gene. Also included in the  
30 invention are the nucleic acid sequences of the promoter and/or regulator of the gene encoding the receptor according to the invention, or one of their allelic variants, the mutated, equivalent or homologous sequences, or one of their fragments.

The invention also relates to the purified nucleic sequences for hybridization comprising at least 8 nucleotides, characterized in that they can hybridize specifically with  
35 a nucleic sequence according to the invention.

Preferably, nucleic acid fragments or oligonucleotides, having as sequences the nucleotide sequences according to the invention can be used as probes or primers.

The invention also comprises methods for screening cDNA and genomic DNA libraries, for the cloning of the isolated cDNAs and/or the genes coding for the receptor according to the invention, and for their promoters and/or regulators, characterized in that they use a nucleic sequence according to the invention.

The nucleic sequences, characterized in that they are capable of being obtained by one of the preceding methods according to the invention or the sequences capable of hybridizing with the said sequences, form part of the invention.

10

### ***Vectors, host cells and transgenic animals***

The invention also comprises the cloning and/or expression vectors containing a nucleic acid sequence according to the invention.

The vectors according to the invention, characterized in that they comprise elements allowing the expression and/or the secretion of the said sequences in a host cell, also form part of the invention.

The invention comprises, in addition, the host cells, in particular the eukaryotic and prokaryotic cells, transformed with the vectors according to the invention, as well as the mammals, except man, comprising one of the said transformed cells according to the invention.

Among the mammals according to the invention, there will be preferred animals such as mice, rats or rabbits, expressing a polypeptide according to the invention, the phenotype corresponding to the normal or variant LSR receptor, in particular mutated of human origin.

These cells and animals can be used in a method of producing a recombinant polypeptide according to the invention and can also serve as a model for analysis and screening.

The invention also relates to the use of a cell, of a mammal or of a polypeptide according to the invention for studying the expression and the activity of the receptor according to the invention, and the direct or indirect interactions between the said receptor and chemical or biochemical compounds which may be involved in the activity of the said receptor.

The invention also relates to the use of a cell, of a mammal or of a polypeptide according to the invention for screening a chemical or biochemical compound capable of interacting directly or indirectly with the receptor according to the invention, and/or capable of modulating the expression or the activity of the said receptor.

35

### ***Production of polypeptides derived from the LSR receptor***

The invention also relates to the synthesis of synthetic or recombinant polypeptides of the invention, in particular by chemical synthesis or using a nucleic acid sequence according to the invention.

5 The polypeptides obtained by chemical synthesis and capable of comprising non-natural amino acids corresponding to the said recombinant polypeptides are also included in the invention.

The method of producing a polypeptide of the invention in recombinant form is itself included in the present invention, and is characterized in that the transformed cells  
10 are cultured under conditions allowing the expression of a recombinant polypeptide having a polypeptide sequence according to the invention, and in that the said recombinant polypeptide is recovered.

The recombinant polypeptides, characterized in that they are capable of being obtained by the said method of production, also form part of the invention.

15

### ***Antibodies***

The mono- or polyclonal antibodies or fragments thereof, chimeric or immunoconjugated antibodies, characterized in that they are capable of specifically recognizing a polypeptide or a receptor according to the invention, form part of the  
20 invention.

There may be noted in particular the advantage of antibodies specifically recognizing certain polypeptides, variants or fragments, which are in particular biologically active, according to the invention.

The invention also relates to methods for the detection and/or purification of a  
25 polypeptide according to the invention, characterized in that they use an antibody according to the invention.

The invention comprises, in addition, purified polypeptides, characterized in that they are obtained by a method according to the invention.

Moreover, in addition to their use for the purification of polypeptides, the antibodies  
30 of the invention, in particular the monoclonal antibodies, may also be used for the detection of these polypeptides in a biological sample.

More generally, the antibodies of the invention may be advantageously used in any situation where the expression, normal or abnormal, of a polypeptide of the LSR receptor, normal or mutated, needs to be observed.

35



### ***Detection of allelic variability and diagnosis***

Also forming part of the invention are the methods for the determination of an allelic variability, a mutation, a deletion, a loss of heterozygosity or a genetic abnormality, characterized in that they use a nucleic acid sequence or an antibody according to the invention.

These methods relate to, for example, the methods for the diagnosis of the predisposition to obesity, to the associated risks, or to pathologies associated with abnormalities in the metabolism of cytokines, by determining, in a biological sample from the patient, the presence of mutations in at least one of the sequences described above. The nucleic acid sequences analysed may be either the genomic DNA, the cDNA or the mRNA.

Nucleic acids or antibodies based on the present invention can also be used to allow a positive and differential diagnosis in a patient taken in isolation, or a pre-symptomatic diagnosis in an at risk subject, in particular with a familial history.

In addition, the detection of a specific mutation may allow an evolutive diagnosis, in particular as regards the intensity of the pathology or the probable period of its appearance.

### ***Screening of compounds of interest***

Also included in the invention are the methods for selecting chemical or biochemical compounds capable of interacting, directly or indirectly, with the receptor or the polypeptide or nucleotide sequences according to the invention, and/or allowing the expression or the activity of the LSR receptor to be modulated.

The invention relates in particular to a method for selecting chemical or biochemical compounds capable of interacting with a nucleic acid sequence contained in a gene encoding an LSR receptor, the said method being characterized in that it comprises bringing a host cell expressing an LSR receptor or a fragment of the said receptor into contact with a candidate compound capable of modifying the expression or the regulation of the expression of the said nucleic sequence, and detecting, directly or indirectly, a modification of the expression or of the activity of the LSR receptor.

The invention also relates to a method for selecting chemical or biochemical compounds capable of interacting with the LSR receptor, the said method being characterized in that it comprises bringing an LSR receptor or a fragment of the said receptor, or a host cell expressing an LSR receptor or a fragment of the said receptor, into contact with a candidate compound capable of modifying the LSR activity, and detecting, directly or indirectly, a modification of the activity of the LSR receptor or the

formation of a complex between the candidate compound and the said LSR receptor or the said polypeptide.

The invention comprises the compounds capable of interacting directly or indirectly with an LSR receptor as well as the compounds capable of interacting with one or more  
 5 nucleic sequences of the LSR receptor. It also comprises the chemical or biochemical compounds allowing the expression or the activity of the receptor according to the invention to be modulated. The compounds, characterized in that they were selected by one of the methods according to the present invention, also form part of the invention.

In particular, among these compounds according to the invention, there are  
 10 preferred the antibodies according to the invention, the polypeptides according to the invention, the nucleic acids, oligonucleotides and vectors according to the invention, or a leptin or one of its derived compounds, preferably one of its protein variants, or leptins which are chemically modified or are obtained by genetic recombination, or the protein gC1qR or one of its analogues, or one of their fragments.

15 The invention comprises, finally, compounds capable of modulating the expression or the activity of the receptor according to the invention, as medicament for the prevention of pathologies and/or of pathogeneses such as obesity and anorexia, hyperlipidemias, atherosclerosis, diabetes, hypertension, and more generally the various pathologies associated with abnormalities in the metabolism of cytokines.

20

## DETAILED DESCRIPTION

### *The LSR receptor*

25 The invention relates to a purified LSR receptor ("Lipolysis Stimulated Receptor"), preferably hepatic, consisting of at least one  $\alpha$  or  $\alpha'$  subunit and at least one  $\beta$  subunit. The  $\alpha$  subunit has a molecular weight of about 66 kDa in rats and in mice and of about 72 kDa in humans. The  $\alpha'$  subunit has a molecular weight of about 64 kDa in rats and in mice and of about 70 kDa in humans. The  $\beta$  subunit has a molecular weight of about 58  
 30 kDa in rats and in mice and of about 64 kDa in humans.

The inventors have formulated the hypothesis according to which the most abundant, and probably the most active, form of the LSR receptor is that in which an  $\alpha$  or  $\alpha'$  subunit and three  $\beta$  subunits exist. It appears, however, possible that the  $\alpha$  and  $\alpha'$  subunits, on the one hand, and the  $\beta$  subunit, on the other, have distinct biological

functions and that these functions can be performed in a cell independently of their assembly in the form of a receptor.

The inventors have also observed that a complex can form between the LSR receptor and the gC1qR receptor having a molecular weight of about 33 kDa, or a homologous protein. It appears that the gC1qR receptor is transiently combined with the LSR receptor and that the presence of a C1q protein or of homologous proteins makes it possible not only to dissociate gC1qR from the LSR receptor but also to activate the LSR receptor, including in the absence of fatty acids.

### 10 ***Activity of the LSR receptor and applications***

The present invention therefore relates to a receptor, in particular of hepatic cells, characterized in that it is capable, in the presence of free fatty acids, of binding lipoproteins, and in the absence of free fatty acids, of binding a cytokine, preferably the bound leptin, lipoproteins and cytokine being incorporated and then degraded by the cell, it being possible for the said receptor, in addition, to bind the gC1qR protein or one of its analogous proteins.

### ***Clearance of lipoproteins***

The LSR receptor represents the principal pathway for the elimination of lipoproteins of intestinal origin and of particles high in triglycerides, in particular VLDLs and chylomicrons. The LSR receptor can also serve as a pathway for the elimination of LDLs, particles high in cholesterol, which are for the most part removed by the LDL receptor pathway, but of which about 30% are eliminated at the hepatic level by pathways different from the LDL receptor.

The inventors have in fact demonstrated that the LSR receptor is capable of binding lipoproteins, in particular the lipoproteins high in triglycerides, and then of internalizing and degrading them. This lipoprotein clearance activity by the receptor requires the presence of free fatty acids, for example oleate, and is inhibited in the presence of antibodies directed against LSR or against peptides derived from LSR.

30

### ***Clearance of cytokines***

The inventors have also demonstrated that in the absence of free fatty acids, for example oleate, the LSR receptor is capable of binding cytokines, preferably leptin. The leptin clearance function is, however, only possible if the receptor has not bound fatty acids produced by the hepatic lipase or by the hormone-sensitive lipase of the adipose tissue. Once the cytokines have been bound, the LSR receptor internalizes them and

35

degrades them. This cytokine, preferably leptin, degradation activity is inhibited by antibodies directed against LSR or against peptides derived from LSR.

The inventors have shown that it is the  $\alpha$  subunit of the LSR receptor which is most particularly involved in the binding of cytokines, and preferably of leptin.

5 Furthermore, the inventors have shown, with the aid of mice, that, *in vivo*, the LSR receptors carry out the hepatic capturing of cytokines, preferably of leptin.

The high levels of leptin in all obese human subjects can be explained by several molecular mechanisms which are capable of reducing the hepatic clearance of leptin, including in particular:

- 10 a) alteration of one or more genes for LSR, and/or of their promoters ;
- b) facilitation, by post-transcriptional modifications, of the allosteric rearrangement allowing the passage from the cytokine-competent conformation to the lipoprotein receptor conformation;
- c) deficiency in the transport of vesicles containing LSR from, or towards, the plasma
- 15 membrane (this function depends on the integrity of the cytoskeleton) ;
- d) increase in the degradation of LSR ;
- e) increase in the lipid calorie ration which, by diverting the receptor towards the clearance of lipoproteins, reduces in part its capacity to degrade leptin.

## 20 ***Control of LSR activity by the cytokines***

Finally, the inventors have demonstrated that cytokines, preferably leptin, modulate the activity of the LSR receptor in the presence of free fatty acids. More particularly, the cytokines increase the lipoprotein clearance activity of the LSR receptor and more precisely, the binding, internalization and degradation of the VLDLs and LDLs.

25 This increase in the LSR activity could be the result of the increase in the apparent number of LSR receptor at the surface of the cells following an increase in protein synthesis and following a mobilization of endocytosis vesicles. In addition, the inventors have shown, with the aid of mice, that, *in vivo*, cytokines, preferably leptin, are capable of reducing postprandial lipaemic response.

30 Leptin, and probably other cytokines, are therefore regulators of the activity of LSR. A syndrome of resistance to leptin, or to other cytokines, can lead to a hypertriglyceridemia, which is either permanent or limited to the postprandial phase.

## ***Treatment of obesity***

35 The role played by LSR in the clearance of leptin makes it possible to formulate a physiopathological model which requires a revision of the strategies used for treating



obesity. It is indeed essential to reduce the concentrations of leptin in obese human subjects in order to restore the physiological fluctuations of this hormone.

Accordingly, it is possible to envisage using compounds for the treatment of obesity allowing modulation of the number of LSR receptors, of their recycling rate, or of the change in their conformation, and/or allowing in particular:

1. leptinemia, and therefore the sensations of satiety and of hunger, to be controlled;
2. normal leptin concentrations to be restored and normal regulation of dietary habit by the normal perception of the sensations of hunger and of satiety ;
3. triglyceridemia to be controlled;
4. the plasma concentrations of residues of chylomicrons, highly atherogenic particles, to be regulated.

The role played by the LSR receptor in the hepatic clearance of lipoproteins of intestinal origin makes it possible to envisage using compounds capable of modulating the expression and/or the activity of LSR in order to modulate the distribution of lipids of dietary origin between the peripheral tissues, in particular the adipose tissues, and the liver. A treatment of obesity will consist in promoting the hepatic degradation of lipoproteins, and thereby reducing their storage in the adipose tissue, and regulating their plasma concentrations. The latter effect makes it possible to envisage the use of such compounds to reduce the risks associated with obesity, in particular the atherogenic risks.

20

### ***Treatments of anorexia and of cachexia***

It is possible to envisage using methods of regulating the activities of LSR to introduce treatments which make it possible to overcome the vicious circle which characterizes anorexia nervosa. By reducing the number of receptors, it should be possible to promote weight gain in anorexic or undernourished subjects.

25

Under these conditions, it is advantageous to selectively inhibit the clearance of leptin by using synthetic peptides or pharmacological molecules which either reduce the synthesis of LSR or block its capacity to bind leptin and/or lipoproteins, or alternatively increase the catabolism of the receptor.

30

### ***Treatment of abnormalities in the metabolism of cytokines***

Analysis of the primary structure of the  $\alpha$  subunit of LSR, as described below, shows a site homologous to the cytokine binding sites present on their receptors, as well as two routing signals which allow endocytosis and rapid degradation of ligands in the lysosomes. This observation is new in the sense that the cytokine receptors do not allow

35

the internalization and the degradation of ligands. These receptors have been characterized on the basis of their intracellular signalling properties.

Thus, in addition to it having the property of allowing the proteolytic degradation of lipoproteins and of leptin, it is highly probable that the LSR receptor also carries out the degradation of other cytokines. This function can be studied by virtue of the anti-LSR antibodies and of transfected CHO cells expressing the  $\alpha$  subunit of LSR as described in Example 4. The involvement of LSR in the clearance of cytokines is essential because these molecules play an important role in the regulation of the metabolism of lipids, of the metabolism of glucose, and in the regulation of food intake and of weight gain.

The molecular mechanisms by which the cytokines modulate the physiological functions involved in obesity and its complications are numerous and complex. It is worth noting, however, the fact that abnormalities in the metabolism of cytokines are associated with hypertriglyceridemia which frequently accompanies viral, bacterial or protozoal infections. Moreover, cytokines, and more particularly Tumor Necrosis Factor (TNF), induce a transient hypertriglyceridemia similar to that observed in certain forms of obesity-related diabetes.

The reduction in the number of LSR receptors expressed in the liver of obese mice could explain a deficiency in the elimination of some cytokines, this deficiency causing metabolic disruptions such as those found in obesity. The use of hepatic cells in culture, and of the various models of obese animals cited below, will make it possible to determine, among all the cytokines and more particularly those which induce weight loss (IL-6, LIF, OSM, CNTF, IL-11, IL-12 $\alpha$ , as well as TNF $\alpha$  and TNF $\beta$ ), those which modulate the expression and/or the activity of LSR. The determination of such cytokines can, for example, be carried out using methods such as those presented in Examples 4 to 6.

Finally, analysis of the primary structure of the  $\alpha$  LSR reveals potential phosphorylation sites. This opens the perspective of a regulation of cellular activity by the LSR receptor. A particularly important example would be the involvement of LSR in the regulation of the production of " Acute Phase Proteins " under the impetus of various stimuli, including cytokines.

The involvement of LSR in the clearance and the degradation of cytokines may, in addition, not be limited to the liver. Indeed, while it has been demonstrated that the expression of LSR is predominantly hepatic, it is also certain that the expression of this receptor is not limited to this organ. Preliminary Northern-blot analysis on various human tissues has been able to reveal, in addition to the hepatic products, expression products in the kidney and in the testicle. A more thorough analysis will make it possible to show the different tissues expressing LSR in humans. In this perspective, LSR could be

involved in the degradation of cytokines not only at the hepatic level, but also at the level of the peripheral tissues. A deficiency in this activity could be involved in the pathogenesis of autoimmune diseases, of multiple sclerosis and of rheumatoid arthritis. Accumulation of cytokines is frequently found in the pathogenesis of these diseases.

5

***Polypeptide sequences of the LSR receptor***

The invention relates to polypeptides, characterized in that they are a constituent of an LSR receptor according to the invention. The invention relates more particularly to the polypeptides characterized in that they constitute the  $\alpha$ ,  $\alpha'$  or  $\beta$  subunits of the LSR  
10 receptor.

The invention relates more particularly to a purified, isolated or recombinant polypeptide comprising a sequence of at least 5, preferably of at least 10 to 15 consecutive amino acids of an LSR receptor, as well as the homologues, equivalents or variants of the said polypeptide, or one of their fragments. Preferably, the sequence of at  
15 least 10 to 15 amino acids of the LSR receptor is a biologically active fragment of an LSR receptor.

Preferably, the invention relates to purified, isolated or recombinant polypeptides comprising a sequence of at least 10 to 15 amino acids of a rat LSR receptor, of a mouse LSR receptor or of a human LSR receptor.

20 In a first preferred embodiment of the invention, the polypeptide is characterized in that it comprises a sequence of at least 10 to 15 consecutive amino acids of a sequence chosen from the group comprising the sequences of SEQ ID 2, SEQ ID 4 and SEQ ID 6, as well as the variants, equivalents or homologues of this polypeptide, or one of their fragments. Preferably, the polypeptide is a homologue or a biologically active fragment of  
25 one of the abovementioned sequences.

In a second preferred embodiment of the invention, the polypeptide is characterized in that it comprises a sequence of at least 10 to 15 consecutive amino acids of a sequence chosen from the group comprising the sequences of SEQ ID 16, SEQ ID 17 and SEQ ID 18, as well as the variants, equivalents or homologues of this polypeptide,  
30 or one of their fragments. Preferably, the polypeptide is a homologue or a biologically active fragment of one of the abovementioned sequences.

In a third preferred embodiment of the invention, the polypeptide is characterized in that it comprises a sequence of at least 10 to 15 consecutive amino acids of a sequence chosen from the group comprising the sequences of SEQ ID 8, SEQ ID 10 and  
35 SEQ ID 12, as well as the variants, equivalents or homologues of this polypeptide, or one

of their fragments. Preferably, the polypeptide is a homologue or a biologically active fragment of one of the abovementioned sequences.

Among the preferred polypeptides of the invention, there will be noted particularly the polypeptides having the human sequence SEQ ID 8, SEQ ID 10 or SEQ ID 12, as well as those having the rat sequence SEQ ID 2, SEQ ID 4 or SEQ ID 6, or those having the mouse sequence SEQ ID 16, SEQ ID 17 or SEQ ID 18. The fragments corresponding to the domains represented in Figures 1 to 6, whose positions on the sequences corresponding to SEQ ID 2, 8 or 16, are indicated in Tables 1, 3 and 4.

Finally, the invention also relates to the polypeptides of SEQ ID 29 and SEQ ID 30.

The present invention also relates to polypeptides comprising the polypeptides described above, as well as their homologous, equivalent or variant polypeptides, as well as the fragments, preferably biologically active, of the said polypeptides.

Among the polypeptides according to the invention, also preferred are the polypeptides comprising or consisting of an amino acid sequence chosen from the amino acid sequences as described above, characterized in that the said polypeptides are a constituent of the receptor according to the invention.

### ***Analysis of the polypeptide sequences of the $\alpha$ , $\alpha'$ and $\beta$ subunits of the LSR receptor***

The systematic analysis of the products of the 3 rat cDNAs described in the present application is schematically represented in Figure 1. The  $\alpha$  subunit of the rat LSR receptor, a protein encoded by the longer cDNA (LSR-Rn-2097), has the following characteristics.

Potential glycosylation sites are found at positions 12-14 and 577-579. A potential site of attachment of glycosaminoglycans is found at position 14-17.

Several phosphorylation sites are located at the level of the  $\text{NH}_2$ -terminal end (positions 193-196, 597-600, 169-171, 172-174, 401-403, 424-426, 464-466, 467-469, 185-188, 222-225, 436-439, 396-399, 504-507, 530-533, 624-627, 608-615), suggesting that the latter is oriented towards the intracellular region.

Moreover, the protein has, on the  $\text{NH}_2$ -terminal side, a hydrophobic amino acid sequence separated into two parts by 2 amino acids inducing a hairpin structure in which the two arms would consist of hydrophobic amino acids. It is reasonable to assume that this region represents the fatty acid binding site of LSR. The glove-finger structure thus produced can accommodate an aliphatic hydrocarbon chain. The two amino acids are,



more precisely in the case of rat LSR, two Prolines situated at positions 31 and 33 of the polypeptide sequence of the  $\alpha$  subunit.

Still on the  $\text{NH}_2$ -terminal side is a consensus sequence for binding to clathrin, a protein which lawns the inner surface of the " coated pits " (Chen et al., 1990). These specific regions of the plasma membrane allow rapid endocytosis of membrane proteins. Such a consensus sequence is found at the level of the LRP- $\alpha_2$ -macroglobulin receptor, of CRAM and of the LDL receptor (Herz et al., 1988 ; Lee et al., 1990 ; Goldstein et al., 1995). The consequence of a mutation at this level is a substantial delay in the internalization of the LDLs and induces familial hypercholesterolemia (Davis et al., 1986).

The receptor then possesses a hydrophobic amino acid sequence which constitutes a potential transmembrane domain. The length of this segment allows only one passage across the phospholipid bilayer (Brendel et al., 1992).

Between this clathrin binding signal and the hydrophobic chain corresponding to the single transmembrane segment are 2 motifs LI et LL (Letourneur et al., 1992). These two motifs are found in the following proteins : glut 4 glucose carrier (Verhey et al., 1994); the nonvariant chain and the histocompatibility complex class II (Zhong et al., 1997 ; Parra-Lopez et al., 1997). These signals control endocytosis and the intracellular addressing of proteins in the peripheral membrane system.

On the C-terminal side, there is then a cysteine-rich region which exhibits homology with the cytokine receptors and more particularly : the TNF 1 and 2 (Tumor Necrosis Factor 1 and 2) receptors; the low-affinity NGF (Nerve Growth factor) receptor; the Shope fibroma virus TNF soluble receptor ; CD40, CD27 and CD30, receptors for the cytokines CD40L, CD27L and CD30L ; the T cell protein 4-1BB, receptor for the putative cytokine 4-1BBL, the FAS antigen (APO 1), receptor for the FASL protein involved in apoptosis, the T cell OX40 antigen, receptor for the cytokine OX40L, and the vaccinia virus A53 protein (Cytokines and their receptors, 1996 ; Banner et al., 1993).

In addition to this cysteine-rich segment, there is a region of amino acids which are alternately charged + and - (Brendel et al., 1992). This region provides a potential binding site for the apoprotein ligands Apo B and Apo E.

This region contains, in addition, an RSRS motif found in lamin (Simos et al., 1994) and in SF2' (Krainer et al., 1991).

The LSR  $\alpha'$  form encoded by the LSR-Rn-2040 cDNA possesses all the domains described above based on the LSR  $\alpha$  sequence encoded by the LSR-Rn-2097 cDNA, with the exception of the LI/LL element, whose Leucine doublet is removed by alternative splicing. Although possessing sequences which are very similar, the subunits  $\alpha$  encoded by LSR-Rn-2097 and  $\alpha'$  encoded by LSR-Rn-2040 could therefore differ in their recycling

rate and their addressing. The  $\beta$  form encoded by LSR-Rn-1893 does not possess a transmembrane domain or a region rich in cysteines and homologous to the cytokine receptors. However, it possesses at the NH<sub>2</sub>-terminal level the hydrophobic region separated by a repetition of prolines, the region rich in charged amino acids and the RSRS motif. This constituent is probably positioned entirely outside the cell where it is bound via disulphide bridges either to the product of LSR-Rn-2040, or to that of LSR-Rn-2097.

Table 1 below lists the different domains or motifs described above, indicates whether or not they belong to each of the subunits of the LSR receptor, as well as the positions of the start and end of the said domains or motifs, or of regions carrying the said domains or motifs, as indicated in the sequence of SEQ ID 2.

Table 1

| Domain or motif                           | Position on SEQ ID 2 |     | Presence on : |           |         |
|-------------------------------------------|----------------------|-----|---------------|-----------|---------|
|                                           | Start                | End | $\alpha$      | $\alpha'$ | $\beta$ |
| Potential fatty acid binding site         | 23                   | 41  | X             | X         | X       |
| Potential clathrin binding site           | 104                  | 107 | X             | X         | X       |
| Signal for transport : LI                 | 183                  | 184 | X             | X         | X       |
| LL                                        | 195                  | 196 | X             |           |         |
| Transmembrane domain                      | 204                  | 213 | X             | X         |         |
| Potential cytokine receptor site          | 214                  | 249 | X             | X         |         |
| RSRS motif                                | 470                  | 473 | X             | X         | X       |
| Potential lipoprotein ligand binding site | 544                  | 557 | X             | X         | X       |

### ***Comparison of the polypeptide sequences of the LSR receptors in rats, mice and humans***

The lengths of the polypeptide sequences, as well as the SEQ IDs of their respective sequences in the listing included, of the three types of subunit of the LSR receptors according to the invention, in rats, mice and humans, are indicated in Table 2a below.

Table 2a

| Polypeptide       | Rat               | M use              | Human              |
|-------------------|-------------------|--------------------|--------------------|
| $\alpha$ subunit  | 593 aa (SEQ ID 2) | 594 aa (SEQ ID 16) | 649 aa (SEQ ID 8)  |
| $\alpha'$ subunit | 574 aa (SEQ ID 4) | 575 aa (SEQ ID 17) | 630 aa (SEQ ID 10) |
| $\beta$ subunit   | 525 aa (SEQ ID 6) | 526 aa (SEQ ID 18) | 581 aa (SEQ ID 12) |

These polypeptide sequences were obtained from each of the three corresponding cDNA sequences, in rats, mice and humans, which will be described in detail later. These polypeptide sequences were obtained from each of the three corresponding cDNA sequences, in rats, mice and humans, which will be described in detail later. The nomenclature used to designate these cDNA sequences, which reflects their length in terms of nucleotides, as well as the SEQ IDs of their respective sequences in the listing included, are presented in Table 2b below.

Table 2b

| cDNAc             | Rat                       | Mouse                      | Human                      |
|-------------------|---------------------------|----------------------------|----------------------------|
| $\alpha$ subunit  | LSR-Rn-2097<br>(SEQ ID 1) | LSR-Mm-1886<br>(SEQ ID 13) | LSR-Hs-2062<br>(SEQ ID 7)  |
| $\alpha'$ subunit | LSR-Rn-2040<br>(SEQ ID 3) | LSR-Mm-1829<br>(SEQ ID 14) | LSR-Hs-2005<br>(SEQ ID 9)  |
| $\beta$ subunit   | LSR-Rn-1893<br>(SEQ ID 5) | LSR-Mm-1682<br>(SEQ ID 15) | LSR-Hs-1858<br>(SEQ ID 11) |

The protein sequence, corresponding to the  $\alpha$  subunit of the LSR receptor, deduced from the LSR-Hs-2062 sequence has a length of 649 amino acids. It is aligned with the protein sequences deduced from LSR-Mm-1886, 594 amino acids long, and from LSR-Rn-2097, 593 amino acids long (Figures 2A and 2B). The conservation of the protein sequences is very high (respectively 80.2% and 82.2% identity for 591 and 590 overlapping amino acids). The functional domains identified in the protein sequence of the rat LSR  $\alpha$  are found in the human LSR  $\alpha$  sequence as well as in that of the murine LSR  $\alpha$  (Figures 2A and 2B).

The human proteins corresponding to the LSR-Hs-2005 ( $\alpha'$ ) and LSR-Hs-1858 ( $\beta$ ) forms have a predicted size of 630 and 581 amino acids respectively. The rat proteins corresponding to the LSR-Rn-2040 ( $\alpha'$ ) and LSR-Rn-1893 ( $\beta$ ) forms have a predicted size

of 574 and 525 amino acids respectively. The mouse proteins corresponding to the LSR-Mm-1829 ( $\alpha'$ ) and LSR-Mm-1682 ( $\beta$ ) forms have a predicted size of 575 and 526 amino acids respectively. The alignment of the three human forms (Figures 3A and 3B), of the three forms described in rats (Figures 4A and 4B) and of the three forms described in mice (Figures 5A and 5B) shows that in the three species, all the protein forms conserve the NPGY signal for binding to clathrin and the RSRS motif. The human (product of LSR-Hs-2062), rat (product of LSR-Rn-2097) and mouse (product of LSR-Mm-1886) long forms ( $\alpha$ ) exhibit all the functional characteristics of LSR. The three short forms ( $\beta$ ) (respective products of LSR-Hs-1817, LSR-Rn-1893 and LSR-Mm-1682) lose the di-leucine domain for lysosomal addressing, the transmembrane domain and the cytokine receptor signature. It is also possible to observe that the three intermediate forms ( $\alpha'$ ) (product of LSR-Hs-2005, of LSR-Rn-2040 and LSR-Mn-1829) lose the di-leucin domain, the transmembrane domain and the domain corresponding to the cytokine receptor signature being conserved (Figures 3A, 3B, 4A, 4B, 5A and 5B). Figure 6 finally represents the proteins derived from the three cDNA forms identified in humans, and the motifs carried by each of them as a result of the splicing from which each is derived.

Table 3 below lists the different domains or motifs described above, as well as the positions of the start and end of the said domains or motifs, or of regions carrying the said domains or motifs, as indicated in the mouse SEQ ID 16 sequence.

20

Table 3

| Domain or motif                           | Position on SEQ ID 16 |     | Presence on : |           |         |
|-------------------------------------------|-----------------------|-----|---------------|-----------|---------|
|                                           | Start                 | End | $\alpha$      | $\alpha'$ | $\beta$ |
| Potential fatty acid binding site         | 23                    | 41  | X             | X         | X       |
| Potential clathrin binding site           | 104                   | 107 | X             | X         | X       |
| Signal for transport : LI<br>LL           | 183                   | 184 | X             | X         | X       |
|                                           | 195                   | 196 | X             |           |         |
| Transmembrane domain                      | 204                   | 213 | X             | X         |         |
| Potential cytokine receptor site          | 214                   | 249 | X             | X         |         |
| RSRS motif                                | 470                   | 473 | X             | X         | X       |
| Potential lipoprotein ligand binding site | 544                   | 558 | X             | X         | X       |

Table 4 below lists the different domains or motifs described above, as well as the positions of the start and end of the said domains or motifs, or of regions carrying the said domains or motifs, as indicated in the human SEQ ID 8 sequence.

25



Table 4

| Domain or motif                           | Position n SEQ ID 8 |     | Pr s nce on : |           |         |
|-------------------------------------------|---------------------|-----|---------------|-----------|---------|
|                                           | Start               | End | $\alpha$      | $\alpha'$ | $\beta$ |
| Potential fatty acid binding site         | 76                  | 94  | X             | X         | X       |
| Potential clathrin binding site           | 157                 | 160 | X             | X         | X       |
| Signal for transport : LI<br>LL           | 236                 | 237 | X             | X         | X       |
|                                           | 248                 | 249 | X             |           |         |
| Transmembrane domain                      | 257                 | 266 | X             | X         |         |
| Potential cytokine receptor site          | 267                 | 302 | X             | X         |         |
| RSRS motif                                | 527                 | 530 | X             | X         | X       |
| Potential lipoprotein ligand binding site | 601                 | 613 | X             | X         | X       |

In conclusion, the similarity in the sequence and structure of LSR which is  
5 described above makes it possible to extrapolate to humans the observations made in  
rats and/or mice.

Homologous polypeptide will be understood to mean the polypeptides exhibiting,  
compared with the natural polypeptide, certain modifications such as in particular a deletion,  
10 truncation, extension, chimeric fusion and/or mutation, in particular a point mutation. Among  
the homologous polypeptides, those in which the amino acid sequence exhibits at least  
80%, preferably 90%, homology with the amino acid sequences of the polypeptides accord-  
ing to the invention are preferred.

Equivalent polypeptide will be understood to mean a polypeptide having at least  
15 one of the activities of the LSR receptor, in particular the activity of the receptor for  
lipoproteins or chylomicrons, the activity of the receptor for cytokine, in particular leptin, or  
the activity of the receptor for the gC1q-R protein or one of its analogous proteins.  
Equivalent polypeptide will also be understood to mean any polypeptide resulting from the  
alternative splicing of the genomic nucleic sequence encoding the polypeptides according  
20 to the invention.

Variant polypeptide (or protein variant) will be understood to mean all the mutated  
polypeptides which may exist, in particular in human beings, and which correspond in  
particular to truncations, deletions and/or additions of amino acid residues, substitutions  
or mutations, in particular point mutations, as well as the artificial variant polypeptides  
25 which will nevertheless be called variant polypeptides. In the present case, the variant  
polypeptides will be in particular partly associated with the onset and with the

development of obesity or anorexia. They may also be associated with the onset and/or development of the risks or complications associated with obesity, in particular at the cardiovascular level, and/or of pathologies associated with abnormalities in the metabolism of cytokines.

5 Polypeptide fragment is understood to mean a polypeptide or a peptide encoded by a nucleic sequence comprising a minimum of 15 nucleotides or bases, preferably 20 bases or 30 bases. These fragments may comprise in particular a point mutation, compared with the normal polypeptide sequence, or may correspond to specific amino acid sequences of variant polypeptides, artificial or existing in humans, such as those linked to a polymorphism  
10 linked in particular to obesity or to the abovementioned pathologies.

Biologically active fragment will be understood to mean in particular a fragment of an amino acid sequence of a polypeptide:

- exhibiting at least one of the LSR receptor activities, in particular the lipoprotein receptor activity, or the cytokine, particularly leptin, receptor activity and/or cell  
15 signalling activity, and/or
- capable of being recognized by an antibody specific for the receptor according to the invention, and/or
- capable of being recognized by a compound capable, for example by neutralizing the binding of a ligand specific for the said receptor, of modulating the activity of the  
20 LSR receptor, and/or
- capable of modulating the addressing and/or cellular location of the LSR receptor, and/or
- more generally constituting a biologically active domain or motif of the LSR receptor.

Among the preferred biologically active fragments according to the invention, there are in particular :  
25

- the fragments comprising a clathrin binding site,
- the fragments comprising a fatty acid binding site, in particular a fatty acid binding site comprising a hydrophobic amino acid sequence separated into two parts by two contiguous prolines, which induce a hairpin structure whose arms consist of  
30 hydrophobic amino acids,
- the fragments comprising a hydrophobic region constituting a transmembrane domain,
- the fragments comprising a region capable of controlling endocytosis and intracellular addressing of the proteins in the peripheral membrane system, in particular a  
35 fragment comprising a site containing the LI and LL motifs,
- the fragments comprising a cytokine binding site, in particular a site including a cysteine-rich region,

- the fragments comprising a region defining a potential binding site for lipoprotein ligands such as ApoB and ApoE, in particular a region comprising a sequence of amino acids alternately charged + and -, and
- the fragments comprising an RSRS motif.

5           There are in particular among these fragments polypeptides as defined in Tables 1, 2 and 4, or any fragments of the nucleotides of SEQ ID 2, 8 or 16, comprising the said polypeptides, and any equivalent, homologous or variant fragments.

Other preferred fragments include antigenic peptides such as those having the sequences SEQ ID 29 and 30.

10

### ***Nucleotide sequences of the LSR receptor***

The subject of the present invention is isolated nucleic acid sequences, characterized in that they encode an LSR receptor or a polypeptide according to the invention.

15           More particularly, the invention relates to a purified nucleic acid, characterized in that it comprises at least 8, preferably at least 10 and more particularly at least 15 consecutive nucleotides of the polynucleotide of SEQ ID 19, as well as the nucleic acid sequences complementary to this nucleic acid.

20           The invention also relates to a purified nucleic acid, characterized in that it comprises at least 8, preferably at least 10 and more particularly at least 15 consecutive nucleotides of the polynucleotide of SEQ ID 41, as well as the nucleic acid sequences complementary to this nucleic acid.

25           The invention also relates to a purified nucleic acid encoding the human LSR receptor, characterized in that it comprises a nucleotide sequence corresponding to nucleotides 1898 to 21094, particularly to nucleotides 2001 to 20979, more particularly to nucleotides 2145 to 20979 of SEQ ID 19, as well as the nucleic acid sequences complementary to this nucleic acid.

30           The invention also relates to the nucleic acid sequences contained in the gene encoding the human LSR receptor, in particular each of the exons of the said gene or a combination of exons of the said gene, or alternatively a polynucleotide extending over a portion of one or more exons. Preferably, these nucleic acids encode one or more biologically active fragments of the human LSR receptor.

35           The invention also relates to a purified nucleic acid, characterized in that it comprises a nucleotide sequence corresponding to nucleotides 1 to 1897 of SEQ ID 19, as well as the nucleic acid sequences complementary to this nucleic acid.

The invention also relates to a purified nucleic acid, characterized in that it comprises a nucleotide sequence corresponding to nucleotides 21095 to 22976 of SEQ ID 19, as well as the nucleic acid sequences complementary to this nucleic acid.

5 The invention also relates to a purified nucleic acid, characterized in that it comprises a nucleotide sequence chosen from the group comprising the sequences of SEQ ID 7, SEQ ID 9 and SEQ ID 11, as well as the nucleic acid sequences complementary to this nucleic acid.

10 The invention also relates to a purified nucleic acid, characterized in that it comprises a nucleotide sequence chosen from the group comprising the sequences of SEQ ID 1, SEQ ID 3 and SEQ ID 5, as well as the nucleic acid sequences complementary to this nucleic acid.

15 The invention also relates to a purified nucleic acid, characterized in that it comprises a nucleotide sequence chosen from the group comprising the sequences of SEQ ID 13, SEQ ID 14 and SEQ ID 15, as well as the nucleic acid sequences complementary to this nucleic acid.

The invention also relates to a purified nucleic acid, characterized in that it comprises a nucleotide sequence corresponding to nucleotides 1898 to 2001 of SEQ ID 19 or preferably to nucleotides 1898 to 2144 of SEQ ID 19, as well as the nucleic acid sequences complementary to this nucleic acid.

20 The invention also relates to a purified nucleic acid, characterized in that it comprises a nucleotide sequence corresponding to nucleotides 20980 to 21094 of SEQ ID 19, as well as the nucleic acid sequences complementary to this nucleic acid.

25 Among the nucleic acids according to the invention, the nucleic acids having the nucleotide sequence chosen from the group comprising the sequences of SEQ ID 7, SEQ ID 9 and SEQ ID 11, the sequences of SEQ ID 1, SEQ ID 3 and SEQ ID 5, as well as the sequences of SEQ ID 13, SEQ ID 14 and SEQ ID 15, as well as their complementary sequences, are preferred.

30 Also forming part of the invention are the variant, mutated, equivalent or homologous sequences of the sequences according to the invention, as well as their fragments and the nucleic sequences capable of hybridizing specifically with the sequences according to the invention.

#### **Human genomic sequence**

35 The invention therefore relates to the genomic sequence of the human LSR receptor, preferably the sequence of SEQ ID 19, as well as their complementary sequences or one of their allelic variants, the mutated, equivalent or homologous sequences, or one of their fragments.

The gene for human LSR (SEQ ID 19) comprises 10 exons distributed over 21 094 bp. The size of the exons is respectively : 356, 345, 120, 57, 147, 174, 60, 132, 626 and 141 bp (Table 5).

5

Table 5

| EXON | START | END   | 5' SPLIC. | BL 5' | 3' SPLIC. | BL 3' |
|------|-------|-------|-----------|-------|-----------|-------|
| Ex1  | 1898  | 2253  | ---       | ---   | GTACGG    | + 2   |
| Ex2  | 3437  | 3781  | CAG       | + 1   | GTATGT    | + 1   |
| Ex3  | 12067 | 12186 | CAG       | + 2   | GTGAGT    | + 1   |
| Ex4  | 15047 | 15103 | CAG       | + 2   | GTACGG    | + 1   |
| Ex5  | 15668 | 15814 | CAG       | + 2   | GTAAGT    | + 1   |
| Ex6  | 19481 | 19654 | CAG       | + 2   | GTGAGG    | + 1   |
| Ex7  | 19801 | 19860 | CAG       | + 2   | GTGAGA    | + 1   |
| Ex8  | 19958 | 20089 | TAG       | + 2   | GTAAGC    | + 1   |
| Ex9  | 20231 | 20856 | CAG       | + 2   | GTGAGG    | 0     |
| Ex10 | 20946 | 21094 | CAG       | 0     | ---       |       |

The EXON column indicates the exons numbered from 1 to 10 in the 5'-3' order of their position on the genomic sequence. The START and END columns indicate respectively the position of the first and of the last nucleotide of the exon considered. The sequences of the splicing site bordering the exon in 5' and 3' are indicated in the 5'SPLIC. and 3'SPLIC columns. The BL 5' and BL 3' columns indicate the number of bases in 5' and in 3', respectively, of an exon which will be used in the reading frame of the messenger only after splicing. For example : as exon 7 has a free base in 3', this exon can be joined to the 5' end of exon 8 which has 2 free bases in 5'. The combination 1 base + 2 bases constitutes the codon which was destroyed by the intron in the genomic sequence. Exon 7 may be joined by its 3' end to any exon having two free bases in 5'; if the new codon created does not correspond to a stop codon, the open reading frame will be conserved.

Exons 1 and 2 as well as 9 and 10 are necessarily co-spliced, thus forming a 5' block corresponding to exons 1 and 2 and a 3' block corresponding to exons 9 and 10. The functional minimal messenger, corresponding to the product of these four exons, could therefore have a size of about 1 331 bp. For the other exons, all the possible combinations make it possible to conserve the open reading frame.



The size of the noncoding exons in 5' could not be determined with precision. Indeed, the rat 5' UTR sequences are too divergent from those of humans to finalize the analysis of these sequences and to identify the real 5' end of the human LSR cDNA. This can be carried out by isolating the 5' end of the human LSR messengers by the 5' end capture methods developed by the inventors (WO 96/34981). The polyadenylation site described below is the only one which is present before the USF2 gene, situated in 3' of the human LSR gene. It is therefore very likely that the untranslated 3' region of this gene is very short (of an estimated size of about 100 bp). All the sizes given in relation to the human LSR cDNA molecules will therefore have to be adjusted according to the size of the untranslated 5' end. The human cDNA sequence obtained taking into account all the exons deduced from the analysis of the genomic sequence have a size of 2 158 bp. This form could correspond to the LSR-Rn-2097 form.

The location of some of the signals for expression of the nucleotide sequence of SEQ ID 19 is presented in Table 6 which follows.

Table 6

| Signal             | Start | End   |
|--------------------|-------|-------|
| preferred ATG      | 2145  | 2147  |
| other possible ATG | 2001  | 2003  |
| STOP               | 20977 | 20979 |
| POLY Ad            | 21065 | 21070 |

The characteristic elements of the messenger RNA molecule are described in the Signal column : Initiation of translation (ATG), termination of translation (STOP) and polyadenylation signal (POLY Ad). The Start and End columns indicate the position as nucleotide for the start and end of these signals on the genomic sequence SEQ ID 19. An ATG signal for initiation of translation is preferred to another because it provides an environment which is more suitable for initiation.

The present invention also relates to the purified nucleic acid sequences encoding one or more elements for regulating the expression of the human LSR gene. Also included in the invention are the nucleic acid sequences of the promoter and/or regulator of the gene encoding the receptor according to the invention, or one of their allelic variants, the mutated, equivalent or homologous sequences, or one of their fragments.

The invention relates more particularly to a purified nucleic acid situated in 5' of the coding sequence of the LSR gene. This nucleic acid is characterized in that it

comprises a nucleotide sequence corresponding to nucleotides 1 to 1897 of SEQ ID 19, as well as the nucleic acid sequences complementary to this nucleic acid. Shorter fragments of this nucleic acid may also be used as promoters for expression of the LSR gene or of any other sequence encoding a heterologous polypeptide.

5           The invention also relates to a purified nucleic acid situated in 3' of the transcribed sequence of the LSR gene. This nucleic acid is characterized in that it comprises a nucleotide sequence corresponding to nucleotides 21095 to 22976 of SEQ ID 19, as well as the nucleic acid sequences complementary to this nucleic acid. Shorter fragments of this nucleic acid can also be used as elements regulating the expression of genes.

10           Finally, the invention also relates to the genomic sequence of the human LSR receptor, preferably the sequence of SEQ ID 41, as well as their complementary sequences, or one or their allelic variants, the mutated, equivalent or homologous sequences, or one of their fragments.

#### **Comparison of the genomic organizations in humans, rats and mice**

15           It is advantageous to note that a syntheny (conservation of the organization of certain chromosomal regions between species) between the mouse chromosome 7 region where the Lisch7 gene is located, in the immediate vicinity of USF2, and the human chromosome 19 region 19q13, carrying LSR, is well described. The organization of the two Lisch7/LSR and USF2 genes is conserved between species. Likewise, Apo E, 20 which is of a more centromeric location relative to these genes, exists both in mice and in humans. It is remarkable that the LSR lipoprotein receptor and one of their ligands ApoE are located in the same chromosomal region. Indeed, the receptor and the ligand are frequently co-regulated. Such a situation would make it possible to envisage that the phenomena observed in mice are applicable to humans.

#### **25 Human, rat and mouse cDNA sequences**

          The invention relates, in addition, to 3 different cDNAs derived from the LSR receptor gene by alternative splicing. These 3 cDNAs have been identified in humans, rats and mice (Table 2b). They encode the three types of LSR receptor subunits,  $\alpha$  (long),  $\alpha'$  (intermediate) and  $\beta$  (short). The longest cDNA contains the totality of the 10 exons of 30 the gene. The intermediate cDNA does not comprise exon 4. Finally, the shortest cDNA does not contain exons 4 and 5.

          The human LSR-Hs-2062 cDNA nucleotide sequence, encoding the  $\alpha$  subunit of the LSR receptor, and the rat LSR-Rn-2097 cDNA nucleotide sequence are 78.6% identical over 1 955 bp which overlap. These figures are respectively 78.8% and 1 851 bp 35 when the murine LSR-Mm-1886 sequence (long form) is aligned with the human sequence. This reflects a very high conservation of the nucleic sequences between

species. The highest divergence levels are observed in the untranslated 5' end (when the sequence is available), in the first coding exon and in the untranslated 3' end (Figures 7 A, 7B, 7C, 7D and 7E).

The invention therefore also relates to a purified nucleic acid, characterized in that it is chosen from the group comprising the sequences of SEQ ID 7, SEQ ID 9 and SEQ ID 11, the sequences SEQ ID 1, SEQ ID 3 and SEQ ID 5, and the sequences SEQ ID 13, SEQ ID 14 and SEQ ID 15, as well as the nucleic acid sequences complementary to this nucleic acid, or one of their allelic variants, the mutated, equivalent or homologous sequences, or one of their fragments.

The nucleic acids constituting the coding frames of the abovementioned nucleic acids, between the codons for initiation and for termination of translation, also form part of the invention.

The nucleic acids encoding the polypeptide fragments according to the invention are also part of the invention. It will be particularly noted that the nucleic acids encode the fragments described in Tables 1, 3 and 4.

Thus, Table 7 describes the position of such nucleic acid fragments on the human sequence of SEQ ID 7.

Table 7

| Domain or motif                           | Position on the cDNA of SEQ 7 |      |
|-------------------------------------------|-------------------------------|------|
|                                           | Start                         | End  |
| Potential fatty acid binding site         | 329                           | 385  |
| Potential clathrin binding site           | 572                           | 583  |
| Signal for transport : LI                 | 809                           | 814  |
| LL                                        | 845                           | 850  |
| Transmembrane domain                      | 872                           | 901  |
| Potential cytokine receptor site          | 902                           | 1009 |
| RSRS motif                                | 1682                          | 1693 |
| Potential lipoprotein ligand binding site | 1904                          | 1942 |

The invention also relates to a purified nucleic acid corresponding to the sequence of the 5'UTR of the cDNAs encoding the human LSR receptor. This nucleic acid is characterized in that it comprises a nucleotide sequence corresponding to nucleotides 1898 to 2001 of SEQ ID 19 or preferably to nucleotides 1898 to 2144 of SEQ ID 19, as

well as the nucleic acid sequences complementary to this nucleic acid. Shorter fragments of this nucleic acid can also be used.

The invention also relates to a purified nucleic acid corresponding to the sequence of the 3'UTR of the cDNAs encoding the LSR receptor. This nucleic acid is characterized in that it comprises a nucleotide sequence corresponding to nucleotides 20980 to 21094 of SEQ ID 19, as well as the nucleic acid sequences complementary to this nucleic acid. Shorter fragments of this nucleic acid can also be used.

The invention also relates to the purified nucleic acids corresponding respectively to the sequences of the 5'UTR or of the 3'UTR of the cDNAs encoding the rat or mouse LSR receptor. Shorter fragments of this nucleic acid can also be used.

The 5'UTR and 3'UTR may contain elements ("responsive elements" and "enhancers") which are involved in the regulation of transcription and of translation. These regions have in particular a role in the stability of the mRNAs. Furthermore, the 5'UTR comprises the Shine-Delgarno motif which is essential for the translation of the mRNA.

Nucleic acid, nucleic sequence or nucleic acid sequence are understood to mean an isolated natural, or a synthetic, DNA and/or RNA fragment comprising, or otherwise, non-natural nucleotides, designating a precise succession of nucleotides, modified or otherwise, allowing a fragment, a segment or a region of a nucleic acid to be defined.

Equivalent nucleic sequences are understood to mean nucleic sequences encoding the polypeptides according to the invention taking into account the degeneracy of the genetic code, the complementary DNA sequences and the corresponding RNA sequences, as well as the nucleic sequences encoding the equivalent polypeptides.

Homologous nucleic sequences are understood to mean the nucleic sequences encoding the homologous polypeptides and/or the nucleic sequences exhibiting a level of homology of at least 80%, preferably 90%. According to the invention, the homology is only of the statistical type, which means that the sequences have a minimum of 80%, preferably 90%, of nucleotides in common. They are preferably sequences capable of hybridizing specifically with a sequence of the invention. Preferably, the specific hybridization conditions will be like those found in the examples, or such that they ensure at least 95% homology.

The length of these nucleic sequences for hybridization can vary from 8, 10, 15, 20 or 30 to 200 nucléotides, particularly from 20 to 50 nucleotides, more particularly from 20 to 30 nucleotides.

Allele or allelic variant will be understood to mean the natural mutated sequences corresponding to polymorphisms present in human beings and, in particular, to polymorphisms which can lead to the onset and/or to the development of obesity or of anorexia. These polymorphisms can also lead to the onset and/or to the development of

risks or complications associated with obesity, in particular at the cardiovascular level, and/or of pathologies associated with abnormalities in the metabolism of cytokines.

Mutated nucleic sequences are understood to mean the nucleic sequences comprising at least one point mutation compared with the normal sequence.

5 While the sequences according to the invention are in general normal sequences, they are also mutated sequences since they comprise at least one point mutation and preferably at most 10% of mutations compared with the normal sequence.

10 Preferably, the present invention relates to mutated nucleic sequences in which the point mutations are not silent, that is to say that they lead to a modification of the amino acid encoded in relation to the normal sequence. Still more preferably, these mutations affect amino acids which structure the LSR complex and/or receptor or the corresponding domains and fragments thereof. These mutations may also affect amino acids carried by the regions corresponding to the receptor sites, for lipoproteins or cytokines, in particular leptin, or to sites for binding of cofactors, in particular or free fatty acids, or alternatively to  
15 phosphorylation sites. These mutations may also affect the sequences involved in the transport, addressing and membrane anchorage of LSR.

In general, the present invention relates to the normal LSR polypeptides, the mutated LSR polypeptides as well as fragments thereof and to the corresponding DNA and RNA sequences, the LSR polypeptides designating polypeptides of the receptor according  
20 to the invention.

According to the invention, the fragments of nucleic sequences may in particular encode domains of receptors and polypeptides possessing a function or a biological activity as defined above, contain domains or regions situated upstream or downstream of the coding sequence and containing elements for regulating the expression of the LSR  
25 gene or alternatively possessing a sequence allowing their use as a probe or as a primer in methods of detection, identification or amplification of nucleic sequences. These fragments preferably have a minimum size of 8, of 10 bases, and fragments of 20 bases, and preferably of 30 bases, will be preferred.

Among the nucleic fragments which may be of interest, in particular for diagnosis,  
30 there should be mentioned, for example, the genomic intron sequences of the gene for the LSR complex, such as in particular the joining sequences between the introns and the exons, normal or mutated.

The nucleic acid sequences which can be used as sense or antisense oligonucleotides, characterized in that their sequences are chosen from the sequences  
35 according to the invention, also form part of the invention.

Among the nucleic acid fragments of interest, there should thus be mentioned, in particular the antisense oligonucleotides, that is to say whose structure ensures, by



hybridization with the target sequence, inhibition of the expression of the corresponding product. There should also be mentioned the sense oligonucleotides which, by interaction with the proteins involved in the regulation of the expression of the corresponding product, will induce either inhibition, or activation of this expression.

5           The sequences carrying mutations which may be involved in the promoter and/or regulatory sequences of the genes for the LSR complex, which may have effects on the expression of the corresponding proteins, in particular on their level of expression, also form part of the preceding sequences according to the invention.

10           The nucleic sequences which can be used as primer or probe, characterized in that their nucleic sequence is a sequence of the invention, also form part of the invention.

          The present invention relates to all the primers which may be deduced from the nucleotide sequences of the invention and which may make it possible to detect the said nucleotide sequences of the invention, in particular the mutated sequences, using in particular a method of amplification such as the PCR method, or a related method.

15           The present invention relates to all the probes which may be deduced from the nucleotide sequences of the invention, in particular sequences capable of hybridizing with them, and which may make it possible to detect the said nucleotide sequences of the invention, in particular to discriminate between the normal sequences and the mutated sequences.

20           The invention also relates to the use of a nucleic acid sequence according to the invention as a probe or a primer for the detection and/or the amplification of a nucleic acid sequence according to the invention.

          All the probes and primers according to the invention may be labelled by methods well known to persons skilled in the art, in order to obtain a detectable and/or quantifiable  
25           signal.

          The present invention also relates to the nucleotide sequences which may comprise non-natural nucleotides, in particular sulphur-containing nucleotides, for example, or nucleotides of  $\alpha$  or  $\beta$  structure.

          The present invention relates, of course, to both the DNA and RNA sequences, as  
30           well as the sequences which hybridize with them, as well as the corresponding double-stranded DNAs.

          In the text which follows, the preceding DNA sequences will be called genes for the LSR complex, whether they are normal or pathologic sequences.

          It should be understood that the present invention does not relate to the genomic  
35           nucleotide sequences in their natural chromosomal environment, that is to say in the natural state. They are sequences which have been isolated, that is to say that they have been

collected directly or indirectly, for example by copying (cDNA), their environment having been at least partially modified.

Thus, this may also be both cDNA and genomic DNA, partially modified or carried by sequences which are at least partially different from the sequences carrying them naturally.

5        These sequences may also be termed non-natural.

The invention also comprises methods for screening cDNA and genomic DNA libraries, for the cloning of the isolated cDNAs, and/or the genes coding for the receptor according to the invention, and for their promoters and/or regulators, characterized in that they use a nucleic sequence according to the invention. Among these methods, there may  
10       be mentioned in particular:

- the screening of cDNA libraries and the cloning of the isolated cDNAs (Sambrook et al., 1989; Suggs et al., 1981; Woo et al., 1979), with the aid of the nucleic sequences according to the invention,

- the screening of 5' end tag libraries (WO 96/34981) for nucleic sequences  
15       according to the invention, and thus the isolation of tags allowing the cloning of complete cDNAs and the corresponding promoters from genomic DNA libraries,

- the screening of genomic libraries, for example of BACs, (Chumakov et al., 1992; Chumakov et al., 1995) and, optionally, a genetic analysis by FISH (Cherif et al., 1990) with the aid of sequences according to the invention, allowing isolation and chromosomal  
20       location, and then the complete sequencing of the genes encoding the LSR receptor.

Also included in the invention is a sequence, in particular a genomic sequence encoding a receptor or a polypeptide according to the invention, or a nucleic acid sequence of a promoter and/or regulator of a gene encoding a receptor or a polypeptide according to the invention, or one of their allelic variants, a mutated, equivalent or homologous  
25       sequence, or one of their fragments, characterized in that it is capable of being obtained by one of the preceding methods according to the invention, or a sequence capable of hybridizing with the said sequences.

### ***Vectors, host cells and transgenic animals***

30       The invention also comprises the cloning and/or expression vectors containing a nucleic acid sequence according to the invention.

The vectors according to the invention, characterized in that they comprise the elements allowing the expression and/or the secretion of the said sequences in a host cell, also form part of the invention.

The vectors characterized in that they comprise a promoter and/or regulator sequence according to the invention, or a sequence for cellular addressing according to the invention, or one of their fragments, also form part of the invention.

5 The said vectors will preferably comprise a promoter, signals for initiation and termination of translation, as well as appropriate regions for regulation of transcription. They must be able to be stably maintained in the cell and may optionally possess particular signals specifying the secretion of the translated protein.

10 These different control signals are chosen according to the cellular host used. To this end, the nucleic acid sequences according to the invention may be inserted into autonomously replicating vectors inside the chosen host, or integrative vectors of the chosen host.

15 Among the autonomously replicating systems, there will be preferably used according to the host cell, systems of the plasmid or viral type, it being possible for the viral vectors to be in particular adenoviruses (Perricaudet et al., 1992), retroviruses, poxviruses or herpesviruses (Epstein et al., 1992). Persons skilled in the art know the technologies which can be used for each of these systems.

When the integration of the sequence into the chromosomes of the host cell is desired, it will be possible to use, for example, systems of the plasmid or viral type; such viruses will be, for example, retroviruses (Temin, 1986), or AAVs (Carter, 1993).

20 Such vectors will be prepared according to the methods commonly used by persons skilled in the art, and the clones resulting therefrom may be introduced into an appropriate host by standard methods such as, for example, lipofection, electroporation or heat shock.

25 The invention comprises, in addition, the host cells, in particular eukaryotic and prokaryotic cells, transformed by the vectors according to the invention, as well as transgenic animals, except humans, comprising one of the said transformed cells according to the invention.

30 Among the cells which can be used for these purposes, there may of course be mentioned bacterial cells (Olins and Lee, 1993), but also yeast cells (Buckholz, 1993), as well as animal cells, in particular mammalian cell cultures (Edwards and Aruffo, 1993), and in particular Chinese hamster ovary cells (CHO), but also insect cells in which it is possible to use methods using baculoviruses, for example (Luckow, 1993). A preferred cellular host for the expression of the proteins of the invention consists of the CHO cells.

35 Among the mammals according to the invention, there will be preferred animals such as mice, rats or rabbits, expressing a polypeptide according to the invention, the phenotype corresponding to the normal or variant LSR receptor, in particular mutated of human origin.

Among the animal models more particularly of interest here, there are in particular:

- transgenic animals exhibiting a deficiency in one of the components of LSR. They are obtained by homologous recombination on embryonic stem cells, transfer of these stem cells to embryos, selection of the chimeras affected at the level of the reproductive lines, and growth of the said chimeras;
- 5 - transgenic mice overexpressing one or more of the genes for the LSR complex of murine and/or human origin. The mice are obtained by transfection of multiple copies of the genes for the LSR complex under the control of a strong promoter of an ubiquitous nature, or selective for a type of tissue, preferably the liver;
- 10 - transgenic animals (preferably mice) made deficient in one or more of the genes for the LSR complex, by inactivation with the aid of the LOXP/CRE recombinase system (Rohlmann et al., 1996) or any other system for inactivating the expression of a gene at a precise age of the animal;
- animals (preferably rats, rabbits, mice) overexpressing one or more of the genes for the LSR complex, after viral transcription or gene therapy;
- 15 - crossings of animals deficient in LSR (in particular mice) with animals deficient in, or overexpressing:
  - > the LDL receptor (Herz et al., 1995; Ishibashi et al., 1993)
  - > hepatic lipase (Homanics et al., 1995; Kobayashi et al., 1996)
  - > apoprotein B (Purcellhuynh et al., 1995; Fan et al., 1995)
  - 20 > apoprotein E (Plump et al., 1992; Zhang et al., 1992; Huang et al., 1996)
  - > apoCIII (Aalto-Setälä et al., 1992; Ito et al., 1990; Maeda et al., 1994).

The production of transgenic animals, and the viral or nonviral transfections will be preferably carried out on the following rat and mouse lines:

- Zucker rat (fa/fa) (Iida et al., 1996)
- 25 - AKR/J mouse (West et al., 1992)
- ob/ob mouse (Zhang et al., 1994)
- ob<sup>2j</sup>/ob<sup>2j</sup> mouse (ibid)
- tubby mouse (Kleyn et al., 1996; Nobben-Trauth et al., 1996)
- fat/fat (Heldin et al., 1995)
- 30 - agouti mouse (Lu et al., 1994; Manne et al., 1995)
- db/db mouse (Chen et al., 1996).

The cells and mammals according to the invention can be used in a method for the production of a polypeptide according to the invention, as described below, and can also serve as a model for analysis and screening.

- 35 The transformed cells or mammals as described above can also be used as models so as to study the interactions between the polypeptides of the LSR complex, between these and their partners, chemical or protein compounds, which are involved directly or

indirectly in the activities of the receptor for lipoproteins or the receptor for cytokines, and in particular for leptin, and in order to study the different mechanisms and interactions called into play according to the type of activity, or according to whether a normal complex is involved, or a complex in which at least one of the domains is a variant.

5 In particular, they may be used for the selection of products which interact with the LSR complex, or one of its normal or variant domains, as cofactor or as inhibitor, in particular a competitive inhibitor, or alternatively having an agonist or antagonist activity on the conformational changes in the LSR complex. Preferably, the said transformed cells will be used as a model allowing, in particular, the selection of products which make it possible  
10 to combat obesity or the pathologies mentioned above. The said cells may also serve for the detection of the potential risks posed by certain compounds.

### ***Production of polypeptides derived from the LSR receptor***

The invention also relates to the synthesis of synthetic or recombinant  
15 polypeptides of the invention, in particular by chemical synthesis or by the use of a nucleic acid sequence according to the invention.

The polypeptides according to the present invention can be obtained by chemical synthesis using any of the numerous known peptide syntheses, for example the techniques using solid phases or techniques using partial solid phases, by condensation  
20 of fragments or by a conventional synthesis in solution.

When the compounds according to the present invention are synthesized by the solid phase method, the C-terminal amino acid is bound to an inert solid support and comprises groups protecting its amino group at the alpha position (and if necessary, protection on its functional side groups).

25 At the end of this step, the group protecting the amino-terminal group is removed and the second amino acid, it too comprising the necessary protection, is bound.

The N-terminal protecting groups are removed after each amino acid has been bound; on the other hand, the protection is of course maintained on the side chains. When the polypeptide chain is complete, the peptide is cleaved from its support and the  
30 side protecting groups are removed.

The solid phase synthesis technique is well known to a person skilled in the art. See in particular Stewart et al. (1984) and Bodansky (1984).

The polypeptides obtained by chemical synthesis and which may comprise corresponding non-natural amino acids are also included in the invention.

35 The method for the production of a polypeptide of the invention in recombinant form is itself included in the present invention, and is characterized in that the transformed



cells, in particular the cells or mammals of the present invention, are cultured under conditions allowing the expression of a recombinant polypeptide encoded by a nucleic acid sequence according to the invention, and in that the said recombinant polypeptide is recovered.

5           Also forming part of the invention is a method for the production of a heterologous polypeptide, characterized in that it uses a vector or a host cell containing at least one of the promoter and/or regulatory sequences according to the invention, or at least one of the sequences for cellular addressing according to the invention, or one of their fragments.

10           The recombinant polypeptides, characterized in that they are capable of being obtained by the said method of production, also form part of the invention.

          The recombinant polypeptides obtained as indicated above may be both in glycosylated and nonglycosylated form and may or may not have the natural tertiary structure.

15           These polypeptides may be produced from the nucleic acid sequences defined above, according to techniques for the production of recombinant polypeptides known to persons skilled in the art. In this case, the nucleic acid sequence used is placed under the control of signals allowing its expression in a cellular host.

          An effective system of production of a recombinant polypeptide requires having a  
20           vector and a host cell according to the invention.

          These cells may be obtained by introducing into the host cells a nucleotide sequence inserted into a vector as defined above, and then culturing the said cells under conditions allowing the replication and/or expression of the transfected nucleotide sequence.

25           The methods for the purification of a recombinant polypeptide which are used are known to persons skilled in the art. The recombinant polypeptide may be purified from cell lysates and extracts, from the culture medium supernatant, by methods used individually or in combination, such as fractionation, chromatographic methods, immunoaffinity techniques with the aid of specific mono- or polyclonal antibodies, and the like.

30           A preferred variant consists in producing a recombinant polypeptide fused with a "carrier" protein (chimeric protein). The advantage of this system is that it allows a stabilization and a reduction in proteolysis of the recombinant product, an increase in solubility during *in vitro* renaturation and/or simplification of the purification when the fusion partner has affinity for a specific ligand.

## ***Antibodies***

The mono- or polyclonal antibodies or fragments thereof, chimeric or immuno-conjugated antibodies, characterized in that they are capable of specifically recognizing a polypeptide or receptor according to the invention, also form part of the invention.

5           Specific polyclonal antibodies may be obtained from a serum of an animal immunized against, for example:

- the LSR receptor purified from membranes of cells carrying the said LSR receptor, by methods well known to persons skilled in the art such as affinity chromatography using, for example, recombinant leptin as specific ligand, or
- 10       - a polypeptide according to the invention, in particular produced by genetic recombination or by peptide synthesis, according to the customary procedures, from a nucleic acid sequence according to the invention.

There may be noted in particular the advantage of antibodies specifically recognizing certain polypeptides, variants or fragments, which are in particular biologically  
15       active, according to the invention.

The specific monoclonal antibodies may be obtained according to the conventional hybridoma culture method described by Kohler and Milstein, 1975.

The antibodies according to the invention are, for example, chimeric antibodies, humanized antibodies, Fab or F(ab')<sub>2</sub> fragments. They may also be in the form of  
20       immunoconjugates or of labelled antibodies so as to obtain a detectable and/or quantifiable signal.

The invention also relates to methods for the detection and/or purification of a polypeptide according to the invention, characterized in that they use an antibody according to the invention.

25           The invention comprises, in addition, purified polypeptides, characterized in that they are obtained by a method according to the invention.

Moreover, in addition to their use for the purification of polypeptides, the antibodies of the invention, in particular the monoclonal antibodies, may also be used for the detection of these polypeptides in a biological sample.

30           They thus constitute a means for the immunocytochemical or immunohistochemical analysis of the expression of the polypeptide of the LSR receptor on specific tissue sections, for example by immunofluorescence, gold labelling, enzymatic immunoconjugates.

They make it possible in particular to detect abnormal expression of these polypeptides in the biological tissues or samples, which makes them useful for the detection  
35       of abnormal expression of the LSR receptor or for monitoring the progress of the method of prevention or treatment.

More generally, the antibodies of the invention may be advantageously used in any situation where the expression of a polypeptide of the LSR receptor, normal or mutated, needs to be observed.

## 5 ***Detection of allelic variability and diagnosis***

Also forming part of the invention are the methods for the determination of an allelic variability, a mutation, a deletion, a loss of heterozygosity or a genetic abnormality, characterized in that they use a nucleic acid sequence or an antibody according to the invention.

10        These methods relate to, for example, the methods for the diagnosis of predisposition to obesity, to the associated risks, or to pathologies associated with abnormalities in the metabolism of cytokines, by determining, in a biological sample from the patient, the presence of mutations in at least one of the sequences described above. The nucleic acid sequences analysed may be either the genomic DNA, the cDNA or the  
15        mRNA.

It will also be possible to use nucleic acids or antibodies based on the present invention in order to allow a positive and differential diagnosis in a patient taken in isolation. The nucleic sequences will be preferably used for a pre-symptomatic diagnosis in an at risk subject, in particular with a familial history. It is also possible to envisage an  
20        ante-natal diagnosis.

In addition, the detection of a specific mutation may allow an evolutive diagnosis, in particular as regards the intensity of the pathology or the probable period of its appearance.

The methods allowing the detection of a mutation in a gene compared with the natural gene are, of course, highly numerous. They can essentially be divided into two large  
25        categories. The first type of method is that in which the presence of a mutation is detected by comparing the mutated sequence with the corresponding nonmutated natural sequence, and the second type is that in which the presence of the mutation is detected indirectly, for example by evidence of the mismatches due to the presence of the mutation.

These methods can use the probes and primers of the present invention which are  
30        described. They are generally purified nucleic sequences for hybridization comprising at least 8 nucleotides, characterized in that they can hybridize specifically with a nucleic sequence chosen from the group comprising SEQ ID 1, SEQ ID 3, SEQ ID 5, SEQ ID 7, SEQ ID 9, SEQ ID 11, SEQ ID 13, SEQ ID 14, SEQ ID 15, SEQ ID 19 and SEQ ID 41. Preferably, the specific hybridization conditions are like those defined in the examples, or  
35        such that they ensure at least 95% homology. The length of these nucleic sequences for

hybridization can vary from 8, 10, 15, 20 or 30 to 200 nucleotides, particularly from 20 to 50 nucleotides, more particularly from 20 to 30 nucleotides.

Among the methods for the determination of an allelic variability, a mutation, a deletion, a loss of heterozygosity or a genetic abnormality, the methods comprising at least one stage for the so-called PCR (polymerase chain reaction) or PCR-like amplification of the target sequence according to the invention likely to exhibit an abnormality with the aid of a pair of primers of nucleotide sequences according to the invention are preferred. The amplified products may be treated with the aid of an appropriate restriction enzyme before carrying out the detection or assay of the targeted product.

PCR-like will be understood to mean all methods using direct or indirect reproductions of nucleic acid sequences, or alternatively in which the labelling systems have been amplified, these techniques are of course known, in general they involve the amplification of DNA by a polymerase; when the original sample is an RNA, it is advisable to carry out a reverse transcription beforehand. There are currently a great number of methods allowing this amplification, for example the so-called NASBA "Nucleic Acid Sequence Based Amplification" (Compton 1991), TAS "Transcription based Amplification System" (Guatelli et al., 1990), LCR "Ligase Chain Reaction" (Landegren et al., 1988), "Endo Run Amplification" (ERA), "Cycling Probe Reaction" (CPR), and SDA "Strand Displacement Amplification" (Walker et al., 1992), methods well known to persons skilled in the art.

The invention comprises, in addition, methods for the diagnosis of pathologies and/or pathogeneses correlated with abnormal expression of a polypeptide and/or a receptor according to the invention, characterized in that an antibody according to the invention is brought into contact with the biological material to be tested, under conditions allowing the possible formation of specific immunological complexes between the said polypeptide and the said antibody, and in that the immunological complexes possibly formed are detected.

Mutations in one or more genes of the LSR complex may be responsible for various modifications of their product(s), which modifications can be used for a diagnostic approach. Indeed, modifications of antigenicity can allow the development of specific antibodies. The discrimination between the various conformations of LSR can be achieved by these methods. All these modifications may be used in a diagnostic approach by virtue of several well-known methods based on the use of mono- or polyclonal antibodies recognizing the normal polypeptide or mutated variants, such as for example using RIA or ELISA.

These diagnostic methods also relate to the methods of diagnosis by imaging *in vivo* or *ex vivo* using the monoclonal or polyclonal antibodies according to the invention, particularly those labelled and corresponding to all or part of the mutated polypeptides

(imaging with the aid of antibodies coupled to a molecule which is detectable in PET-scan type imaging, for example).

### ***Screening of compounds of interest***

5 Also included in the invention are the methods for selecting the chemical or biochemical compound capable of interacting, directly or indirectly, with the receptor according to the invention, and/or allowing the expression or the activity of the said receptor to be modulated, characterized in that they use a receptor, a nucleic acid, a polypeptide, a vector, a cell or a mammal according to the invention.

10

### ***Screening of compounds modifying the activity of the LSR receptor***

The invention relates to a method for screening compounds modifying the activity of the LSR receptor, consisting in measuring the effect of candidate compounds on  
15 various parameters reflecting, directly or indirectly, taken independently or in combination, an LSR receptor activity.

For the screening of compounds capable of modulating the LSR activity for lipoprotein clearance, the preferred principal effect is the effect of the compound on the activity of binding, internalization and degradation of the lipoproteins by the LSR receptor.

20 This effect can be analysed in the absence or in the presence of free fatty acids, or of any other agent known to induce or to inhibit the activity of LSR on the clearance of lipoproteins, or in the absence or the presence of leptin, or of any other agent capable of inducing or of inhibiting the LSR function of cytokine clearance. It can, in addition, be measured in the absence or in the presence of agents capable of promoting or reducing  
25 the lipase activities, either intracellular or extracellular, as well as in the presence or in the absence of alternative known routes of degradation of lipoproteins.

Various indirect parameters can also be measured, including the following :

- the change in weight induced by the administration of the compound
- the food intake induced by the administration of the compound
- 30 - the postprandial lipemic response induced by the administration of the compound, before, during or after ingestion of a meal, for example high in fat.

The selection of compounds capable of influencing the plasma triglyceride concentrations, and/or the binding, internalization and hepatic degradation of lipoproteins or particles high in triglycerides, will be preferred.

35 For the screening of compounds capable of modulating the LSR activity of clearance of cytokines, in particular of leptin, the preferred principal effect is the effect of



the compound on the activity of binding, internalization and hepatic degradation of cytokines by the LSR receptor, in the absence or in the presence of free fatty acids.

The measurement of the binding, internalization and/or degradation of lipids or of cytokines can be carried out, for example, on hepatocytes or fibroblasts in culture, or on  
 5 any other cell expressing the LSR receptor at its surface. The cells will be preferably cells expressing a recombinant LSR receptor, more particularly cells expressing a recombinant LSR receptor and whose endogenous LSR receptor would be inactivated or absent. These cells may or may not express the LDL receptor.

The screening of compounds modulating the LSR activity preferably uses cells or  
 10 model animals according to the invention, in particular mice, rats or humans, more particularly those described above and in the examples which follow.

### ***Screening of compounds modifying the expression of the LSR receptor***

15 Screening may be used to test compounds capable of modifying the level and/or the specificity of expression of the LSR receptor either by binding competitively to the sites for binding of transcription factors situated in the LSR promoter or by binding directly to the transcription factors.

The level of expression of the LSR receptor and its location can be analysed by  
 20 hybridization in solution with large probes as indicated in Patent PCT WO 97/05277, the teaching of this document being incorporated by reference. Briefly, a cDNA or the genomic DNA for the LSR receptor or alternatively a fragment thereof is inserted at a cloning site situated directly downstream of a bacteriophage (T3, T7 or SP6) RNA polymerase promoter in order to produce an antisense RNA. Preferably, the insert  
 25 comprises at least 100 consecutive nucleotides of the genomic sequence of the LSR receptor or of one of the cDNAs of the present invention, more particularly one or more of the cDNAs of SEQ ID 9, SEQ ID 11 or SEQ ID 13. The plasmid is linearized and transcribed in the presence of ribonucleotides comprising modified ribonucleotides such as Biotin-UTP and Digoxigenin-UTP. An excess of this labelled RNA is hybridized in  
 30 solution with the mRNAs isolated from cells or from tissues of interest. The hybridizations are carried out under stringent conditions (40-50°C for 16 h in a solution containing 80% formamide and 0.4 M NaCl, pH 7-8). The non-hybridized probe is eliminated by digestion with ribonucleases specific for single-stranded RNAs (CL3, T1, PhyM, U2 or A RNases). The presence of modified nucleotides biotin-UTP allows the capture of the hybrids on  
 35 microtitre plates carrying streptavidine. The presence of the DIG modification allows the

detection and quantification of the hybrids by ELISA using anti-DIG antibodies coupled to alkaline phosphatase.

A quantitative analysis of the expression of the gene for the LSR receptor can also be carried out using DNA templates, the term DNA templates designating a one-dimensional, two-dimensional or multi-dimensional arrangement of a plurality of nucleic acids having a sufficient length to allow a specific detection of the expression of mRNAs capable of hybridizing thereto. For example, the DNA templates may contain a plurality of nucleic acids derived from genes for which it is desired to estimate the level of expression. The DNA templates may include the genomic sequences of LSR, that of a cDNA of the present invention, more particularly one or more of the cDNAs of SEQ ID 9, SEQ ID 11 or SEQ ID 13, any sequences complementary thereto or any fragments thereof. Preferably, the fragments comprise at least 15, at least 25, at least 50, at least 100 or at least 500 consecutive nucleotides of the nucleic sequences from which they are derived.

For example, a quantitative analysis of the expression of the LSR receptor can be carried out with a DNA template having the cDNA for the LSR receptor as described in Schena et al. (1995 and 1996). cDNAs for the LSR receptor or fragments thereof are amplified by PCR and bound in the form of a template from a 96-well microplate onto a silylated microscope slide using a very fast automated machine. The DNA template thus produced is incubated in a humid chamber in order to allow its rehydration. It is then rinsed once in 0.2% SDS for 1 min, twice in water for 1 min and once for 5 min in a sodium borohydride solution. The template is then submerged in water for 2 min at 95°C, transferred into 0.2% SDS for 1 min, rinsed twice with water, dried and stored in the dark at 25°C.

The mRNAs of cells and of tissues are isolated or obtained from a commercial source, for example the company Clontech. The probes are prepared by a reverse transcription cycle. The probes are then hybridized with the DNA template of 1 cm<sup>2</sup> under a glass coverslip of 14x14 mm for 6-12 hours at 60°C. The template is washed for 5 min at 25°C in a washing buffer at low stringency (1 × SSC/0.2% SDS) and then for 10 min at room temperature in a highly stringent buffer (0.1 × SSC/0.2% SDS). The template is analysed in 0.1 × SSC using a laser fluorescence microscope with a set of appropriate filters. Measurements of precise differential expression are obtained by taking the mean of the ratios of two independent hybridizations.

A quantitative analysis of the expression of the LSR receptor can also be carried out with cDNAs for the LSR receptor or fragments thereof on DNA templates according to the description by Pietu et al. (1996). The cDNAs for the LSR receptor or fragments

thereof are amplified by PCR and bound to membranes. The mRNAs obtained from different tissues or cells are labelled with radioactive nucleotides. After hybridization and washing under controlled conditions, the hybridized mRNAs are detected with a Phosphor Imager or by autoradiography. The experiments are carried out in duplicate and a quantitative analysis of the differentially expressed mRNAs can be carried out.

Alternatively, the analysis of the expression of the LSR receptor can be made with DNA templates at high density as described by Lockhart et al. (1996) and Sosnowski et al. (1997). Oligonucleotides of 15 to 50 nucleotides, preferably about 20 nucleotides, extracted from genomic DNA or cDNA sequences for the LSR receptor or of their complementary sequences are synthesized directly on a chip or synthesized and then addressed onto the chip.

LSR cDNA probes labelled with an appropriate compound such as biotin, digoxigenin or a fluorescent molecule are synthesized from a population of mRNA and are fragmented into oligonucleotides of 50 to 100 nucleotides on average. The probes thus obtained are then hybridized to a chip. After washing as described in Lockhart et al (1996) and an application of various electric fields (Sosnowski et al. 1997), the labelled compounds are detected and quantified. The hybridizations are duplicated. A comparative analysis of the intensity of the signals generated by the probes on the same target oligonucleotide in various cDNA samples indicates a differential expression of the mRNAs for the LSR receptor.

The techniques mentioned above allow the analysis of the levels of expression of the LSR receptor, in the same cell or the same tissue depending on various conditions, for example of induction or of noninduction, but also the analysis of the tissue specificity of this expression, under conditions which can also vary. It will be possible, by virtue of these techniques, to analyse the expression of either of the subunits of the LSR receptor, and more generally of different forms derived from alternative splicing, by adequately defining the probes.

The effect of compounds which are candidates for modulating the level or the specificity of expression, or of splicing of the different forms of the LSR receptor can thus be analysed on a large scale by exposing the cells which are the source of messenger RNA, in particular the model cells according to the invention, whether they express LSR naturally or whether they are recombinant cells, to the said candidate compounds.

### ***Screening of compounds interacting with the LSR receptor***

Another aspect of the present invention consists in methods of identifying molecules capable of binding to the LSR receptor. Such molecules can be used to

modulate the activity of the LSR receptor. For example, such molecules can be used to stimulate or reduce the degradation of lipoproteins, preferably of lipoproteins high in triglycerides, or of cytokines, preferably of leptin. Such molecules can also be used to inhibit the activation by leptin or the activation by free fatty acids of the LSR activity.

5            Numerous methods exist for identifying ligands for the LSR receptor. One of these methods is described in Patent US 5,270,170, whose teaching is incorporated by reference. Briefly, a library is constructed which consists of random peptides, comprising a plurality of vectors each encoding a fusion between a peptide which is a candidate for binding to the LSR receptor and a protein binding to DNA such as the Lac repressor  
10           encoded by the *lacI* gene. The vectors for the library of random peptides also contain binding sites for the proteins binding to DNA such as the LacO site when the protein is the Lac repressor. The library of random peptides is introduced into a host cell in which the fusion protein is expressed. The host cell is then lysed under conditions allowing the binding of the fusion protein to the sites of the vector.

15           The vectors which have bound the fusion protein are brought into contact with the immobilized LSR receptor, a subunit of the immobilized LSR receptor or a fragment of the immobilized LSR receptor under conditions allowing the peptides to bind specifically. For example, the LSR receptor, a subunit thereof or a fragment thereof comprising at least 10, at least 20, at least 30, or more than 30 consecutive amino acids can be immobilized  
20           by binding to a surface such as a plate or a plastic particle.

             The vectors which encode the peptides capable of binding to the LSR receptor are specifically retained at the surface by interactions between the peptide and the LSR receptor, a subunit of the receptor or a fragment thereof.

             Alternatively, molecules capable of interacting with the LSR receptor can be  
25           identified using a double hybrid system such as the Matchmaker Two Hybrid System 2. According to the instructions of the manual accompanying the Matchmaker Two Hybrid System 2 (Catalogue No. K1604-1, Clontech), whose teaching is incorporated by reference, the nucleic acids encoding the LSR receptor, a subunit thereof or a fragment thereof comprising at least 10, at least 20, at least 30, or more than 30 consecutive amino  
30           acids are inserted into an expression vector so that they are in phase with the DNA encoding the DNA binding domain of the transcription activator of yeast GAL4. The nucleic acids of a library encoding proteins or peptides capable of interacting with the LSR receptor are inserted into a second expression vector so that they are in phase with the DNA encoding the activation domain of the GAL4 activator. The yeasts are  
35           transformed with the two expression plasmids and they are placed in a medium which makes it possible to select the cells expressing markers contained in each of the vectors as well as those expressing the HIS3 gene whose expression is dependent on GAL4. The



transformed cells capable of growing on a histidine-free medium are analysed for expression of LacZ under the dependence of GAL4. The cells which grow in the absence of histidine and express LacZ contain a plasmid which encodes proteins or peptides which interact with the LSR receptor, a subunit thereof or a fragment thereof comprising  
5 at least 10, at least 20, at least 30, or more than 30 consecutive amino acids thereof.

To study the interaction of the LSR receptor, a subunit thereof or a fragment thereof comprising at least 10, at least 20, at least 30, or more than 30 consecutive amino acids with small molecules such as those generated by combinatorial chemistry, it is possible to use an HPLC-coupled microdialysis as described in Wang et al. (1997), or an  
10 affinity capillary electrophoresis as described in Busch et al. (1997), the teaching of these documents being incorporated by reference.

In other methods, the peptides or small molecules capable of interacting with the LSR receptor, a subunit thereof or a fragment thereof comprising at least 10, at least 20, at least 30, or more than 30 consecutive amino acids may be linked to detectable markers  
15 such as radioactive, fluorescent or enzymatic markers. These labelled molecules are brought into contact with the immobilized LSR receptor, an immobilized subunit thereof or an immobilized fragment thereof comprising at least 10, at least 20, at least 30, or more than 30 consecutive amino acids under conditions allowing a specific interaction. After elimination of the molecules which are not specifically bound, the bound molecules are  
20 detected by appropriate means.

These methods may allow in particular the identification of fatty acids or analogues capable of binding to the fatty acid binding site on the LSR, of lipoproteins or analogues, capable of binding to the lipoprotein binding site on the LSR receptor, of leptin derivatives or analogues capable of binding to the leptin binding site on the LSR, and of derivatives of  
25 the gC1qR receptor or analogues capable of binding to the gC1qR binding site on the LSR.

In addition, the peptides or small molecules which bind to LSR, preferably to the binding sites on the LSR receptor for fatty acids, lipoproteins, cytokines, in particular leptin, or gC1qR or one of its analogous proteins, can be identified by competition  
30 experiments. In such experiments, the LSR receptor, a subunit thereof or a fragment thereof comprising at least 10, at least 20, at least 30, or more than 30 consecutive amino acids is immobilized on a surface such as a plastic support. Increasing quantities of peptides or of small molecules are brought into contact with the immobilized LSR receptor, an immobilized subunit thereof or an immobilized fragment thereof comprising  
35 at least 10, at least 20, at least 30, or more than 30 consecutive amino acids in the presence of a labelled ligand for the receptor, it being possible for this ligand to be, for example, leptin, oleate, the LDLs or gC1qR. The ligand for the LSR receptor may be



labelled with a radioactive, fluorescent or enzymatic marker. The capacity of the molecule tested to interact with the LSR receptor, a subunit thereof or a fragment thereof comprising at least 10, at least 20, at least 30, or more than 30 consecutive amino acids is determined by measuring the quantity of labelled ligand bound in the presence of the molecule tested. A decrease in the quantity of bound ligand when the molecule tested is present indicates that the latter is capable of interacting with the LSR receptor, a subunit thereof or a fragment thereof comprising at least 10, at least 20, at least 30, or more than 30 consecutive amino acids.

These methods can in particular allow the identification of fatty acids or analogues capable of binding to the fatty acid binding site on the LSR, of lipoproteins or analogues, capable of binding to the lipoprotein binding site on the LSR receptor, of leptin derivatives or analogues capable of binding to the leptin binding site on the LSR, and of derivatives of the gC1qR receptor or analogues capable of binding to the gC1qR binding site on the LSR. The capacity of such compounds, or of any other candidate compound, to compete with the binding of oleates, lipoproteins, leptin or gC1qR to LSR can be measured in particular.

The BIACORE technology can also be used to carry out the screening of compounds capable of interacting with the LSR receptor. This technology is described in Szabo et al. (1995) and in Edwards and Leartherbarrow (1997), of which the teaching is incorporated by reference, and makes it possible to detect interactions between molecules in real time without the use of labelling. It is based on the phenomenon of SPR (surface plasmon resonance). Briefly, the molecule to be analysed is bound to a surface (typically using a carboxymethyl dextran matrix). A light ray is directed onto the face of the surface which does not contain the sample and is reflected by the said surface. The SPR phenomenon causes a reduction in the intensity of the reflected light with a specific combination of angle and of wavelength. The molecule binding events cause a change in the refractive index at the surface which is detected as a modification of the SPR signal. To carry out a screening of compounds capable of interacting with the LSR receptor, the LSR receptor, a subunit thereof or a fragment thereof comprising at least 10, at least 20, at least 30, or more than 30 consecutive amino acids, is immobilized on a surface. This surface constitutes one face of a cell through which passes the molecule to be tested. The binding of the molecule to the LSR receptor, a subunit thereof or a fragment thereof comprising at least 10, at least 20, at least 30, or more than 30 consecutive amino acids is detected by a change in the SPR signal. The molecules tested may be proteins, peptides, carbohydrates, lipids or small molecules generated, for example, by combinatorial chemistry. The candidate proteins can be extracted from any tissue, obtained from any species. The BIACORE technology can also be used by immobilizing

eukaryotic or prokaryotic cells or lipid vesicles having an endogenous or recombinant LSR receptor at their surface.

One of the main advantages of this method is that it allows the determination of the association constants between the LSR receptor and the interacting molecules. Thus,  
 5 it is possible to specifically select the molecules interacting with high or low association constants.

The proteins or other molecules interacting with the LSR receptor, a subunit thereof or a fragment thereof comprising at least 10, at least 20, at least 30, or more than 30 consecutive amino acids can be identified using affinity columns which contain the  
 10 LSR receptor, a subunit thereof or a fragment thereof comprising at least 10, at least 20, at least 30, or more than 30 consecutive amino acids. The LSR receptor, a subunit thereof or a fragment thereof comprising at least 10, at least 20, at least 30, or more than 30 consecutive amino acids may be attached to the column using conventional techniques including chemical coupling to an appropriate column matrix such as agarose,  
 15 Affi Gel, or other matrices known to a person skilled in the art. In another aspect of the invention, the affinity column may contain chimeric proteins in which the LSR receptor, a subunit thereof or a fragment thereof comprising at least 10, at least 20, at least 30, or more than 30 consecutive amino acids would be fused, for example, with glutathione S-transferase. The molecules to be tested which are described above are then deposited on  
 20 the column. The molecules interacting with the LSR receptor, a subunit thereof or a fragment thereof comprising at least 10, at least 20, at least 30, or more than 30 consecutive amino acids are retained by the column and can be isolated by elution. In the case where the molecules tested are proteins, they can then be analysed on a 2-D electrophoresis gel as described in Ramunsen et al. (1997), of which the teaching is  
 25 incorporated by reference. Alternatively, the proteins or the other molecules retained by the affinity column can be purified by electrophoresis and sequenced. A similar method can be used to isolate antibodies, to screen "phage display" products or "phage display" derived human antibodies.

### 30 ***Screening of compounds interacting with the promoter and/or regulatory sequences of the LSR receptor***

The invention also relates to a method of screening compounds interacting with the promoter and/or regulatory sequences of the LSR receptor.

The nucleic acids encoding proteins interacting with the promoter and/or  
 35 regulatory sequences of the LSR receptor gene, more particularly a nucleotide sequence corresponding to nucleotides 1 to 1897 of SEQ ID 19 or a fragment thereof, can be

identified using a single hybrid system such as that described in the manual accompanying the Matchmaker One-Hybrid System from Clontech (Catalogue No. K1603-1), of which the teaching is incorporated by reference. Briefly, the target nucleotide sequence is cloned upstream of a selectable marker gene and integrated into a yeast genome. The yeasts containing the integrated marker gene are transformed by a library containing fusions between cDNAs encoding candidate proteins for binding to the promoter and/or regulatory regions of the gene for the LSR receptor and the yeast transcription factor activating domain such as GAL4. The yeasts are placed in a medium which makes it possible to select the cells expressing the marker gene. The yeasts selected contain a fusion protein capable of binding to the promoter and/or regulatory target region. The cDNAs of the genes encoding the fusion proteins are then sequenced. The corresponding inserts can then be cloned into expression or transcription vectors in vitro. The binding of the polypeptides thus encoded to the promoter target sequences can be confirmed by techniques familiar to persons skilled in the art, including gel retardation or protection to DNase experiments.

The screening of compounds capable of modifying the expression of the LSR receptor by binding to its regulatory and/or promoter sequences can also be carried out with the aid of "reporter" genes. For example, a genomic region situated in 5' of the coding sequence of the LSR receptor, more particularly a nucleotide sequence corresponding to nucleotides 1 to 1897 of SEQ ID 19 or a fragment thereof, can be cloned into a vector such as pSEAP-Basic, pSEAP-Enhancer, p $\beta$ gal-Basic, p $\beta$ gal-Enhancer, or pEGFP-1 available from Clontech. Briefly, each of these vectors contains multiple cloning sites situated upstream of a marker gene encoding an easily detectable protein such as alkaline phosphatase,  $\beta$ -galactosidase or GFP (green fluorescent protein). After insertion of the genomic region situated in 5' of the coding sequence of the LSR receptor, more particularly a nucleotide sequence corresponding to nucleotides 1 to 1897 of SEQ ID 19 or a fragment thereof, the level of expression of the marker proteins is measured and compared with a vector containing no insert. The effect of candidate compounds on the expression resulting from the regulatory and/or promoter sequences of LSR can thus be evaluated.

The screening of the compounds capable of binding to the regulatory and/or promoter regions of the gene for the LSR receptor can also be carried out by gel retardation experiments well known to persons skilled in the art and described in Fried and Crothers (1981), Garner and Revzin (1981) and Dent and Latchman (1993), of which the teaching is incorporated by reference. These experiments are based on the principle that a DNA fragment bound to a protein migrates more slowly than the same fragment

without protein. Briefly, the target nucleotide sequence is labelled. It is then brought into contact either with a nuclear or total cell extract prepared so as to contain the transcription factors, or with various compounds to be tested. The interaction between the regulatory and/or promoter region of the gene for the LSR receptor and the transcription factor or compound is detected after electrophoresis by retardation of migration.

## **Compounds**

The chemical or biochemical compounds, characterized in that they make it possible to modulate the expression or the activity of the receptor according to the invention, also form part of the invention.

The chemical or biochemical compounds, characterized in that they are capable of interacting, directly or indirectly, with the receptor according to the invention, also form part of the invention.

The chemical or biochemical compounds, characterized in that they are selected by the said methods defined above, also form part of the invention.

In particular, among these compounds according to the invention, a leptin or one of its derived compounds, preferably one of its protein variants, or leptins which are chemically modified or which are obtained by genetic recombination, or one of their fragments, are preferred.

Compounds which make it possible to modulate the expression or the activity of the receptor are understood to mean the compounds which make it possible in particular to reduce, stabilize or increase the number, the recycling rate and/or the change in the conformation of the receptor according to the invention, or to promote or inhibit the overall activity or the activity of one of the domains of the said receptor or alternatively to reestablish normal expression of the said receptor in the case, for example, where a genetic abnormality is observed. These compounds may, for example, interact as ligands specific for the said receptor or for one of its domains as cofactor, or as inhibitor, in particular a competitive inhibitor, or alternatively having an agonist or antagonist activity on the conformational changes in the complex. These compounds may also interact by neutralizing the natural ligands specific for the said receptor and by thereby inhibiting the receptor activity induced by these ligands.

Among these compounds, the compounds which make it possible to modulate the number of polypeptides of the said receptor, its recycling rate and/or the selectivity of their activity, are preferred.

Also preferred are the compounds according to the invention, characterized in that they allow an increase in the total activity or in the expression of the receptor according to

the invention, and/or a specific increase in the clearance activity for cytokines, in particular leptin, of the said receptor, and/or a specific increase in the clearance activity for lipoproteins, of the said receptor.

Also preferred are the compounds characterized in that they allow a decrease in the total activity or in the expression of the receptor according to the invention, and/or a specific decrease in the clearance activity for cytokines, in particular leptin, of the said receptor, and/or a specific decrease in the clearance activity for lipoproteins, of the said receptor.

Also preferred are the compounds characterized in that they allow modulation of the elimination of the cytokines, in particular leptin, and/or modulation of the elimination of the lipoproteins, chylomicron residues, and/or triglycerides.

The invention also comprises the compounds according to the invention, characterized in that they allow modulation of the level of cytokines, in particular leptinemia, and/or modulation of the level of lipoproteins, chylomicron residues, and/or triglycerides.

The compounds according to the invention, characterized in that they allow control of the level of cytokines, in particular leptinemia, are more particularly preferred.

Still preferably, the invention comprises the compounds according to the invention, characterized in that they allow control, preferably a decrease, of the level of lipoproteins, a decrease in the plasma concentration of chylomicron residues, and/or a decrease in triglyceridemia.

Among the compounds which are most preferred, there are preferred those characterized in that they are chosen from:

- a. an antibody according to the invention;
- b. a polypeptide according to the invention;
- c. a polypeptide according to the invention, characterized in that it corresponds to a soluble form of the receptor according to the invention;
- d. a vector according to the invention;
- e. a vector according to the invention, characterized in that it has on its outer surface a site for specific recognition of hepatic cells;
- f. a vector according to the invention, characterized in that the product of expression of the nucleic acid inserted by the vector into the target cell is either anchored in or excreted by the said transformed target cell;
- g. a sense or antisense oligonucleotide according to the invention;
- h. a leptin, or one of its protein variants, or a leptin which is chemically modified or which is modified by genetic recombination, or one of their fragments.

The invention finally relates to the compounds according to the invention as a medicament.



The compounds according to the invention as a medicament for the prevention and/or treatment of pathologies and/or of pathogeneses linked to disorders in dietary habit are preferred in particular.

5 The compounds according to the invention as a medicament for the prevention and/or treatment of pathologies and/or of pathogeneses linked to disorders in the metabolism of cytokines are also preferred.

Preferably, the invention also relates to the compounds according to the invention as medicament for the prevention or treatment of obesity or anorexia.

10 The compounds according to the invention as a medicament for the prevention and/or treatment of pathologies and/or of pathogeneses associated with, or induced by obesity, are the preferred compounds.

In particular, there are preferred the compounds according to the invention, as a medicament for the prevention and/or treatment of cardiac insufficiency, of coronary insufficiency, of cerebrovascular accidents, of atheromatous disease, of atherosclerosis, of  
15 high blood pressure, of non-insulin-dependent diabetes, of hyperlipidemia and/or of hyperuricemia.

The most preferred are the compounds according to the invention, as a medicament for the prevention and/or treatment of atheromatous disease and/or of atherosclerosis.

20 Finally, the invention comprises compounds according to the invention for the prevention and/or treatment by gene therapy, of pathologies and/or of pathogeneses linked to disorders in dietary habit, of obesity and/or of pathologies and/or of pathogeneses associated with, or induced by, obesity.

The compounds of the invention as active ingredients of a medicament will be preferably in soluble form, combined with a pharmaceutically acceptable vehicle.

25 Such compounds which can be used as a medicament offer a new approach for preventing and/or treating pathologies and/or pathogeneses linked to disorders in dietary habit such as obesity or anorexia, and the related risks and/or complications.

30 Preferably, these compounds will be administered by the systemic route, in particular by the intravenous route, by the intramuscular or intradermal route or by the oral route.

Their modes of administration, optimum dosages and galenic forms can be determined according to the criteria generally taken into account in establishing a treatment suited to a patient, such as for example the age or body weight of the patient, the seriousness of his general condition, the tolerance to treatment and the side effects  
35 observed, and the like.

As mentioned above, depending on the cases, it may be advisable to amplify the activity of LSR, by promoting, for example, the expression of its genes or by increasing the

activity of their expression products, in pathological cases resulting from the fact that at least one of these genes is not expressed, is insufficiently expressed or is expressed in an abnormal form which does not allow the expression product to carry out its functions, or on the contrary to repress an overexpression or an abnormal expression of these genes. It is therefore advisable in general to compensate for the deficiency or the overexpression of expression products of this gene by a so-called "replacement" therapy allowing the amplification or the reduction in the activities of the LSR complex.

The replacement therapy may be carried out by gene therapy, that is to say by introducing the nucleic acid sequences according to the invention and/or the corresponding genes with the elements which allow their expression *in vivo*, in the case where one of the genes is insufficiently expressed for example, or alternatively when it is expressed in an abnormal form.

The principles of gene therapy are known. It is possible to use viral vectors according to the invention; it is also possible to envisage nonviral, that is to say synthetic, vectors which mimic viral sequences or alternatively which consist of naked RNA or DNA according to the technique developed in particular by the company VICAL.

In most cases, it is necessary to envisage targeting elements ensuring expression specific for the liver so as to be able to limit the zones of expression of the proteins which remain involved in the clearance of leptin and that of lipoproteins. It is even advantageous, in some cases, to have vectors for transient expression or at least for controlled expression which it will be possible to block when necessary.

Other characteristics and advantages of the invention appear in the remainder of the description with the examples and figures whose legends are represented below.

## 25 LEGEND TO THE FIGURES

**FIGURE 1 :** Schematic representation of the three forms of the rat LSR protein : LSR 66 ( $\alpha$  subunit), LSR 64 ( $\alpha'$  subunit), and LSR 58 ( $\beta$  subunit).

**FIGURE 2 :** Alignment of the protein sequences of the long forms ( $\alpha$  subunits) of the human LSR (LSR1.Hs; SEQ ID NO:8), rat LSR (LSR1.Rn; SEQ ID NO:2) and mouse LSR (LSR1.Mm; SEQ ID NO:16). The (\*) symbols placed under the alignments indicate the conserved amino acids, the (.) symbols indicate the conservative substitutions of amino acids. Boxed, from the NH<sub>2</sub>-terminal end to the COOH-terminal end, the potential fatty acid (FFA) binding site boxed, the clathrin binding site [NPGY], the lysosomal addressing consensus : di-leucine LI-X10-LL, the transmembrane TM domain overlined, the motif [RSRS], the potential lipoprotein binding site (+-+-) boxed. Overlined, the signature of the

TNF receptor with (arrow) ; indicated, the amino acids conserved in the signature. The transmembrane domain is situated between the last di-leucine and the TNF signature.

**A** : Alignment shown from amino acid positions 1 to 539 of SEQ ID NO:8.

**B** : Alignment shown from amino acid positions 540 to 649 of SEQ ID NO:8.

- 5 **FIGURES 3**: Alignment of the protein sequences of the three types of subunits of the human LSR ( $\alpha$  : LSR1.Hs, SEQ ID NO:8;  $\alpha'$  : LSR2.Hs, SEQ ID NO:10;  $\beta$  : LSR3.Hs, SEQ ID NO:12). The meaning of the symbols, of the boxes and of the overlines is the same as that in Figures 2A and 2B.

**A** : Alignment shown from amino acid positions 1 to 540 of SEQ ID NO:8.

- 10 **B** : Alignment shown from amino acid positions 541 to 649 of SEQ ID NO:8.

**FIGURE 4** : Alignment of the protein sequences of the three types of subunits of rat LSR. ( $\alpha$  : LSR1.Rn, SEQ ID NO:2;  $\alpha'$  : LSR2.Rn, SEQ ID NO:4;  $\beta$  : LSR3.Rn, SEQ ID NO:6). The meaning of the symbols, of the boxes and of the overlines is the same as that in Figures 2A and 2B.

- 15 **A** : Alignment shown from amino acid positions 1 to 540 of SEQ ID NO:2.

**B** : Alignment shown from amino acid positions 541 to 593 of SEQ ID NO:2.

**FIGURE 5** : Alignment of the protein sequences of the three types of subunits of mouse LSR ( $\alpha$  : LSR1.Mm, SEQ ID NO:16;  $\alpha'$  : LSR2.Mm, SEQ ID NO:17;  $\beta$  : LSR3.Mm, SEQ ID NO:18). The meaning of the symbols, of the boxes and of the overlines is the same as that in Figures 2A and 2B.

**A** : Alignment shown from amino acid positions 1 to 540 of SEQ ID NO:16.

**B** : Alignment shown from amino acid positions 541 to 594 of SEQ ID NO:16.

**FIGURE 6** : Schematic representation of the three LSR forms identified in humans, indicating the motifs conserved on each of them.

- 25 **A** : Schematic representation of the genomic organization of the human LSR starting from the first coding exon. The exons are indicated by boxes, the introns by interrupted bars. The size, in nucleotides, of the exons and introns is indicated above them. The elements characterizing the messenger and the encoded protein are presented in this figure. The box on the right gives the meaning of the symbols used.

- 30 **B** : Structure of the LSR-Hs-2062 form of human LSR. This form encodes a protein of 649 amino acids.

**C** : Structure of the LSR-Hs-2005 form of human LSR. This form encodes a protein of 630 amino acids.

- 35 **D** : Structure of the LSR-Hs-1858 form of human LSR. This form encodes a protein of 581 amino acids.

**FIGURE 7:** Alignment of the nucleotide sequences of the long forms of cDNA (encoding the  $\alpha$  subunit) or portions thereof for human LSR (lslr1.HS; nucleotides 1 to 2062 of SEQ ID NO:7), rat LSR (lslr1.Rn; SEQ ID NO:1) and mouse LSR (lslr1.Mm; SEQ ID NO:13). The nucleotides conserved in the three sequences are identified by an \* sign placed under the sequences. Dashes are added inside the sequences when the optimum alignment of the sequences cannot be achieved without creating microdeletions.

**A :** Alignment shown from amino acid positions 1 to 486 of SEQ ID NO:1.

**B :** Alignment shown from amino acid positions 487 to 1026 of SEQ ID NO:1.

**C :** Alignment shown from amino acid positions 1027 to 1551 of SEQ ID NO:1.

10 **D :** Alignment shown from amino acid positions 1552 to 2080 of SEQ ID NO:1.

**E :** Alignment shown from amino acid positions 2081 to 2097 of SEQ ID NO:1.

**FIGURE 8 :** Identification of the LSR receptor by ligand and Western blotting on solubilized proteins of rat liver membranes (lanes 1, 2 and 4), or on the partially purified protein of 240 kD (lane 3).

15 Lanes 1, 2 and 3 : Ligand blotting. Lane 1 : in the absence of oleate and of  $^{125}\text{I}$ -LDL; lane 2 : in the presence of oleate and of  $^{125}\text{I}$ -LDL; lane 3 : in the presence of oleate and of  $^{125}\text{I}$ -LDL.

Lane 4 : Western blotting with anti-LSR antibodies.

**FIGURE 9 :** Effect of anti-LSR antibodies on the LSR activity.

20 **A.** Binding of  $^{125}\text{I}$ -LDL onto the plasma membranes of rat hepatocytes in the presence of oleate and of increasing concentrations of anti-LSR antibody (v) or of control antibody (o), expressed as % of the total quantity of  $^{125}\text{I}$ -LDL bound in the absence of antibodies.

**B.** Binding, incorporation and degradation of  $^{125}\text{I}$ -LDL in rat hepatocytes in primary culture in the presence of oleate and of anti-LSR antibody (v) or of control antibody (o), expressed respectively as % of the binding, incorporation and total degradation of  $^{125}\text{I}$ -LDL in the presence of non-specific antibodies.

30 **FIGURE 10 :** Identification of the LSR receptor by immunoprecipitation of  $^{35}\text{S}$ -methionine- and  $^{35}\text{S}$ -cysteine-labelled hepatocyte lysates, in the presence of control antibodies (lane 1), or of anti-LSR antibodies (lanes 2 to 4), after separation by electrophoresis under nonreducing (lanes 2 and 3) or reducing (lanes 1 and 3) conditions.

**FIGURE 11 :** Cloning of the cDNA encoding  $\alpha$  and  $\beta$ -LSR.

**A.** Northern-blot analysis showing several sizes of LSR messenger RNA.

**B.** Multi-tissue Northern-blot analysis of LSR mRNA with a probe specific for LSR and a control probe specific for  $\beta$ -actin.

C. RT-PCR analysis of LSR mRNA using 5 pairs of primers covering the entire sequence and identification of three forms derived from alternative splicing in the amplification fragment obtained by means of the bc' primers. The diagram represents the results of sequence analysis of the three corresponding forms of LSR cDNA : the squared region is  
 5 absent from the two short forms, the hatched region is absent only from the shortest form.  
**FIGURE 12 :** Translation *in vitro* of the two complete cDNAs encoding the longest (66 kDa, lane 2) and the shortest (58 kDa, lane 3) forms of rat LSR, and of a control cDNA, an antisense of the cDNA encoding the longest form of LSR (lane 1).

The products of translation *in vitro*, labelled with  $^{35}\text{S}$ -methionine, are analysed after  
 10 electrophoresis under nonreducing conditions.

**FIGURE 13 :** Identification of the  $\alpha$ - and  $\beta$ -LSR subunits as being responsible for the LSR activity.

A. Diagram showing the location and the sequence of LSR N-terminal peptide used to generate anti-LSR peptide antibodies.

15 B. Effect of antibodies directed against a synthetic LSR peptide on the LSR activity of rat liver plasma membranes. The LSR activity is measured in the presence of a control antibody (o) or of the anti-LSR peptide antibody (v).

C. Western and Ligand blotting of the  $\alpha$  and  $\beta$  subunits of LSR. The Western blotting is carried out using the anti-LSR (lane 1) or anti-LSR peptide (lane 2) antibody. The ligand  
 20 blotting is carried out in the presence of  $^{125}\text{I}$ -LDL, with (lane 4) or without (lane 3) oleate.

**FIGURE 14 :** Identification of the subunits of the LSR receptor and inhibitory effect of antibodies directed against a C-terminal synthetic peptide derived from LSR.

A- Diagram showing the location and the sequence of the synthetic peptide 170.

25 B- Western blotting of rat hepatocyte lysates using antibodies directed against the synthetic peptide 170 (lane 2), or a control antibody (lane 1); lane 3 : molecular weight markers.

C- Binding of  $^{125}\text{I}$ -LDL by the LSR receptor in the presence of oleate and of control antibodies or antibodies directed against the LSR 170 peptide.

**FIGURE 15 :** Effect of a transient transfection of CHO-K1 cells with the plasmids  
 30 expressing the  $\alpha$  and  $\beta$  subunits of the LSR receptor on the binding of LDLs in the presence or in the absence of oleate. Increasing concentration of  $\alpha$  plasmid alone ( $\bigcirc\square$ ) ; fixed concentration of  $\alpha$  plasmid and increasing concentration of  $\beta$  plasmid ( $\bullet\square$ ).

**FIGURE 16 :** Effect of a transient transfection of CHO-K1 cells with plasmids expressing the  $\alpha$  and  $\beta$  subunits of the LSR receptor on the internalization and degradation of LDLs.

35 Increasing concentration of  $\alpha$  plasmid alone ( $\blacksquare$ ) ; fixed concentration of  $\alpha$  plasmid and



increasing concentration of  $\beta$  plasmid ( ). The results are expressed as the difference between the measurements in the presence and in the absence of oleate.

**FIGURE 17 :** Characterization of the LSR activity obtained in CHO-K1 cells transiently transfected with the nucleic sequences encoding the  $\alpha$  and  $\beta$  subunits of the LSR receptor, compared with the LSR activity obtained in the same cells not transfected (control).

**A-** Binding of  $^{125}\text{I}$ -LDL in the presence of a control antibody or of an anti-LSR antibody.

**B-** Binding of  $^{125}\text{I}$ -LDL in the presence of increasing concentrations of unlabelled lipoproteins ; rat chylomicrons ( $\nu$ ), human VLDL ( $\blacksquare$ ), LDL ( $\square$ ), HDL ( $\sigma$ ), LDLs treated with pronase ( $\bigcirc$ ), or LDLs modified with cyclohexanedione (LDL-chd,  $\bullet$ ).

**FIGURE 18 :** Effect of oleate, of RAP-39, of anti-LSR antibodies and of chloroquine on the specific degradation of leptin in primary cultures of rat hepatocytes.

**FIGURE 19 :** Western blot analysis with anti-LSR antibodies, of the fraction of rat liver plasma membrane proteins retained on an affinity chromatography column containing leptin.

**FIGURE 20 :** Clearance of  $^{125}\text{I}$ -leptin on control ( $\circ$ ), *ob/ob* ( $\nu$ ) and *db/db* ( $\searrow$ ) mice in the liver and the kidney. The results are expressed as the difference between the quantities of  $^{125}\text{I}$ -leptin and  $^{125}\text{I}$ - $\beta$ 2-microglobulin found in the liver and in the kidney.

**FIGURE 21 :** Apparent number of LSR receptors expressed in the liver of control, *ob/ob* and *db/db* mice.

**FIGURE 22 :** Effect of anti-LSR antibodies on the proportion between the quantities of  $^{125}\text{I}$ -leptin distributed in the liver and in the kidney.

**FIGURE 23 :** Effect of increasing leptin concentrations on the LSR activity of rat hepatocytes in primary cultures. The results represent the differences in activity which are obtained between the cells incubated with and without oleate in the presence either of  $^{125}\text{I}$ -LDL, or of  $^{125}\text{I}$ -VLDL.

**FIGURE 24 :** Capacity for inducing, by leptin, the LSR activity of rat hepatocytes in primary culture.

**A.** Apparent number of receptors expressed at the surface of the hepatocytes in the presence or in the absence of leptin, estimated by the measurement of the quantity of  $^{125}\text{I}$ -LDL bound in the presence of oleate.

**B.** Effect of cycloheximide, of colchicine and of cytochalasin B on the induction, by leptin, of the LSR activity.

**FIGURE 25 :** Effect of leptin on the postprandial lipemic response in control ( $\bigcirc$ ), *ob/ob* ( $\nu$ ) and *db/db* ( $\circ$ ) mice, reflected by the variation in the plasma concentration of

triglycerides (TG) after ingestion of a high-fat meal, with (B) and without (A) injection of murine recombinant leptin.

**FIGURE 26** : Effect of leptin, in the presence and in the absence of lactoferrin, on the postprandial lipemic response of *ob/ob* mice, expressed by the measurement of the plasma concentration of triglycerides (TG) after ingestion of a high-fat meal.

**FIGURE 27** : Effect of leptin injection on the apparent number of LSR receptors expressed in the liver of *ob/ob* and *db/db* mice.

**FIGURE 28** : Postprandial lipemic response and LSR activity in control (C57BL6), *ob/ob* and *db/db* mice.

10 **A-** Weight of control, *ob/ob* and *db/db* male mice.

**B-** Postprandial lipemic response in control, *ob/ob* and *db/db* mice.

**C-** Apparent number of LSR receptors estimated by measurement of the binding of LDL and expressed in arbitrary unit by comparison with the 5'-nucleotidase activity in each plasma membrane preparation.

15 **D-** Northern blot on an extract of liver total RNA. GAPDH is used as control.

**FIGURE 29** : Effect of a long-term treatment by leptin on *ob/ob* mice.

**A-** Weight change over 30 days

**B-** Postprandial lipemic response on the 29th day of treatment

20 **C-** Apparent number of LSR receptors on day 30, estimated by the measurement of the binding of LDL and expressed in arbitrary unit by comparison with the 5'-nucleotidase activity in each plasma membrane preparation

**D-** Northern blot analysis of the expression of LSR established on a total extract of liver RNA. GAPDH and actin are used as controls.

25 **FIGURE 30** : Effect of the oleates on the binding and internalization of the  $^{125}\text{I}$ -LDL in normal human fibroblasts, under normal conditions.

**FIGURE 31** : Effect of increasing concentrations of leptin on the LSR activity of human fibroblasts HF (familial hypercholesterolemia).

30 **FIGURE 32** : Inhibitory effect of antibodies directed against an  $\text{NH}_2$ -terminal (v) or COOH-terminal (O) peptide of gC1qR, or of control antibodies (o) on the LSR activity of plasma membranes of rat hepatocytes, expressed as a percentage of the quantity of  $^{125}\text{I}$ -LDL bound in the absence of antibodies.

**FIGURE 33** : Effect of increasing concentrations of C1q on the binding, internalization and degradation of  $^{125}\text{I}$ -LDL on rat hepatocytes in primary culture, in the presence (v) or in the absence (o) of oleate.

35 **FIGURE 34** : Effect of 25 ng/ml of recombinant AdipoQ on the LSR activity in a primary culture of rat hepatocytes.

**FIGURE 35 :** Effect of two successive injections of 1 mg of AdipoQ on the postprandial lipemic response in rats after ingestion of a high-fat meal.

**FIGURE 36 :** Effect of an intraperitoneal administration of AdipoQ for 3 days on the weight and the concentrations of plasma triglycerides in rats on a normal diet or on a fatty diet.

**FIGURE 37 :** Effect of a daily injection of 100 µg of AdipoQ over 5 days, on food intake in *ob/ob* and *db/db* obese mice.

## EXAMPLES

### *Experimental procedures*

#### **Materials**

Na<sup>125</sup>I is provided by Amersham (Les Ulis, France). Oleic acid, bovine serum albumin (A 2153) (BSA) and Triton X100 are obtained from Sigma (St Quentin Fallavier, France). Human lactoferrin (Serva) and sodium heparin are provided by Biowhittaker (Fontenay sous Bois, France) and Choay laboratories (Gentilly, France) respectively. The enzymatic kits for the determination of triglycerides (TG) are obtained from Boehringer Mannheim (Meylan, France). Suramin sodium is obtained from CBC Chemicals (Woodburg, CT). Dulbecco's modified Eagle medium (DMEM), trypsin and foetal calf serum are provided by Life Technologies, Inc. (Eragny, France).

#### **Animals**

The mice C57BL/6J of the wild type, C57BL/6J *ob/ob*, C57BL/Ks of the wild type and C57BL/Ks *db/db* are obtained from R. Janvier Breeding Center (Le Genest St Isle, France).

#### **Cells**

Normal fibroblasts (GM08333) and HF (GM00486A, GM007001B, GM00488C) are provided by the NIGMS human genetic mutant cell repository (Camden, NJ). The cells were plated on Petri dishes of 36 mm as described above (300,000 normal fibroblasts per well, 150,000 HF fibroblasts per well), and are cultured in a humidified CO<sub>2</sub> incubator, in DMEM medium containing 10% (normal fibroblasts) or 20% (HF fibroblasts) foetal calf serum, 2 mM glutamine, 100 U/ml of penicillin and 100 U/ml of streptomycin.

The hepatocytes in primary culture are obtained according to the procedure described above (Mann et al., 1995). The cells are then plated at 900,000 cells per well or  $22 \times 10^6$  cells per flask of 165 cm<sup>2</sup>. The cells are used for the studies after 48 hours in culture.

### ***Preparation and radiolabelling of the lipoproteins***

The VLDLs ( $d < 1.006$  g/ml) and LDLs ( $1.025 < d < 1.055$  g/ml) are isolated by sequential ultracentrifugation of fresh plasma from volunteers (Bihain and Yen, 1992; Goldstein et al., 1983) and used before 2 weeks. The lipoproteins are radioiodinated  
 5 (Bilheimer et al., 1972) and used less than one week after the labelling.  $^{125}\text{I}$ -LDL and  $^{125}\text{I}$ -VLDL are filtered (0.22  $\mu\text{m}$  membrane, Gelman) immediately before use.

### ***Preparation and radiolabelling of mouse recombinant leptin***

The leptin cDNA is obtained from the mRNA of adipose tissue of the mouse C57BL/6J by PCR. The 5' PCR primer introduces an initiation codon after the signal  
 10 sequence which is deleted and a sequence encoding a hexahistidine end. The modified sequence encoding murine leptin is cloned into an expression vector pSE280 (Invitrogen, France) and expressed in *E. coli*. The sequencing of the plasmid DNA confirms the coding sequence. The bacteria are cultured at 37°C and the synthesis of the protein is induced by 1 mM isopropyl  $\beta$ -D-thiogalactopyranoside. The bacteria, recovered after gentle centri-  
 15 fuge, are lysed by freeze-thaw and the DNA is digested with a deoxyribonuclease I. The cellular membranes are extracted with the aid of a detergent and the inclusion bodies are separated after centrifugation. After 3 washes in 1% sodium deoxycholate in PBS, the inclusion bodies are solubilized in a 6 M guanidine HCl solution. The renaturation of the recombinant protein is achieved by diluting 1/100 in PBS. The renatured protein is then  
 20 purified and concentrated on a nickel-based chelate metal affinity chromatography column (Probond, Invitrogen). The elution is carried out with imidazole. The purity of the recombinant leptin is controlled by SDS-PAGE electrophoresis and its activity by the evaluation of satiety in mice C57BL/6J ob/ob after intraperitoneal injection of 25  $\mu\text{g}$  of leptin. The recombinant leptin is then radiolabelled using Iodobeads (Pierce) and according to the  
 25 method recommended by the manufacturer.

### ***Cloning of the AdipoQ mRNA. Production and purification of recombinant AdipoQ proteins***

#### **Cloning of the cDNA into an expression vector**

Mouse adipose tissue is obtained from C57BL/6J mice and the mRNA is extracted with the  
 30 aid of polydT<sub>s</sub> bound to magnetic beads (Dynabeads, Dynal, France). A cDNA library is constructed from mouse adipose tissue by reverse transcription at 40°C using a commercial kit (Superscript Life Technologies) using the supplier's instructions. The cDNA specific for AdipoQ is amplified using the following two primers :

5' CTACATGGATCCAGTCATGCCGAAGAT 3' (SEQ ID 37)

35 5' CGACAACTCGAGTCAGTTGGTATCATGG 3' (SEQ ID 38).

The amplification product is then digested with the restriction enzymes BamHI and XhoI and inserted into an expression vector pTRC HisB (Invitrogen, France) at the corresponding sites. The B version of pTRC allows the expression of heterogeneous sequences downstream of a hexahistidine peptide which carries a recognition site for an enterokinase and an epitope for the anti-Xpress antibody.

#### **Bacterial transfection and checking of the construct**

The plasmid thus obtained is transfected into *E. coli* Dll5  $\alpha$ . Furthermore, the DNA of the plasmid is extracted and the heterologous insert is sequenced.

#### **Cell culture, extraction and purification of the recombinant protein**

The recombinant bacterial cells are cultured at 37°C in an LB medium containing antibiotics until the OD at 600 nm reaches 0.2. The production of recombinant protein is then induced by adding 1 mM isopropyl- $\beta$ -D-thiogalactopyranoside to the culture medium. The bacterial culture is continued for 16 h at 37°C. The cells are recovered by centrifugation. The cells are lysed using lysozyme in a Tris buffer pH 7.4 in the presence of NaCl, PMSF and sodium deoxycholate. The DNA is degraded by sonication. After centrifugation, the recombinant protein is separated from the supernatant using a Probond column (Invitrogen, France). This column contains charged nickel which has affinity for the hexahistidine peptides. The elution is carried out in the presence of imidazole. The protein concentration is estimated by the Lowry method after having dialysed the product of the elution. The purity of the protein obtained is tested by SDS-PAGE electrophoresis, which shows a single band.

#### ***Example 1 : Identification of the protein complex responsible for the LSR activity : partial purification and characterization by means of polyclonal antibodies***

The technique of ligand blotting was used to identify the protein complex responsible for the LSR activity. This technique, described in detail by Mann et al., 1995, is detailed below.

#### ***Ligand blotting***

The technique consists in isolating, by differential centrifugation (Belcher et al., 1987) rat liver membranes, and in solubilizing the membrane proteins in a solution containing 125 mM octylglucoside, 20 mM Tris and 2 mM EDTA, pH 8. The proteins thus solubilized are separated under nondenaturing conditions on a preparative SDS gel (thickness 5 mm) consisting of a gradient from 4 to 12% polyacrylamide (35-50 mg of protein per gel). For part of the gel, the proteins are then electrotransferred (semi-dry



transfer, 21 V, 45 min, Biorad) onto a nitrocellulose membrane. After blocking the free sites of this membrane in a PBS solution containing 3% albumin, the membrane is incubated with 40 µg/ml of <sup>125</sup>I-LDL in the presence (Figure 8, lane 2) or in the absence (Figure 8, lane 1) of 0.8 mM oleate. The membrane is then washed five times for 10 minutes in PBS containing  
 5 0.5% (v/v) Triton X100, and exposed on a Phosphor Imager screen.

Analysis of the image obtained in the presence (Figure 8, lane 2) or in the absence (Figure 8, lane 1) oleate shows the presence of 3 main bands which have bound the LDLs. The apparent MW of the first band is about 240 kDa, that of the second is 115 kDa and that of the third is 90 kDa. On the basis of these observations, two hypotheses are formulated:  
 10 on the one hand, the LSR activity is linked to the presence of several distinct proteins; on the other hand, the same type of image can be explained by a multimeric organization of a protein complex.

In order to check this hypothesis, the inventors undertook the purification of the band having the highest apparent molecular weight (240 kDa). The partial purification of this  
 15 protein, designated "band A", is carried out by preparative electrophoresis as follows.

### ***Partial purification of LSR***

The technique consists in isolating, by differential centrifugation (Belcher et al., 1987) rat liver membranes, and in solubilizing the membrane proteins in a solution containing 125 mM octylglucoside, 20 mM Tris and 2 mM EDTA, pH 8. The proteins thus  
 20 solubilized are separated under nondenaturing conditions on a preparative SDS gel (thickness 5 mm) consisting of a gradient from 4 to 12% polyacrylamide (35-50 mg per gel). For part of the gel, the proteins are then electrotransferred (semi-dry transfer, 21 V, 45 min, Biorad) onto a nitrocellulose membrane. After blocking the free sites of this membrane in a PBS solution containing 3% albumin, the membrane is incubated with 40 µg/ml of <sup>125</sup>I-LDL  
 25 in the presence (Figure 8, lane 2) or in the absence (Figure 8, lane 1) of 0.8 mM oleate. The membrane is then washed five times for 10 minutes in PBS containing 0.5% (v/v) Triton X100, and exposed on a Phosphor Imager screen. The proteins of interest are electroeluted (Electroeluter, Biorad).

The rat liver plasma membrane proteins were prepared and separated on a  
 30 polyacrylamide gel as above. The precise location of band A was established by ligand blotting carried out after electrotransfer of preparative gel sample removed at various levels.

The gel fragments containing band A are then collected, electroeluted and concentrated (speedvac), and then tested for their capacity to bind the LDLs in the

presence of oleate after electrophoresis and transfer onto nitrocellulose membranes (Figure 8, lane 3 ; 80 µg of protein/lane).

The proteins thus obtained were also used to produce polyclonal antibodies whose specificity was tested by Western blotting (Figure 8, lane 4).

5

### ***Preparation of polyclonal antibodies***

The LSR proteins used as antigens for the production of anti-LSR antibodies were prepared as indicated above.

The antigen preparation is injected subcutaneously into a rabbit in the presence of complete Freund's adjuvant, followed by a conventional immunization procedure. The titer of the antibody directed against the rat proteins is determined regularly (dot-blot technique). When the latter is judged to be sufficient, the specificity of the antibodies obtained is tested by Western blotting on a preparation of solubilized proteins of rat liver membranes as described above, with anti-rabbit IgG goat antibodies labelled with iodine  $I^{125}$  as second antibodies.

15

The Western blot results after electrophoresis under nonreducing conditions indicate that the antibodies produced from the proteins of band A bind to 3 main protein bands (240 kDa, 115 kDa and 90 kDa) which bind the  $^{125}I$ -LDL in the presence of oleate (Figure 8, lane 4). To verify the link between these protein complexes and the LSR activity, the effect of these polyclonal antibodies on the LSR activity was tested.

20

The methods used are described in detail below (Mann et al., 1995 ; Troussard et al., 1995). The LSR activity is estimated by measuring the binding of lipoproteins to plasma membranes and by measuring the binding, internalization and degradation of the lipoproteins on primary cultures of rat hepatocytes.

25

### ***Measurement of the binding of lipoproteins on plasma membranes***

The LSR activity is measured on a preparation of rat liver plasma membranes (Bartles and Hubbard, 1990). These membranes exhibit 10 to 15-fold enrichment with 5-nucleotidase (marker specific for plasma membranes). 100 µg aliquots of proteins are incubated for 30 minutes at 37°C in the presence or in the absence of 0.8 mM oleate in a final volume of 250 µl supplemented with 100 mM PBS, 2 mM EDTA, 350 mM NaCl, pH 8 (buffer A). The oleate is added in a volume of 5 to 10 µl of isopropanol. The excess and

35

unbound oleate is then removed by 6 washes. The pellets are resuspended in 250  $\mu$ l of incubation buffer, sonicated for 5 seconds, power 1.90% in the active cycle, and then centrifuged for 15 min at 18,000 rpm. The activated membranes are incubated for 1 hour at 4°C with various concentrations of antibody and then with 5  $\mu$ g/ml of  $^{125}$ I-LDL (1 hour at 4°C). 25  $\mu$ l of 2% BSA are added to the incubation mixture. The quantity of  $^{125}$ I-LDL bound to the membranes is measured by sedimenting the membranes by centrifugation after having deposited 200  $\mu$ l of the incubation mixture on a layer of 5% (W/V) of BSA in buffer A. The supernatants are removed by aspiration, the tube bottoms are cut off and their radioactivity is counted in a  $\gamma$  counter.

The inhibitory effect of anti-LSR antibodies on the LSR activity, compared to that of any preparation of rabbit immunoglobulins is shown in Figure 9 A. The inhibition of the LSR activity by the anti-LSR antibodies confirms that the multimeric complex described above is responsible for the activity of the receptor and validates the ligand blotting technique used to identify it. The effect of the anti-band A antibodies was, in addition, tested on the other steps of the activity of the receptor : the internalization and the degradation of lipoproteins by the LSR expressed at the surface of hepatocytes in primary cultures.

### ***Measurement of the binding, internalization and degradation of lipoproteins by hepatocytes***

The LSR activity in the primary cultures of rat hepatocytes is measured by the binding, internalization and degradation of  $^{125}$ I-LDL and  $^{125}$ I-VLDL (LDL : low-density lipoprotein ; VLDL : very low-density lipoprotein), as described in Bihain and Yen, 1992 and Mann et al., 1995.

To measure the effect of the anti-LSR antibodies on the binding, internalization and degradation of LDLs by LSR, primary cultures of rat hepatocytes (48 h after plating) are incubated in the presence of 20 ng of leptin/well for 30 min at 37°C, followed by the addition of anti-LSR antibodies in the presence or in the absence of oleate. After incubating at room temperature for 30 min,  $^{125}$ I-LDL (20  $\mu$ g/ml) is added and then the cells are incubated for 4 h at 37°C. The binding, incorporation and degradation of  $^{125}$ I-LDL are measured as described in Bihain and Yen, 1992 and Mann, et al., 1995.

The data in Figure 9 B show that the anti-band A antibodies inhibit most of the activity of binding of the LDLs to the LSRs present at the level of the hepatocytes. This inhibition induces a decrease in the same proportions in the internalization and proteolytic degradation of the lipoproteins.

The anti-band A antibodies are thus characterized as anti-LSR. Their relative specificity was defined by a selective immunoprecipitation method. Extracts of hepatocytes in primary culture are immunoprecipitated by means of the anti-LSR antibodies described above, according to the protocol described below.

### ***Immunoprecipitation of extracts of hepatocytes in the presence of specific antibodies***

Primary cultures of rat hepatocyte (Oukka et al., 1997) are incubated for 60 minutes to 2 hours in the presence of a mixture of  $^{35}\text{S}$ -methionine and  $^{35}\text{S}$ -cysteine (Promix, Amersham). This medium is then removed and the cells are washed and then incubated in PBS containing 1% of Triton X100. This cellular lysate is then incubated in the presence of non-specific antibodies and then of protein A. The equivalent of 40  $\mu\text{g}$  of specific anti-LSR antibodies is then added and the LSR-antibody complexes are precipitated with the aid of a second preparation of protein A. After washing, the complexes are dissociated in the presence of 1% SDS supplemented or otherwise with 5%  $\beta$ -mercaptoethanol, incubated at  $100^\circ\text{C}$  for 5-10 minutes, and separated on a 10% acrylamide gel. The gels are dried and exposed on a Phosphor Imager screen. Each of the lanes contains the equivalent of a  $165\text{ cm}^2$  flask, that is to say  $22 \times 10^6$  cells.

20

Analysis of the immunoprecipitation results indicates that under nonreducing conditions (Figure 10, lanes 2 - without incubation at  $100^\circ\text{C}$  - and 3 - with incubation at  $100^\circ\text{C}$  -), the antibodies reveal 3 principal protein bands : 2 of apparent molecular weight 240 kDa and 180 kDa, 1 of apparent molecular weight 68 kDa. The presence of 2 bands of weaker intensity, corresponding to a molecular weight of 115 kDa and 90 kDa, can also be noted. This experimental approach therefore essentially identifies the same protein elements as those identified by the ligand blotting method. It can be observed, moreover, that under reducing conditions (Figure 10, lanes 1 and 4), the elements of high molecular weight dissociate into 3 elements of apparent molecular weight 68 kDa, 56 kDa and 35 kDa, respectively.

30

The relative intensity of the 68 kDa and 56 kDa bands is similar whereas that of the 35 kDa band is about  $\frac{1}{4}$  of that of the other two.

### ***Example 2 : Cloning of the c-DNA encoding the $\alpha$ - and $\beta$ -LSR***

The screening of an expression library by means of the anti-LSR antibodies described above was carried out as indicated below.

35

### ***Screening of an expression library***

After infection of bacteria with lambda GT11 bacteriophages containing rat liver cDNA (commercially obtained from Clontech Laboratories Inc.) (*5' Strech Plus c-DNA Library*), the cells are plated on LB MgSO<sub>4</sub> medium. After 4 hours of culture at 42°C, a nitrocellulose membrane, previously incubated in a 10 mM IPTG solution, is deposited in the Petri dishes. Four hours later, the first membrane is removed and a second is applied to the Petri dish.

Each membrane is immersed in a Petri dish containing blocking buffer kept stirring for one hour. Next, the antibody is added to a final concentration of 10 µg/ml of blocking buffer (Huynh et al., 1984; Young and Davis, 1983a and 1983b). The membranes are then washed three times for 10 minutes with TNT (10 mM Tris, 150 mM NaCl, 0.05% Tween 20).

The membranes are incubated in the presence of secondary antibodies (alkaline phosphatase-conjugated affinipure F(ab')<sub>2</sub> fragment goat anti-rabbit IgG; Immunotech) at a final concentration of 0.08 µg/ml of blocking buffer (TNT + 5% powdered skimmed milk, Pâturage trademark).

After washing the membranes in TNT, they are incubated in the presence of BCIP (5-bromo-4-chloro-3-indolyl phosphate) and of NBT (nitro blue tetrazolium) until a colour is obtained.

The positive clones are then recovered on the dishes, titrated and subjected to the same immunoscreening procedure so as to confirm that they are true positives (secondary screening). Optionally, a tertiary screening may be carried out. The phage DNA of the selected clones, isolated from a bacterial lysate (Clontech protocol), and digested with the restriction enzyme EcoR1 is inserted at the EcoR1 site of the plasmid pBluescript SK+.

Two clones containing an insert of 1.8 kb were thus obtained, and proved to be of identical sequences. The hybridization of rat liver mRNA (2 µg of polyA<sup>+</sup> mRNA) with a probe corresponding to the BglIII-XbaI fragment of this insert revealed two bands of sizes 1.9 kb and 2.1 kb (Figure 11 A) respectively. Northern blot analysis, with a probe corresponding to the XbaI-XbaI fragment of this insert, of the tissue distribution of the corresponding messengers showed that they are preferably expressed in the liver (Figure 11 B). The Northern blotting was carried out according to the following protocol.

### ***Northern blotting***

The membranes containing the mRNAs of different rat tissues (Clontech) were hybridized with fragments of the cDNA for the LSR gene and of the cDNA for human β-actin (Clontech), labelled with [<sup>33</sup>P]dCTP, in 5xSSPE, 10xDenhardt buffer containing 0.5%



SDS, 100 µg/ml of salmon sperm DNA, 50% deionized formamide, at 42°C for 16 hours. The membranes were then washed in 2xSSC, 0.5% SDS at room temperature and in 1xSSC, 0.1% SDS at 65°C, and then exposed on the Phosphor Imager (Molecular Dynamics).

5

A cDNA corresponding to the 1.9 kb band was reconstructed by 5'RACE PCR from the 1.8 kb fragment and sequenced.

In order to elucidate the presence of multiple bands in Northern blotting, several pairs of primers defining fragments of a rat cDNA sequence were synthesized and used as primers for a PCR amplification (Figure 11 C). The sequences of the oligonucleotides used are listed below :

- a : 5'- GTTACAGAATTCGCCGCGATGGCGCCGGCG -3' (SEQ ID 20)
- b : 5'- GCCAGGACAGTGTACGCACT -3' (SEQ ID 21)
- c : 5'- ACCTCAGGTGTCCCGAGCAT - 3' (SEQ ID 22)
- 15 • d : 5'- GAAGATGACTGGCGATCGAG - 3' (SEQ ID 23)
- e : 5'- ACCTCTATGACCCGGACGAT - 3' (SEQ ID 24)
- b' : 5'- CACCACCCTGACAGTGCGTA - 3' (SEQ ID 25)
- c' : 5'- CTGGGGGGCATAGATGCTCGG - 3' (SEQ ID 26)
- d' : 5'- GCCCTGGAAGGCCTCGATCG - 3' (SEQ ID 27)
- 20 • e' : 5'- CAAGTCCCTAGGATCGTCCG - 3' (SEQ ID 28)

Whereas each pair of primers shows a single fragment, the bc' pair makes it possible to amplify three fragments of different sizes. Analysis of the sequences of these fragments makes it possible to reconstitute the sequence of three complete cDNAs for rat LSR, having sizes of 2097 bp (SEQ ID 1), 2040 bp (SEQ ID 3) and 1893 bp (SEQ ID 5) respectively, and all three corresponding to the same precursor messenger by alternative splicing.

These three cDNAs contain an open reading frame starting with an AUG codon at position 219 surrounded by a Kozak consensus sequence (Kozak, 1987 and 1990). The predicted molecular weights of the proteins encoded by these three cDNAs are 66 kDa, 64 kDa and 58 kDa, respectively.

30

The two cDNAs encoding respectively the longest and the shortest forms of rat LSR were then translated *in vitro* as indicated below.

## ***Translation in vitro***

The cDNAs are subcloned into the plasmid pcDNA3 ; transcription and translation *in vitro* are carried out using the Promega TNT kit. The products of translation, labelled with <sup>35</sup>S-methionine and <sup>35</sup>S-cysteine, are visualized after electrophoresis on a polyacrylamide gradient gel (10%) and exposure on Phospor Imager.

The molecular weights of the products obtained, that is to say 68 kDa and 56 kDa (Figure 12), correspond closely to those of the  $\alpha$  and  $\beta$  subunits of LSR.

To define if the products of these mRNAs are responsible for the receptor activity, three different experimental approaches were used.

Firstly, two peptides corresponding to residues 169-186 (SAQDL DGNNEAYAELIVLGR : SEQ ID 29) of the LSR produced from the mRNA of size 2097 bp and to residues 556-570 (EEGQYPPAPPYSET : SEQ ID 30) were synthesized. The sequence of these peptides is common to the three proteins identified above. Antibodies directed against these synthetic peptides were obtained according to the protocols indicated above. Figures 13 C and 14 C show that these anti-LSR peptide antibodies have an inhibitory effect on the binding of the LDLs to the LSRs present on rat plasma membranes, measured according to the protocol described in Example 1.

Secondly, a partial purification of the  $\alpha$  and  $\beta$  subunits was obtained by selective solubilization with the aid of sarkosyl ; a study using Western and ligand blotting showed that the  $\alpha$  and  $\beta$  components bind the anti-LSR polyclonal antibodies (Figure 13 B, lane 1), the anti-LSR peptide antibodies (Figure 13 B, lane 2 and Figure 14 B, lane 2), and the LDLs after incubation with oleates (Figure 13 B, lane 4). Ligand blotting was carried out according to the protocol described in Example 1 ; Western blotting was carried out as indicated below.

## ***Western blotting***

Primary cultures of rat hepatocytes are prepared as indicated in " Experimental procedures " The cells harvested after 48 hours of culture are washed and lysed in PBS containing 1% Triton X100. The lysates are deposited on a 10% SDS-PAGE gel under reducing conditions (2% SDS, 5%  $\beta$ -mercaptoethanol and 20 mM DTT, at 56°C for 1 h). After transferring onto a nitrocellulose membrane, the Western blotting is carried out with IgG antibodies directed against the LSR receptor.

Thirdly, the labelled proteins LSR 66 and 58 obtained by *in vitro* translation from the cDNAs LSR-Rn-2097 and LSR-Rn-1893 are used to estimate the effect of oleate on the binding of the LDLs according to the protocol detailed below.

### ***Binding of the LDLs onto the LSR proteins expressed in vitro (" flotation ")***

The  $^{35}\text{S}$ -cysteine or  $^{35}\text{S}$ -methionine labelled products of translation in vitro (17  $\mu\text{l}$ ) are incubated for 1 hour at 37°C in the presence of 100  $\mu\text{g/ml}$  of LDL, 1 mM oleate in buffer A, in a final volume of 400  $\mu\text{l}$ . An equal volume of 8% (w/v) BSA is added. The density is adjusted to 1.21 g/ml (assuming an initial density of 1.025 g/ml), with sodium bromide. The samples are then deposited on a sodium bromide solution at 1.063 g/ml, and then centrifuged for 20 hours at 4°C (Beckman SW41 rotor). A volume of 1 ml is collected at the surface, dialysed against electrophoresis elution buffer, and the radioactivity is counted (Beckman  $\beta$  counter).

Oleate increases the binding of LDL to LSR 56 (respectively LSR 68) by a factor of 2 (5 respectively). It can thus be shown that the  $\alpha$  and  $\beta$  subunits of rat LSR, encoded respectively by the cDNAs LSR-Rn-2097 and LSR-Rn-1893 (LSR 56 and LSR 68), preferably bind the LDLs after incubation with oleate.

All these results indicate that the cDNAs LSR-Rn-2097 and LSR-Rn-2040 encode two proteins which are indistinguishable by electrophoresis and whose apparent molecular weight is 68 kDa ; these proteins correspond to the band comprising the  $\alpha$  and  $\alpha'$  subunits of LSR, which is identified after immunoprecipitation under reducing conditions. The  $\beta$  subunit of LSR is presumably the product of translation of the cDNA LSR-Rn-1893. The analyses of stoichiometry after immunoprecipitation indicate that the multimeric complex of apparent molecular weight 240 kDa is the result of an assembly of an  $\alpha$  subunit with three  $\beta$  subunits. Analysis of the various domains of the proteins corresponding to the  $\alpha$ - and  $\beta$ -LCRs is compatible with a lipoprotein receptor function.

### ***Example 3 : Analysis of the activity of a recombinant LSR receptor, and its subunits, in transfected cells***

The inventors also expressed a recombinant LSR receptor in CHO cells according the following protocol.

### ***Transfection with cDNA sequences encoding the LSR receptor***

In order to study the activity of each of the recombinant subunits of LSR, as well as the activity of a reconstituted receptor, the inventors used the expression plasmid pcDNA3 (No et al., 1996) to study the expression, in animal cells, of either cDNA encoding the  $\alpha$  subunit ( $\alpha$  plasmid), or of a cDNA encoding the  $\beta$  subunit ( $\beta$  plasmid), of rat LSR. The LSR cDNAs were subcloned into the plasmid pcDNA3 (Invitrogen) using the

EcoRI and/or NotI restriction sites. Once obtained, these constructs are used to transfect CHO (Chinese hamster ovary) animal cells.

After 48 hours of culture, CHO (Chinese hamster ovary) cells (CHO-K1, CCL-61, ATCC, Rockville, MD) were distributed into 6-well plates (Falcon) at  $2.5\text{--}2.75 \times 10^5$  cells/well. After 24 h of culture in a Ham F-12 medium containing 10% (v/v) FBS, 2 mM glutamine and 100 units/ml of penicillin and streptomycin, a maximum of 2  $\mu\text{g}$  of plasmid/well were transfected using Superfect (Qiagen) according to the supplier's instructions (10  $\mu\text{l}$  Superfect/well, 2 h at 37°C in a Ham F-12 medium free of serum). The plates were then washed in PBS in order to remove the transfection reagents and the cells were then cultured in a Ham F-12 medium containing serum. The LSR activity was measured 48 h after transfection according to the protocols detailed in Example 1.

The inventors tested the effect of a co-transfection with the  $\alpha$  and  $\beta$  plasmids compared with that of a transfection with the  $\alpha$  plasmid alone, or with the  $\beta$  plasmid alone, on the three stages of the activity of the LSR receptor according to the protocols detailed below. Figures 15 and 16 show the comparisons between the LSR activities obtained on the recombinant cells expressing the  $\alpha$  subunit alone, or the two  $\alpha$  and  $\beta$  subunits; similar results are obtained for the  $\beta$  versus  $\alpha + \beta$  comparison, which is compatible with the comparative analysis of the primary sequences of each of the subunits (each of them also carrying the potential binding sites for lipoprotein ligands and fatty acids, such as oleate).

### ***Effect of a transfection with the LSR ( $\alpha$ ) plasmid alone, or of a co-transfection with the LSR ( $\alpha$ ) and LSR ( $\beta$ ) plasmid, on the binding, internalization and degradation of the LDLs***

The CHO-K1 cells were transiently transfected with increasing concentrations of  $\alpha$  plasmid and co-transfected with 0.4  $\mu\text{g}$  of  $\alpha$  plasmid and increasing concentrations of  $\beta$  plasmid. After 48 h of culture, the cells were washed once with PBS and incubated for 3 h at 37°C with 20  $\mu\text{g}/\text{ml}$   $^{125}\text{I}$ -LDL in the presence or in the absence of 1 mM oleate in DMEM containing 0.2% BSA, 5 mM Hepes, and 2 mM  $\text{CaCl}_2$ , pH 7.5. Next, the cells were washed as described above and incubated at 4°C for 1 h with 10 mM suramin in PBS.

To measure the binding of the LDLs (Figure 15), the medium was recovered and passed through a  $\gamma$  counter in order to evaluate the quantity of bound  $^{125}\text{I}$ -LDL. The results are the mean values of two measurements. For the measurement of the internalization and the degradation of LDLs (Figure 16), the quantity of  $^{125}\text{I}$ -LDL internalized and degraded was measured according to the protocols detailed in Example 1.

The co-transfection with  $\alpha$  and  $\beta$  plasmids makes it possible to establish three stages of LSR activity (Figures 15 and 16).

The inventors also observed that the co-transfection with the  $\alpha$  and  $\beta$  plasmids increases the LSR activity compared with a transfection with only an  $\alpha$  plasmid. The results suggesting a more efficient activity of the LSR when the  $([\beta] / [\alpha])$  ratio between the concentrations of  $\beta$  and  $\alpha$  subunits expressed increases, is compatible with the observation that the LSR receptor might consist of the assembly of an  $\alpha$  (or  $\alpha'$ ) subunit, and of several, probably three,  $\beta$  subunits.

The results show that only the co-transfection of the  $\beta$  and  $\alpha$  subunits allows the overexpression of a completely functional LSR receptor in the sense that it allows the complete proteolytic degradation of the protein.

In order to characterize the lipoprotein degradation activity obtained above in cells transfected with the LSR cDNAs, the inventors finally tested the capacity of anti-LSR antibodies to inhibit the binding of LDLs as measured above, as well as the substrate-specificity thereof.

### ***Characterization of the lipoprotein degradation activity obtained in transfected cells expressing a recombinant LSR receptor***

The CHO cells were transfected with the  $\alpha$  and  $\beta$  plasmids in a concentration ratio of 1 to 3.

Figure 17A shows that the LDL binding activity obtained in the transfected cells (expressed relative to the same activity observed in nontransfected control cells) is specifically inhibited by the anti-LSR antibodies.

Figure 17B shows the LDL binding activity obtained in the cells transfected in the presence of various nonlabelled lipoproteins acting as competitive ligands. The results show a ligand specificity similar to that observed for the endogenous LSR activity in rats (Mann et al., 1995): the rat chylomicrons are the preferred substrates for the rat recombinant LSR ; then come in particular, in decreasing order of specificity, the VLDLs and then the LDLs.

### ***Example 4 : Involvement of LSR in the clearance of cytokines***

The analysis of the sequence of the  $\alpha$  subunit of LSR reveals a cysteine-rich region which corresponds to a Tumor Necrosis Factor type cytokine receptor signature. LSR is, however, distinguishable from the cytokine receptors by the presence of signals allowing rapid endocytosis of the receptor/ligand complex (clathrin motif).



The inventors formulated the hypothesis that this receptor could serve for the removal of cytokines, and in particular of leptin ; in order to verify this hypothesis they analysed the degradation of recombinant leptin by hepatocytes in primary culture according to the protocol below.

5

### ***Degradation of leptin by hepatocytes in primary culture***

Primary cells of rat hepatocytes are incubated for 4 hours at 37°C with 20 ng/ml of <sup>125</sup>I-leptin in the absence or in the presence of 0.5 mM oleate, 75 µg/ml of RAP, 200 µg/ml of non-specific antibodies or anti-LSR specific antibodies, or 50 µM chloroquine. The  
10 medium is then recovered and the quantity of <sup>125</sup>I-leptin degraded is measured.

As indicated in Figure 18, the degradation of leptin by hepatocytes in primary culture is inhibited by :

- a) polyclonal antibodies directed against LSR. These antibodies also inhibit, in the same  
15 proportions, the LSR activity,
- b) the 39 kD Receptor Associated Protein (RAP); this protein blocks the LSR activity *in vitro* and retards the clearance of chylomicrons *in vivo* (Troussard et al., 1995; Willow et al., 1994)
- c) chloroquine; this cellular poison prevents the acidification of the endocytosis vesicles and  
20 inhibits the activity of the lysosomal proteases,
- d) oleate; this free fatty acid induces a change in the conformation of LSR which unmasks the lipoprotein binding site.

This indicates that the FAF (Fatty Acid Free) conformation of LSR is probably the only one which is compatible with the role of binding followed by degradation of leptin. The  
25 non-specific immunoglobulins are without effect on the degradation of leptin (Figure 18).

In order to verify the binding of leptin to LSR, the rat liver plasma membrane proteins were deposited on an affinity chromatography column containing recombinant leptin, according to the protocol detailed below.

30

### ***Leptin affinity chromatography***

A Hi-trap column (Pharmacia) is used: 5 mg of leptin are bound onto 1 ml of column according to the methods recommended by the manufacturer. The plasma membrane proteins are solubilized from rat livers as indicated above (Mann et al., 1995), and then  
35 dialysed overnight against PBS pH 7.4, 0.1% Tween 20. The column is washed in the same buffer and the protein extract is deposited at a rate of 0.2 ml/minute. The column is washed

with 6 ml of the same buffer. It is then eluted with the same buffer supplemented with 100 mM glycine pH 3; 20 fractions of 500  $\mu$ l are then neutralized with 5  $\mu$ l of PBS, 0.1% Tween 20, pH 8. 50  $\mu$ l of each fraction are deposited on a nitrocellulose membrane for dot-blot analysis by means of anti-LSR antibodies. The positive fractions (1, 3, 4, 7 and 8) are  
 5 dialysed against 24 mM ammonium bicarbonate, 0.01% Tween 20, pooled and concentrated in a Speedvac in a final volume of 300  $\mu$ l. 40  $\mu$ l of the final product are analysed by Western blotting by means of anti-LSR antibodies.

Figure 19 shows that the anti-LSR antibodies specifically recognize the  $\alpha$  subunit  
 10 which, after binding to leptin, was released by the glycine buffer.

Experiments of stable transfection of the  $\alpha$  subunit will make it possible to measure the affinity of leptin for this new receptor.

15 All these results suggest that LSR represents one of the pathways for the degradation and elimination of leptin. The *in vivo* injection of radiolabelled recombinant leptin showed, both in the obese mice and in the control mice, a rapid speed of clearance and a preferential capture of leptin by the liver and the kidney: 50% of the injected dose is found after 10 minutes in these two organs. In order to analyse the mechanisms for the  
 20 selective capture of leptin, the inventors compared the quantities of leptin and of  $\beta$ 2-microglobulin (soluble protein having a molecular weight close to that of leptin, chosen as control) present in the kidney and liver of normal mice and of two obese mouse lines 5 minutes after injection of the same tracer dose of these two radiolabelled proteins.

## 25 ***Measurement of the clearance of leptin in mice***

The female control, *ob/ob*, or *db/db* mice (6-8 weeks), on an empty stomach, are anaesthetized and receive via the saphenous vein an injection of 80 ng of murine recombinant  $^{125}$ I-leptin or of  $^{125}$ I- $\beta$ 2-microglobulin (Sigma, labelled by the Iodobeads method, like leptin). Five minutes later, the animals are infused with a physiological saline  
 30 solution (15 ml, at 4°C). The tissues are collected and counted for their radioactivity (Gamma counter). In some cases, an anti-LSR antibody or a control protein are injected 30 minutes after injection of  $^{125}$ I-leptin. It is important to note that the labelling of leptin with  $^{125}$ I has no effect on its biological activity.

35 The results presented in Figure 20 show that the quantity of leptin selectively captured by the liver is reduced in the obese mice, compared with the control mice;

moreover, no difference is observed between the various lines as regards the renal capture of leptin.

The inventors then measured the number of LSR receptors in control, *ob/ob* and  
5 *db/db* mice according to the following protocol.

### ***Measurement of the apparent number of LSR receptors on plasma membranes***

The apparent number of LSR receptors on plasma membranes is measured as  
10 previously described (Mann et al., 1995) by estimating the quantity of LDL bound to a plasma membrane preparation. The plasma membranes (100 µg) are incubated with 1 mM oleate ; they are then washed three times as indicated above, and then incubated for 1 hour at 37°C with 40 µg/ml of <sup>125</sup>I-LDL. The quantity of <sup>125</sup>I-LDL bound to the plasma membranes is then determined by counting. The mean is established on 3 measurements  
15 per animal for 3 different animals in each of the groups.

Figure 21 shows that the number of LSR receptors in obese animals exhibiting either a deficiency in leptin (*ob/ob*), or a deficiency in the ob receptor (*db/db*), is significantly reduced. The reduction in the selective hepatic capture of leptin in obese  
20 mice coincides with the reduction, in these animals, of the apparent number of LSR receptors.

The inventors finally tested, according to the protocol presented below, the effect of anti-LSR antibodies on the distribution of leptin between the liver and the kidney, 5  
25 minutes after injection of a tracer dose.

### ***Measurement of the distribution of leptin between the liver and the kidney in the presence of anti-LSR antibodies***

Control mice are anaesthetized and then they are injected intravenously with 1 mg  
30 of non-specific IgG antibody or of anti-LSR IgG antibody. After 30 minutes, 80 ng of <sup>125</sup>I-leptin are injected and, after 5 minutes, an infusion of physiological saline solution at 4°C. The tissues are removed immediately and the radioactivity is measured. The results represent the mean and the standard deviation obtained for 3 animals for each of the groups.

As shown in Figure 22, the hepatic capture of leptin is reduced and the renal capture is increased by the anti-LSR antibodies, compared with the control immunoglobulins.

These results therefore indicate that LSR is responsible for the selective hepatic capture of leptin and that a reduction in the number of receptors is observed in the obese animals. Such a reduction may explain the leptin-resistance syndrome and the increase in the plasma concentration of leptin which is observed in most obese human subjects.

It is also possible that the LSR receptor serves as degradation pathway for other cytokines, in particular those produced by the adipose tissue. The importance of Tumor Necrosis Factor  $\alpha$  and Nerve Growth Factor will be noted in particular. These two cytokines exert a significant slimming effect when they are injected into human subjects (Cytokines and their receptors, 1996).

#### ***Example 5 : Control of the LSR activity by cytokines***

The  $\alpha$  subunit of the LSR receptor binds leptin and possesses potential phosphorylation sites. This makes it a receptor which not only mediates endocytosis, but could also serve in cell signalling.

The inventors therefore tested the hypothesis according to which leptin modulates the activity of LSR, as described below.

#### ***Measurement of the LSR activity of binding, internalization and degradation of lipoproteins in the presence of leptin***

Rat hepatocytes in primary culture are incubated at 37°C for 30 min with an increasing concentration of leptin, and then incubated at 37°C for 4 hours with either 50  $\mu\text{g/ml}$  of  $^{125}\text{I}$ -LDL (specific activity : 209 cpm/ng) or 50  $\mu\text{g/ml}$  of  $^{125}\text{I}$ -VLDL (specific activity : 157 cpm/ng) in the absence or in the presence of 500  $\mu\text{M}$  oleate. The cells are then washed and the quantities of  $^{125}\text{I}$ -lipoproteins bound, incorporated and degraded are measured as described above in Example 1 (Bihain and Yen, 1992). The results shown in Figure 23 represent the differences obtained between the cells incubated with or without oleate. Each point represents the mean of 3 measurements. The standard deviation for each point is included in the symbol.

The addition of increasing concentrations of leptin to hepatocytes in culture increases the binding, internalization and degradation of VLDLs and LDLs (Figure 23).

## ***Analysis of the capacity for inducing the LSR activity by leptin***

**Measurement, in the presence of leptin, of the apparent number of LSR receptors expressed at the surface of rat hepatocytes in primary culture**

Primary cultures of rat hepatocytes are incubated for 30 min at 37°C in the presence or in the absence of 20 ng/ml of leptin, for 10 min at 37°C in the presence of 0.8 mM oleate. The cells are washed with PBS buffer precooled to 4°C, and then incubated for 2 hours at 4°C in the presence of increasing concentrations of <sup>125</sup>I-LDL. The cells are then washed, lysed and the quantity of bound <sup>125</sup>I-LDL is measured.

**Comparative effects of leptin in the presence of cycloheximide, colchicine and cytochalasin B**

The initial conditions are identical to those described above ; after incubation with leptin, the cells are incubated for 30 min at 37°C with 5 µM cycloheximide, 5 µM colchicine or 2.5 µM cytochalasin B. The cells are then incubated for 10 min at 37°C in the presence of 0.8 mM oleate. The cells are then washed with PBS buffer precooled to 4°C, and then incubated for 2 hours at 4°C in the presence of 50 µg/ml of <sup>125</sup>I-LDL. 2 measurements are carried out, and the mean results are presented.

It is thus shown that the increase in the LSR activity by leptin is obtained through an increase in the apparent number of receptors expressed at the surface of the hepatocytes (Figure 24 A). This increase results, on the one hand, from an increase in protein synthesis (it is partially inhibited by cycloheximide, an inhibitor of protein synthesis). It involves, on the other hand, the mobilization of the endocytosis vesicles by the microtubule system (it is indeed inhibited by cytochalasin B which blocks microtubular transport) (Figure 24 B).

In order to check the *in vivo* effect of leptin on the LSR activity, the inventors characterized the postprandial triglyceridemic response of control, *ob/ob* and *db/db* mice after a force-fed test meal according to the following protocols.

## ***Measurement of the postprandial lipemic response in mice***

Control, *ob/ob* and *db/db* mice, starved since the day before, are force-fed with a meal which is very high in fat [60% fat (37% saturated, 27% monounsaturated and 36% polyunsaturated fatty acids), 20% protein and 20% carbohydrate] providing 56 kcal of energy/kg of the weight of the animal. Immediately after the meal (time = 0 hour), the mice are injected intravenously with 200 µl of physiological saline solution. At various times, 20 µl of blood are collected via the caudal vein in tubes containing 90 µg of



disodium EDTA, and after separating the plasma by centrifugation, the plasma concentration of triglyceridemia is determined with the aid of an enzymatic assay kit. Each point on the curves presented corresponds to the mean with standard deviation obtained for 3 measurements per animal and for 3 different animals.

5

### ***Measurement of the effect of leptin on the postprandial lipemic response in mice***

The procedure is the same as above, except that immediately after the meal (time = 0 hour), the mice are injected intravenously with either 200 µl of physiological saline solution, or 200 µl of the same solution containing 50 µg of murine recombinant leptin.

10

### ***Measurement of the postprandial lipemic response in mice in the presence of lactoferrin and/or leptin***

*ob/ob* mice, starved since the day before, are force-fed with a meal identical to that described above. Immediately after the meal (time = 0 hour), the mice are injected intravenously with 200 µl of saline solution containing either no supplement, or 0.5 µg of leptin, or 2.5 mg of lactoferrin or alternatively a mixture of 0.5 µg of leptin and 2.5 mg of lactoferrin. Blood is collected between 2 and 3 hours after the meal and the plasma concentration of triglycerides (TG) is measured. The values obtained represent the mean with standard deviation obtained for 4 measurements per animal and for 2 different animals [ $p < 0.02$  (*ob/ob* compared with *ob/ob* + leptin),  $p < 0.01$  (*ob/ob* compared with *ob/ob* + lactoferrin), NS (*ob/ob* + lactoferrin compared with *ob/ob* + leptin + lactoferrin)].

20

In agreement with the reduction in the number of LSR receptors observed in the obese mice, an amplification of the postprandial lipemic response also exists in the untreated obese mice. The administration of leptin by the intravenous route, at the same time as the test meal, makes it possible to reduce the postprandial lipemic response in the two obese mouse lines and in the control mice (Figure 25).

25

This reduction in the lipemic response induced by leptin is suppressed by the administration of lactoferrin (Figure 26), which blocks the activity of LSR (Yen et al., 1994; Mann et al., 1995). This strongly suggests that the reduction in the lipemic response is explained by an increase in the LSR activity.

30

Finally, also *in vivo*, the administration of leptin induces an increase in the apparent number of LSR receptors expressed at the level of the surface of the hepatocytes. This increase is significant both in the *ob/ob* mice and in the *db/db* mice (Figure 27).

35

Leptin and probably other cytokines are therefore regulators of the activity of LSR. A syndrome of resistance to leptin or to other cytokines can lead to hypertriglyceridemia, which is either permanent or limited to the postprandial phase.

#### 5 ***Example 6 : Effect of leptin on the expression of LSR ; therapeutic effects***

To reinforce correlation between the administration of leptin, the reduction in the postprandial lipemic response, and an enhanced expression or activity of the LSR receptor, and to better evaluate the possible therapeutic implications of the induction of the activity of hepatic clearance of lipoproteins by leptin, the inventors supplemented the  
10 preceding analysis with monitoring of the weight variation, of the LSR activity and of the expression of LSR mRNA, in control or obese animals treated with leptin or otherwise.

#### ***Postprandial lipemic response and LSR activity in control and obese mice***

Control male mice (C57BL6) (n=8) and obese male mice (ob/ob, n=8 - animals  
15 deficient in the leptin gene - and db/db, n=8 - animals deficient in the gene for the leptin receptor -) (aged 17 weeks old) were weighed in order to quantitatively establish the differences in weight between lines (Figure 28A). The postprandial lipemic responses of the animals of each line were measured in the absence of treatment with leptin as described above. The apparent number of LSR receptors expressed at the surface of the  
20 hepatic cells was measured on 4 animals of each line, as described above, and expressed in comparison with the 5'-nucleotidase activity (enzyme selectively measured at the level of the plasma membranes ; Sigma kit). Finally, Northern blotting made it possible to estimate the level of expression of the LSR receptor in three animals of each line, according to the protocol described above.

25

The higher postprandial lipemic response in the obese animals (Figure 28B) is in agreement with the smaller apparent number of hepatic LSR receptors in these same animals (Figure 28C). Furthermore, the Northern blotting results (Figure 28D) indicate that this reduction in the apparent number of LSR receptors in the obese animals is  
30 accompanied by a reduction in the level of expression of the said receptor in the same animals. The inventors have shown that indeed, a reduction in the number of mRNA encoding the LSR receptor is observed in the obese mice *ob/ob* and *db/db*.

The inventors also studied the effect of a long-term treatment of a treatment with leptin on ob/ob mice (Figure 29).

### ***Effect of a long-term treatment with leptin on ob/ob mice***

- 5           The ob/ob obese mice received a daily injection of either leptin, or of an equivalent volume of sterile PBS, for 30 days. The injected doses are 50 µg/animal from day 0 to day 4, 100 µg/animal from day 5 to day 17, and 150 µg/animal from day 18 to day 30. Several parameters indicated below are measured:
- *the weight* (Figure 29 A) : the change in weight is measured for 6 animals, over the
  - 10           duration of the treatment;
  - *the postprandial lipemic response* (Figure 29 B) : it is measured according to the protocol detailed in Example 5 on three animals in each group, on day 29;
  - *the apparent number of LSR receptors* (Figure 29 C) : it is measured according to the protocol detailed in Example 4 on three animals in each group, on day 30;
  - 15           - *the quantity of LSR mRNA* (Figure 23 D) : it is estimated by Northern blotting as indicated in the protocol of Example 2.

20           The inventors thus observed a very significant loss of weight in the ob/ob obese mice treated over 30 days with leptin. Furthermore, the treatment with leptin causes a clear reduction in the postprandial lipemic response. This reduction in the postprandial lipemic response is correlated with an increase in the apparent number of LSR receptors at the surface of the cells and with an increase in the quantity of mRNA encoding the subunits of the LSR receptor.

25           These results establish *in vivo* that LSR represents the limiting step in the elimination of dietary lipids. Furthermore, the treatment of this obesity inducing a weight loss causes an increase in the activity of hepatic degradation of dietary lipids, and a reduction in the postprandial lipemic response.

### ***Example 7 : Characterization of the human LSR receptor***

30

#### ***Northern-blot analysis***

35           Nucleic probes for rat LSR were used to carry out Northern-blot analyses with a membrane (Human Multiple Tissue Northern Blot, Clontech #7760-1) comprising human heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas poly A RNAs. A band of about 2 kbp is detected in the liver and in the kidney. Approximate quantification

of the hybridization results indicate that LSR is expressed in the liver at least 5 times more than in the kidney.

### ***Cloning of the cDNA ; study of the splicing zone***

5 Reverse transcription-PCR experiments on the mRNA made it possible to determine with greater precision the size of exon 1 on the 5' side and splicing sites between exons 1 and 2. However, it is not certain that this end constitutes the start of this exon. In addition, a second initiation site exists in exon 1 which is more downstream from the first and which exhibits a greater probability than the latter. The splicing between  
10 exons 1 and 2 was different between the human RNA and the rat RNA.

The amplification was carried out with several pairs of primers :

|    |                                           |         |             |
|----|-------------------------------------------|---------|-------------|
|    | a : 5' - ATGCAACAGGACGGACTTGGA - 3'       | exon1   | (SEQ ID 31) |
|    | b : 5' - TCAGACGACTAACTTTCCCGACTCAGG - 3' | exon 10 | (SEQ ID 32) |
|    | c : 5' - CTACAACCCCTACGTTGAGT - 3'        | exon 2  | (SEQ ID 33) |
| 15 | d : 5' - TCGTGACCTGACCTTTGACCAGAC -3'     | exon 3  | (SEQ ID 34) |
|    | e : 5' - CCTGAGCTACTCCTGTCAACGTCT -3'     | exon 6  | (SEQ ID 35) |
|    | f : 5' - AGGCCGAGATCGCCAGTCGT -3'         | exon 9  | (SEQ ID 36) |

The amplification carried out with the ab pair of primers led to two products 1.8 kb and 2 kb in size after separation on an electrophoresis gel. Given that the sizes of these  
20 two products can be explained by an alternative splicing similar to that described in rats, the other amplification primers were drawn. These primers made it possible to identify the three forms of cDNA resulting from the alternative splicing of the RNA.

The first cDNA which contains the totality of the ten exons is called LSR-Hs-2062 and corresponds to SEQ ID 7. It corresponds to the rat cDNA LSR-Rn-2097. The second  
25 cDNA contains exons 1, 2, 3, 5, 6, 7, 8, 9 and 10, and is called LSR-Hs-2005. It corresponds to SEQ ID 9. This cDNA corresponds to the rat cDNA LSR-Rn-2040. Finally, the cDNA containing exons 1, 2, 3, 6, 7, 8, 9 and 10 is called LSR-Hs-1858 and its sequence is listed in SEQ ID 11. It corresponds to the rat cDNA LSR-Rn-1893.

It should be noted that it was possible to demonstrate a slippage of the splicing  
30 site at the boundary of exon 8. This slippage, of the triplet TAG at position 19953-19955 of SEQ ID 19 to the contiguous triplet AAG at position 19956-19958 of SEQ ID 19, results in the loss of the Glu residue at position 386 of the cDNA of SEQ ID 8.

The sequences of the proteins encoded by the cDNA LSR-Hs-2062, LSR-Hs-2005 and LSR-Hs-1858 correspond respectively to SEQ ID 8, 10 and 12. The biological protein  
35 sequences can start at the first ATG codon observed in the reading frame (position 35 of the protein sequence). However, the preferred codon for initiation of translation is more

downstream at position 83 of the protein sequence. Furthermore, it is quite possible that this initiation codon is more upstream in the 5' region of exon 1 not yet determined or in a possible exon preceding the latter.

Finally, Figures 3A and 3B represents a schematic representation of the various protein forms identified in humans, indicating the conserved motifs.

This analysis makes it possible to conclude that three  $\alpha$ ,  $\alpha'$  and  $\beta$  subunits of LSR, which are equivalent to the LSR 66, LSR 64 and LSR 58 forms in rats, exists in humans.

### ***Identification and isolation of the genomic sequence for human LSR***

Screening of public data banks of nucleic sequences (Genebank, version: 101) both with the sequence of mouse lisch7 (Accession No.: U49507) and with that of rat LSR\_2097 isolated by the inventors made it possible to isolate two human genomic DNA sequences. They are cosmids whose accession numbers are AC002128 and AD000684, of respective sizes 45,328 bp and 41,936 bp. These two cosmids partially overlap. The 3' end of the cosmid AC002128 overlaps, over 12838 bp, the 5' end of the cosmid AD000684. On the common portion of 12,838 bp, the sequences are 100% identical, apart from two deletions at positions 822 and 3170 of the cosmid AD000684. The human LSR gene is distributed over the two cosmids. To facilitate the study of this region, a complete genomic sequence was reconstituted: the 45,328 bp of the cosmid AC002128 were added to the sequence of the cosmid AD000684 between the 12,839 base and the 41,936 base. The combination constitutes a sequence of 74,426 bp. A genomic sequence covering the LSR gene, was extracted (SEQ ID 19).

The putative exons of the LSR gene were determined after alignment of the sequence described above with the sequences of the RNAs for mouse Lisch7 and rat LSR. The validity of the splicing sites on either side of the putative exons was verified.

Moreover, a human genomic library consisting of BACs was screened by the methods described in Chumakov et al., 1995.; the clones thus isolated were contiged, subcloned and then sequenced in order to obtain the human genomic sequence encoding LSR (SEQ ID 41).

The two sequences thus obtained (SEQ ID 19 and 41) carry minor differences which are mentioned in the accompanying listings.



### ***Example 8 : LSR activity in humans***

Primary cultures of human fibroblasts, isolated from subjects having a deletion affecting the promoter and the first exon of the LDL receptor gene, were obtained.

5 The incubation of these cells in the presence and in the absence of oleate shows that the latter induces LDL binding, internalization and degradation activity which follows a saturation kinetics (Bihain and Yen, 1992). The affinity of this receptor, induced by oleate, is maximum for the particles high in triglycerides (VLDL and chylomicrons) as well as for triolein and phosphatidylcholine supplemented with recombinant apoprotein E. The affinity of the LDLs for the receptor is lower than that of the VLDLs and the chylomicrons but,  
10 however, higher than those of triolein and phosphatidylcholine particles not containing ApoE, or than those of VLDLs isolated from a subject with type III hyperlipidemia and the ApoE E<sub>2/2</sub> phenotype (Yen et al., 1994).

15 It was also possible to measure the LSR activity in fibroblasts of normal human subjects (Figure 30), according to the protocol below.

### ***Measurement of the binding, internalization and degradation of LDLs by fibroblasts.***

20 The fibroblasts are cultured beforehand for one week as described above, except that the medium contains 20% foetal bovine serum (Goldstein et al., 1983). Next, they are incubated with increasing concentrations of <sup>125</sup>I-LDL in the absence or in the presence of 1 mM oleate. The cells are then washed, lysed and counted for their radioactivity.

### ***Example 9 : Effect of leptin on the LSR activity in humans***

25 The LSR activity of human fibroblasts HF (familial hypercholesterolemia) is also increased after incubation with leptin (Figure 31), suggesting that as in rats, LSR participates, in humans, in the clearance of cytokines, and its activity is modulated by the latter. The corresponding measurements were carried out as indicated below.

### ***Effect of leptin on the LSR activity on human fibroblasts***

30 The fibroblasts HF are incubated for 30 minutes at 37°C with increasing concentrations of leptin, and then for 2 hours at 37°C with 50 µg/ml of <sup>125</sup>I-LDL, in the presence of 500 µM oleate. The binding, internalization and degradation of the LDLs are measured as indicated in Example 1.

**Example 10 : Cloning of the cDNA for mouse LSR ; analysis of the products of alternative splicing**

The cloning of the cDNA for mouse LSR was carried out using a mouse liver mRNA library. The cloning method used is the same as that for the cDNA for human LSR.

- 5 The mRNAs were purified and a reverse transcription PCR amplification was carried out with the specific DNA primers. The amplification fragment was cloned to a TA cloning vector (Introgene).

A study of the products of alternative splicing with primers situated in exon 2 and in exon 9 was also carried out in a manner similar to that carried out for the human LSR.

- 10 Three products of alternative splicing were observed : LSR-Mm-1886, LSR-Mm-1829 and LSR-Mm-1682. LSR-Mm-1886 contains all the exons from 1 to 10. LSR-Mm-1829 and LSR-Mm-1682 lack exon 4 and exons 4 and 5, respectively. These three biological forms of cDNA indeed correspond to what was observed in humans and rats. The nucleotide sequences of the cDNAs LSR-Mm-1886, LSR-Mm-1829 and LSR-Mm-1682 are illustrated in SEQ ID 13, 14 and 15, respectively. The protein sequences encoded by the cDNAs LSR-Mm-1886, LSR-Mm-1829 and LSR-Mm-1682 are illustrated in SEQ ID 16, 17 and 18.

**Example 11 : Identification of the  $\gamma$  subunit of LSR**

- 20 The  $\alpha$  and  $\beta$  subunits of LSR were identified as indicated above. Analysis of the products of translation of the RNAs encoding these two subunits does not allow the presence of a third subunit of molecular weight  $\approx 35$  kDa to be explained. This subunit is detected only after reduction of the LSR complex (Figure 10, lane 4).

We purified and obtained the NH<sub>2</sub>-terminal sequence of this  $\gamma$  subunit.

- 25 The purification was carried out by immunoaffinity chromatography according to the following procedure.

**Purification of the  $\gamma$  subunit of LSR**

- 30 Anti-LSR antibodies (band A) are coupled to a resin [2.5 mg of IgG per 3.5 ml of affigel Hz immunoaffinity kit resin (Biorad 153-6060)] which is then incubated with proteins solubilized from total membranes of rat liver (20 mM Tris buffer, 2 mM EDTA, 0.125 M octyl glucoside (5 X CMC), 1% inhibitor cocktail, pH = 7.4: 160 mg of membrane proteins give 41.3 mg of solubilized proteins (SP) in a volume of 17 ml.

- The incubation is carried out for 12 hours: 17 ml filled to 50 ml with 20 mM Tris buffer, 2 mM EDTA, pH 7.4 and the 3.5 ml of resin, with rotary shaking, at room temperature. The

resin is washed with 40 ml of 20 mM Tris buffer, 2 mM EDTA, pH 7.4 and then eluted with 20 mM Tris buffer, 2 mM EDTA, 200 mM glycine, pH 2.5 in 30 fractions of 500  $\mu$ l. The pH of each fraction is neutralized with 100  $\mu$ l per tube of 1 M Tris buffer, 2 mM EDTA, pH 9. 50  $\mu$ l of each fraction are deposited on a nitrocellulose membrane for dot-blot analysis: incubation with anti-LSR antibody, and then with a second antibody coupled to alkaline phosphatase.

- The positive fractions from 7 to 28 are pooled in pairs and concentrated 2.5-fold in a Speedvac. *Western blotting* is carried out on the pooled, concentrated and separated fractions on a 10% PAGE-SDS gel. Bands are observed in fractions 7 to 14 (the fractions are pooled).
- The two pools are dialysed against 24 mM ammonium bicarbonate and then freeze-dried in a Speedvac. The powder is taken up in 80  $\mu$ l of 20 mM Tris buffer, 2 mM EDTA, 2% SDS, 3% urea, pH 7.4 and reduced in the presence of 5%  $\beta$ -mercaptoethanol for 30 minutes at 100°C.
- After migration and wet transfer in 50 mM Tris, 50 mM borate on a sequencing membrane (PVDF) at 30 mA, the membrane is stained with amido black.

A band with an apparent MW of about 35 kDa was thus identified and sent for sequencing according to the Edman method.

- The sequence obtained is LHTGDKAFVEFLTDEIKEE. This sequence corresponds identically to that of a protein of molecular weight 33 kDa identified above as a protein of the cellular surface which binds the globular heads of C1q (gC1q-R) (Ghebrehiwet et al., 1994). A more recent observation indicates that this potential receptor for C1q is also located in the vesicles situated under the cellular surface (van den Berg et al., 1997). This protein also corresponds to a protein previously identified as p34, and which combines with a lamin receptor. This receptor possesses a long NH<sub>2</sub>-terminal segment oriented inwards in the cell nucleus as well as 8 transmembrane domains. This receptor binds to lamin in a manner which depends on the degree of phosphorylation. Finally, gC1q-R combines with "splicing factor 2" (Honoré et al., 1993). The lamin receptor and "splicing factor 2" have in common the characteristic of containing a repeated sequence of serine and arginine (RSRS) situated at the level of the NH<sub>2</sub>-terminal segment in the case of the lamin receptor and at the level of the carboxy-terminal segment in the case of SF2.

It is remarkable to observe that both  $\alpha$ -LSR and  $\beta$ -LSR exhibit repeated segments high in serine and arginine (Figure 1). Our hypothesis is that the  $\gamma$ -LSR protein represents a molecular chaperone which combines with the  $\alpha$  and  $\beta$  subunits of LSR *via* their RSRS domain.

In order to verify this hypothesis, we obtained polyclonal antibodies directed against two synthetic peptides whose sequence was situated at the carboxy- or NH<sub>2</sub>-terminal end of the gC1q-R protein:

-NH<sub>2</sub>-terminal peptide of gC1q-R : LRCVPRVLGSSVAGY\* (amino acids 5 to 19 of gC1q-R) (SEQ ID 39)

-COOH-terminal peptide of gC1q-R : C\*YITFLEDLKSFVKSQ (amino acids 268 to 282 of gC1q-R) (SEQ ID 40).

\*: amino acids differing from the protein sequence, so as to optimize the antigenicity of the peptides.

Figure 32 shows these antibodies specifically inhibit the activity of LSR. The antibody directed against the COOH-terminal end appears to be the most effective. These results indicate that gC1q-R, or one of its structurally similar homologues, represents a molecular chaperone noncovalently combined with the LSR multimeric complex.

### **Example 12 : Regulation of the LSR activity by C1q and its homologues**

It has been shown that gC1q-R could bind the globular head of complement factor 1. We sought to use this property of C1q to displace gC1q-R combined with LSR, and we measured the effect of increasing doses of C1q on the binding, internalization and degradation of the LDLs by hepatocytes in primary culture. Figure 33 shows an increase in the capture and degradation of LDLs induced by human C1q, even in the absence of oleate.

A less substantial, but nevertheless significant, increase is also observed in the presence of oleate. However, under these conditions, the maximum effect is obtained for lower concentrations of C1q.

It therefore appears that gC1q-R exerts on LSR an inhibitory effect which is comparable to that induced by the 39 kD RAP for LRP, the LDL receptor and LSR (Troussard et al., 1995). The displacement of the chaperone gC1q-R using its capacity to bind to complement C1q makes it possible to lift the inhibitory effect. Analysis of the gC1q-R sequence shows that it may be a typical membrane receptor. Indeed, the protein possesses no hydrophobic sequence capable of crossing the phospholipid bilayer.

The effect of complement C1q on the activity of LSR opens major perspectives in the context of the genetics of obesity. It is possible, indeed, that mutations affecting either the gene for C1q, that for gC1q-R, or alternatively that for their analogues such as for example AdipoQ, cerebellin, collagen alpha 1-10, SPA and SPD (pulmonary surfactant proteins), mannan-binding protein, and the scavenger receptor or its homologue LRP (Hu et al., 1996; Drickamer et al., 1986; Krieger and Herz, 1994; Elomaa et al., 1995) modulate the activity of LSR, both as regards clearance of lipoproteins and as regards that of leptin.

Several proteins can interact with gC1q-R because they exhibit homologies with complement C1q. In particular, two proteins isolated in mice, AdipoQ (Hu et al., 1996) and acrp30 (Scherer et al., 1995), and a human protein APM1 (Maeda et al., 1996) exhibit marked homologies. These three proteins, like the components of complement C1q (C1q A, B, C), are secreted proteins; they have an NH<sub>2</sub>-terminal end which resembles collagen (repetition of Gly-X-Y motifs) and a COOH-terminal end corresponding to the globular domain of complement C1q. These three proteins are preferably expressed in the adipose tissue. There are only 3 amino acids differing between AdipoQ and acrp30. APM1, a protein whose messenger has been characterized as being highly expressed in adipocytes, exhibits 79.7% nucleic acid identity and 80.6% amino acid identity with AdipoQ. APM1 is therefore certainly the human homologue of AdipoQ.

### ***Example 13 : Screening of compounds modifying the activity of the LSR receptor***

As described above, the inventors formulated the hypothesis that the LSR “ $\gamma$  band”, a protein which is highly homologous to gC1qR, might interact with the LSR receptor like a molecular chaperone and might thus form an “LSR complex”, comprising the  $\alpha$  or  $\alpha'$  and  $\beta$  subunits of the LSR receptor and a gC1qR type molecule. gC1qR has been previously identified as a cell surface protein which binds the globular heads of the complement factor C1q. In addition to C1q, several proteins exhibiting homologies with the C1q proteins, in particular AdipoQ and acrp30 in mice and APM1 in humans, are capable of interacting with the protein homologous to gC1qR in the LSR complex and of modifying the LSR activity.

### ***Screening parameters***

The screening of a compound such as C1q or AdipoQ was carried out through the measurement of various parameters of which the most important is the measurement of the effect of the compound on the activity of the LSR receptor. The various parameters are the following :

- change in weight
- food intake
- postprandial lipemic response
- binding, internalization and/or degradation of lipoproteins such as the LDLs.

### ***Change in weight***

Osmotic pumps were surgically inserted into the abdominal cavities of 12 Sprague-Dawley male rats of 400-450 g. The osmotic pumps contained either 2 ml of PBS (phosphate buffered saline), pH 7.4 (control 6 rats), or 2 ml of recombinant AdipoQ



protein (5 mg/ml PBS, 6 rats). These pumps were designed to deliver 10  $\mu$ l/h (50  $\mu$ g AdipoQ/h). The animals are weighed and individually housed in metabolic cages. 3 animals in each group are subjected ad libitum either to a normal diet or to a fatty diet (day 0). The fatty diet consists of a normal diet supplemented with 2% (w/w) cholesterol, 10% (w/w) saturated fatty acid in the form of vegetaline, [lacuna] % (w/w) sunflower oil and 15% (w/w) sucrose. On day 3, the animals are weighed and blood samples are obtained from the caudal vein. The quantity of plasma triglycerides was measured using an enzymatic kit.

#### **Food intake**

Recombinant AdipoQ protein (100  $\mu$ g) or PBS alone were injected daily for 5 days through the caudal vein of ob/ob or db/db mice kept in a metabolic cage. The mice are weighed each day and the quantity of food consumed was also measured. The results correspond to a mean food intake and a standard deviation for 4 mice in each group.

#### **Postprandial lipemic response**

Male Sprague-Dawley rats (400-450 g), starved since the day before, were forced with a meal which was very high in fat (t=0) (60% fatty acid of which 37% saturated, 27% monounsaturated and 36% polyunsaturated, 20% protein and 20% carbohydrate, the total providing 56 kcal/kg of body weight) and received immediately afterwards an intravenous injection (femoral vein) of either 300  $\mu$ l of PBS alone or of the same volume containing 1 mg of mouse recombinant AdipoQ protein. Blood samples were collected at various times (0, 2, 4 and 6 h). The quantity of plasma triglycerides was measured using an enzymatic kit. The results are presented as mean values and standard deviations on 3 animals.

#### **LSR activity or binding, internalization and degradation of lipoproteins**

Primary cultures of rat hepatocytes were prepared and distributed into 6-well plates (9000,000 cells/well). After 48 h, the cells were washed once with PBS (2 ml/well) and incubated for 30 min at 37°C with 20 ng/ml of recombinant murine leptin. The cells were then incubated for 4 h at 37°C with increasing concentrations of recombinant murine AdipoQ proteins and 20  $\mu$ g/ml  $^{125}$ I-LDL in the presence or in the absence of 0.5 mM oleate. The binding, internalization and degradation of lipoproteins were measured as indicated in Example 1.

### **C1q**

The compound C1q was tested for its capacity to modulate the activity of the LSR receptor (binding, internalization and degradation of lipoproteins). Figure 33 shows that the compound C1q exhibits the property of increasing the activity in the presence and in

the absence of oleate. Thus, it was possible for this compound C1q to be selected as modulator of the LSR activity through the test of activity described above.

## **AdipoQ**

5           The compound AdipoQ was tested according to the four parameters presented above.

Figure 34 shows that the compound AdipoQ modulates the LSR activity in the presence of oleate. Indeed, at the concentration of 25 ng/ml, it increases the LSR activity.

Figure 35 shows that the administration of AdipoQ makes it possible to massively  
10       reduce the postprandial lipemic response.

Figure 36 shows that a 3-day ip infusion treatment with AdipoQ causes a loss in weight which is much greater when the rat is subjected to a fatty diet. Furthermore, the inventors observed that the level of plasma triglycerides is reduced in the animals treated with AdipoQ.

15           Figure 37 shows that an injection of AdipoQ reduces the food intake in obese animals.

The increase in the LSR activity induced by 25 ng/ml of AdipoQ can explain the reduction in the postprandial lipemic response and the weight loss.

Thus, the AdipoQ protein is a very valuable compound which could be used in  
20       particular in the treatment of obesity. The selection of this protein as a candidate molecule in the treatment of obesity validates the parameters for screening a compound of interest modulating the LSR activity, the most important parameter consisting in measuring the LSR activity.

## **REFERENCES**

- 25       Aalto-Setälä, K., Fisher, E.A., Chen, X., Chajek-shaul, T., Hayek, T., Zechner, R., Walsh, A., Ramakrishnan, R., Ginsberg, H.N., and Breslow, J.L.. *J.Clin.Invest.* **90** : 1889-1900, 1992.
- Banner, D.W., D'Arcy, A., Janes, W., Gentz, R., Schoenfeld, H.-J., Broger, C., Loetscher, H., and Lesslauer, W.. *Cell* **73**: 431-445, 1993.
- 30       Bartles, J.R., and Hubbard, A.L. *Methods Enzymol.* **191** : 825-841, 1990.
- Belcher, J.D., Hamilton, R.L., Brady, S.E., Hornick, C.A., Jaeckle, S., Schneider, W.J., and  
Havel, R.J.. *Proc. Natl. Acad. Sci.* **84** : 6785-6789, 1987.
- Bihain, B.E., and Yen, F.T. *Biochemistry* **31** :4628-4636, 1992.
- 35       Bilheimer, D.W., Eisenberg, S., and Levy, R.I. *Biochim. Biophys. Acta* **260** : 212-221, 1972.

- Bodansky M., Principles of peptide synthesis, (1984).
- Brendel, V., Bucher, P., Nourbakhsh, I., Blaisdell, B.E., and Karlin, S. *Proc. Natl. Acad. Sci. USA* **89**: 2002-2006, 1992.
- Buckholz, R.G.. *Curr. Op. Biotechnology* **4** : 538-542, 1993.
- 5 Busch et al. *J. Chromatogr.* **777** 311-328 (1997)
- Carter, B.J. *Curr. Op. Biotechnology* **3** : 533-539, 1993.
- Chen, W.-J., Goldstein, J.-L., and Brown, M.S. *J. Biol. Chem.* **263**: 3116-3123, 1990.
- Chen, H., Charlat, O., Targlia, L.A., et al. *Cell* **84** : 491-495, 1996.
- Cherif D., Julier, C., Delattre, O., Derré, J., Lathrop, G.M., and Berger, R. *Proc. Natl. Acad. Sci. USA*. **87** : 6639-6643, 1990.
- 10 Chumakov, I., Rigault, P., Guillou, S., Ougen, P., Billault, A., Guasconi, G., Gervy, P., Le Gall, I., Soularue, P., Grinas, P., et al. *Nature* **359** : 380-386, 1992.
- Chumakov, I.M., Rigault, P., Le Gall, I., et al. *Nature* **377** : 175-183, 1995.
- Compton, J. *Nature* **350**: 91-92, 1991.
- 15 Cytokines and Their Receptors (Nicola, N.A., ed.). Oxford University Press, Oxford. 1996.
- Davis, C.G., Lehrman, M.A., Russell, D.W., Anderson, R.G.W., Brown, M.S., and Goldstein, J.L. *Cell* **45** : 15-24, 1986.
- Edwards, C.P., and Aruffo, A. *Curr. Op. Biotechnology* **4** : 558-563, 1993.
- Elomaa, O., Kangas, M., Sahlberg, C., Tuukkanen, J., Sormunen, R., Liakka, A.,
- 20 Thesleff, I., Kraal, G., and Tryggvason, K. *Cell* **80** (4) : 603-609, 1995.
- Epstein, A. *Médecine/Sciences* **8** : 902-911, 1992.
- Fan, J.L., McCormick, S.P.A., Krauss, R.M., Taylor, S., Quan, R., Taylor, J.M., and Young, S.G. *Arterioscler. Thromb. Vasc. Biol* **15** : 1889-1899, 1995.
- Goldstein, J.L., Basu, S.K., and Brown, M.S. *Methods Enzymol.* **98** : 241-260, 1983.
- 25 Goldstein, J.L., Hobbs, H.H., Brown, M.S. Familial Hypercholesterolemia In The Metabolic and Molecular Bases of Inherited Disease, Volume II, 7th Edition (Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D., ed). Mc Graw-Hill, New-York. pp.1981-2030, 1995.
- Guatelli J.C. et al. *Proc. Natl. Acad. Sci. USA* **87**: 1874-1878, 1990.
- Gura T. *Science* **275** : 751-753, 1997.
- 30 Heldin, C.H. *Cell* **80** : 213-223, 1995.
- Herz, J., Hamann, U., Rogne, S., Myklebost, O., Gausepohl, H., and Stanley, K.K. *EMBO J.* **7** : 4119-4127, 1988.
- Herz, J., Qiu, S.-Q., Oesterle, A., DeSilva, H.V., Shafi, S., and Havel, R.J. *Proc. Natl. Acad. Sci. USA* **92** : 4611-4615, 1995.
- 35 Homanics, G.E., de Silva, H.V., Osada, J., Zhang, S.H., Wong, H., Borensztajn, J., and Maeda, N. *J. Biol. Chem.* **270** : 2974-2980, 1995.

- Honoré, B., Madsen, P., Rasmussen, H.H., Vandekerckhove, J., Celis, J.E., and Leffers, H. *Gene* **134** : 283-287, 1993.
- Huang, Y.D., Schwendner, S.W., Rall, S.C., and Mahley, R.W. *J.Biol Chem.* **271** : 29146-29151, 1996.
- 5 Huynh, T.U., Young R.A. and Davis R.W. DNA cloning techniques: A practical approach, ed Glover D. (IRL Press, Oxford), 1984.
- Iida, M., Murakami, T., Ishida, K., Mizuno, A., Kuwajima, M., and Shima, K. *Biochem. Biophys. Res. Commun.* **224** : 597-604, 1996.
- Ishibashi, S., Brown, M.S., Goldstein, J.L., Gerard, R.D., Hammer, R.E., and Herz, J. *J. Clin. Invest.* **92** : 883-893, 1993.
- 10 Ito, Y., Azrolan, N., O'Connell, A., Walsh, A., and Breslow, J.L. *Science* **249**: 790-793, 1990.
- Kleyn, P.W., Fan, W., Kovats, S.G., et al. *Cell* **85** : 281-290, 1996.
- Kobayashi, J., Applebaum-Bowden, D., Dugi, K.A., Brown, D.R., Kashyap, V.S., Parrott, C., Duarte, C., Maeda, N., and Santamarina-Fojo, S. *J.Biol.Chem.* **271** : 26296-26301, 1996.
- 15 Köhler et Milstein. *Nature* **256**, 495-497, 1975.
- Kosak M. *Nucleic Acids Res.* **15**: 8125-8148, 1987.
- Kosak M. *Proc. Natl. Acad. Sci. USA* **87**: 8301-8305, 1990.
- 20 Krainer, A.R., Mayeda, A., Kozak, D., and Binns, G. *Cell* **66** : 383-394, 1991.
- Krieger, M., and Herz, J. *Ann. Rev. Biochem.* **63**: 601-637, 1994.
- Landegren U., Kaiser R., Sanders J. & Hood L. *Science* **241**: 1077-1080, 1988.
- Lee, M.G-S., Bihain, B.E., Russell, D.G., Deckelbaum, R.J., and Van Der Ploeg, L.H.T. *Molec. Cell. Biol.* **10** : 4506-4517, 1990.
- 25 Letourneur, F., and Klausner, R.D. *Cell* **69** : 1143-1157, 1992.
- Lockhart et al. *Nature Biotechnology* **14**: 1675-1680, 1996
- Lu, D., Willard, D., Patel, I.R., et al. *Nature* **371** : 799-802, 1994.
- Luckow, V.A. *Curr. Op. Biotechnology* **4** : 564-572, 1993.
- Maeda, N., Li, H., Lee, D., Oliver, P., Quarfordt, S.H., and Osada, J. *J.Biol.Chem.* **269** : 23610-23616, 1994.
- 30 Mann, C.J., Khallou, J., Chevreuil, O., Troussard, A.A., Guermani, L.M., Launay, K., Delplanque, B., Yen, F.T., and Bihain, B.E. *Biochemistry* **34** : 10421-10431, 1995.
- Manne, J., Argeson, A.C., Siracusa, L.D. *Proc. Natl. Acad. Sci. USA* **92** : 4721-4724, 1995.

- Montague, C.T., Farooqi, I.S., Whitehead, J.P., Soos, M.A., Rau, H., Wareham, N.J., Sewter, C.P., Digby, J.E., Mohammed, S.N., Hurst, J.A., Cheetham, C.H., Earley, A.R., Barnett, A.H., Prins, J.B., and O'Rahilly, S.O. *Nature* **387** :903-908, 1997.
- No D., Yao T.P. and Evans R.M. *Proc. Natl. Acad. Sci. USA*, **93**: 3346-3351, 1996.
- 5 Nobben-Trauth, K., Naggert, J.K., North, M.A., and Nishina, P.M. *Nature* **380** : 534-538, 1996.
- Olins, P.O., and Lee, S.C. *Curr. Op. Biotechnology* **4** : 520-525, 1993.
- Oukka, M., André, P., Turmel, P., Besnard, N., Angevin, V., Karlsson, L., Trans, P.L., Charron, D., Bihain, B., Kosmatopoulos, K., Lotteau, V. *Eur. J. Immunol.* **27** : 855-859,
- 10 1997.
- Parra-Lopez, C.A., Lindner, R., Vidavsky, I., Gross, M., and Unanue, E.R. *J. Immunol.* **158**: 2670-2679, 1997.
- Perricaudet, M., Stratford-Perricaudet, L. and Briand, P. *La Recherche* **23** : 471-473, 1992.
- 15 Pietu et al. *Genome Research* **6**:492-503, 1996
- Plump, A.S., Smith, J.D., Hayek, T., Aalto-Setälä, K., Walsh, A., Verstuyft, J.G., Rubin, E.M., and Breslow, J.L. *Cell* **71** : 343-353, 1992.
- Purcellhuynh, D.A., Farese, R.V., Johnson, D.F., Flynn, L.M., Pierotti, V., Newland, D.L., Linton, M.F., Sanan, D.A., and Young, S.G. *J.Clin.Invest.* **95** : 2246-2257, 1995.
- 20 Rohlmann, A., Gotthardt, M., Willnow, T.E., Hammer, R.E., and Herz, J. *Nature Biotech.* **14** : 1562-1565, 1996.
- Sambrook, J., Fritsch, E.F., and Maniatis, T. *Molecular cloning : a laboratory manual*. Sec. Ed. Cold Spring Harbor Lab., Cold Spring Harbor, New York.
- Schena et al. *Science* **270**:467-470, 1995
- 25 Simos, G., Georgatos, S.D. *FEBS Letters* **346** : 225-228, 1994.
- Sosnowski RG, et al., *Proc Natl Acad Sci U S A* 1997;**94**:1119-1123
- Stewart J.M. et Yound J.D., *solid phase peptides synthesis*, Pierce Chem. Company, Rockford, 111, 2<sup>nd</sup> edit., (1984).
- Suggs S.V., Wallace R.B., Hirose T., Kawashima E.H. and Itakura K. *PNAS* **78**: 6613-6617, 1981.
- 30 Szabo A. et al. *Curr Opin Struct Biol* **5**, 699-705 (1995)
- Temin, H.M. Retrovirus vectors for gene transfer. In Kucherlapati R., ed. *Gene Transfer*, New York, Plenum Press, 149-187, 1986.
- Troussard, A.A., Khallou, J., Mann, C.J., André, P., Strickland, D.K., Bihain, B.E., and
- 35 Yen, F.T. *J. Biol. Chem.* **270** : 17068-17071, 1995.
- Verhey, K.J., and Birnbaum, M.J. *J. Biol. Chem.* **269** : 2353-2356, 1994.



- Walker G.T., Fraiser M.S., Schram J.L., Little M.C., Nadeau J.G., & Malinowski D.P. *Nucleic Acids Res.* **20** : 1691-1696, 1992.
- Wang et al. *Chromatographia*, **44** 205-208 (1997)
- West, D.B., Boozer, C.N., Moody, D.L., and Atkinson, R.L. *Am. J. Physiol.* **262** : R1025-  
 5 R1032, 1992.
- Willow, T.E., Sheng, Z., Ishibashi, S., Herz, J. *Science*, **264** : 1471-1474, 1994.
- Woo S.L.C. *Methods Enzymol.* **68**: 389, 1979.
- Yen, F.T., Mann, C.J., Guermani, L.M., Hannouche, N.F., Hubert, N., Hornick, C.A.,  
 Bordeaux, V., Agnani, G., and Bihain, B.E. *Biochemistry* **33** : 1172-1180, 1994.
- 10 Young R.A. and Davis R.W. *PNAS* **80**: 1194-1198, 1983a.  
 Young R.A. and Davis R.W. *Science* **222** : 778-782, 1983b.
- Zhang, S.H., Reddick, R.L., Piedrahit, J.A., and Maeda, N. *Science* **258** : 468-471, 1992.
- Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., Friedman, J.M. *Nature*, **372** :  
 4425-4432, 1994.
- 15 Zhong, G., Romagnoli, P., and Germain, R.N. *J. Exp. Med.* **185** : 429-438, 1997.